Allergan 10-K 25 Feb 14 2013 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2013	Feb. 20, 2014	Jun. 28, 2013
Document Information [Line Items]	'	'	'
Entity Registrant Name	'ALLERGAN INC.	'	'
Entity Central Index Key	'0000850693	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Large Accelerated Filer	'	'
Entity Public Float	'	'	$24,964
Entity Common Stock, Shares Outstanding	'	307,592,460	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Current assets:	'	'
Cash and equivalents	$3,046.10	$2,701.80
Short-term investments	603	260.6
Trade receivables, net	883.3	739
Inventories	285.3	272.3
Other current assets	493	448.6
Assets of discontinued operations	9	512.6
Total current assets	5,319.70	4,934.90
Investments and other assets	213.2	192.1
Deferred tax assets	128.8	206.9
Property, plant and equipment, net	923.2	851.5
Goodwill	2,339.40	2,133.80
Intangibles, net	1,650	860.1
Total assets	10,574.30	9,179.30
Current liabilities:	'	'
Notes payable	55.6	48.8
Accounts payable	283.2	232.2
Accrued compensation	269.1	222.4
Other accrued expenses	597.5	586.8
Income taxes	38.9	0
Liabilities of discontinued operations	0	5.3
Total current liabilities	1,244.30	1,095.50
Long-term debt	2,098.30	1,512.40
Other liabilities	762.2	708.8
Commitments and contingencies	'	'
Allergan, Inc. stockholders' equity:	'	'
Preferred stock, $.01 par value; authorized 5,000,000 shares; none issued	0	0
Common stock, $.01 par value; authorized 500,000,000 shares; issued 307,554,060 and 307,537,860 shares as of December 31, 2013 and 2012, respectively	3.1	3.1
Additional paid-in capital	3,032.80	2,900.60
Accumulated other comprehensive loss	-226.6	-244.6
Retained earnings	4,646.70	3,832.10
Stockholders' equity subtotal before treasury stock	7,456	6,491.20
Less treasury stock, at cost (9,947,345 and 7,213,757 shares as of December 31, 2013 and 2012, respectively)	-992.8	-654.1
Total stockholders' equity	6,463.20	5,837.10
Noncontrolling interest	6.3	25.5
Total equity	6,469.50	5,862.60
Total liabilities and equity	$10,574.30	$9,179.30

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Allergan, Inc. stockholders' equity:	'	'
Preferred stock, par value (in dollars per share)	$0.01	$0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized (in shares)	500,000,000	500,000,000
Common stock, shares issued (in shares)	307,554,060	307,537,860
Treasury stock, shares (in shares)	9,947,345	7,213,757

CONSOLIDATED_STATEMENTS_OF_EAR

CONSOLIDATED STATEMENTS OF EARNINGS (USD $)	12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues:	'	'	'
Product net sales	$6,197.50	$5,549.30	$5,144
Other revenues	102.9	97.3	72
Total revenues	6,300.40	5,646.60	5,216
Operating costs and expenses:	'	'	'
Cost of sales (excludes amortization of intangible assets)	795.8	751.2	718
Selling, general and administrative	2,519.40	2,193.10	2,158.30
Research and development	1,042.30	977.3	871.5
Amortization of intangible assets	116.7	90.2	86.1
Impairment of intangible assets and related costs	11.4	22.3	7.6
Restructuring charges (reversal)	5.5	1.5	-0.1
Operating income	1,809.30	1,611	1,374.60
Non-operating income (expense):	'	'	'
Interest income	6.8	6.7	6.9
Interest expense	-75	-63.6	-71.8
Other, net	-10.3	-23.1	-0.5
Total non-operating income (expense)	-78.5	-80	-65.4
Earnings from continuing operations before income taxes	1,730.80	1,531	1,309.20
Provision for income taxes	458.3	430.3	359.6
Earnings from continuing operations	1,272.50	1,100.70	949.6
Discontinued Operations:	'	'	'
Earnings (loss) from discontinued operations, net of applicable income tax expense of $6.9 million, $0.5 million and $2.0 million for the years ended December 31, 2013, 2012 and 2011, respectively	14.1	1.8	-11.5
Loss on sale of discontinued operation, net of applicable income tax benefit of $110.3 million	-297.9	0	0
Discontinued operations	-283.8	1.8	-11.5
Net earnings	988.7	1,102.50	938.1
Net earnings attributable to noncontrolling interest	3.6	3.7	3.6
Net earnings attributable to Allergan, Inc.	$985.10	$1,098.80	$934.50
Basic earnings per share attributable to Allergan, Inc. stockholders:	'	'	'
Continuing operations (in dollars per share)	$4.28	$3.64	$3.11
Discontinued operations (in dollars per share)	($0.96)	$0	($0.04)
Net basic earnings per share attributable to Allergan, Inc. stockholders (in dollars per share)	$3.32	$3.64	$3.07
Diluted earnings per share attributable to Allergan, Inc. stockholders:	'	'	'
Continuing operations (in dollars per share)	$4.20	$3.57	$3.05
Discontinued operations (in dollars per share)	($0.94)	$0.01	($0.04)
Net diluted earnings per share attributable to Allergan, Inc. stockholder (in dollars per share)	$3.26	$3.58	$3.01

CONSOLIDATED_STATEMENTS_OF_EAR1

CONSOLIDATED STATEMENTS OF EARNINGS (Parenthetical) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Earnings (loss) from discontinued operations, applicable income tax expense	$6.90	$0.50	$2
Loss on sale of discontinued operations, applicable income tax benefit	$110.30	$0	$0

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]	'	'	'
Net earnings	$988.70	$1,102.50	$938.10
Other comprehensive income (loss), net of tax:	'	'	'
Foreign currency translation adjustments	-8.6	9.6	-42.6
Reclassification adjustment for foreign currency translation gains included in net earnings from the substantially complete liquidation of an investment in a foregin subsidiary	0	0	-9.4
Amortization of deferred holding gains on derivatives designated as cash flow hedges included in net earnings, net of tax benefit of $0.5 million, $0.6 million and $0.5 million for the years ended December 31,2013 and 2012 and 2011, respectively	-0.8	-0.7	-0.8
Pension and postretirement benefit plan adjustments:	'	'	'
Net gain (loss), net of tax (expense) benefit of $(9.0) million, $1.1 million and $24.9 million for the years ended December 31, 2013, 2012 and 2011, respectively	9.1	-35.9	-62.7
Net gain on remeasurement of postretirement benefit plan liability, net of tax expense of $7.4 million	0	0	13.1
Amortization, net of tax expense of $14.1 million, $0.8 million and $5.1 million for the years ended December 31, 2013, 2012 and 2011, respectively	14.2	25.1	12.7
Other comprehensive income (loss)	13.9	-1.9	-89.7
Total comprehensive income	1,002.60	1,100.60	848.4
Comprehensive income attributable to noncontrolling interest	2.8	5	2.4
Comprehensive income attributable to Allergan, Inc.	$999.80	$1,095.60	$846

CONSOLIDATED_STATEMENTS_OF_COM1

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Other Comprehensive Income (Loss), Tax [Abstract]	'	'	'
Amortization of deferred holding gains on derivatives designated as cash flow hedges included in net earnings, tax benefit	$0.50	$0.60	$0.50
Net gain (loss), tax (expense) benefit	-9	1.1	24.9
Net gain on remeasurement of postretirement benefit plan liability, tax expense	0	0	7.4
Amortization, tax expense	$14.10	$0.80	$5.10

CONSOLIDATED_STATEMENTS_OF_EQU

CONSOLIDATED STATEMENTS OF EQUITY (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Noncontrolling Interest [Member]
In Millions, except Share data
Beginning balance at Dec. 31, 2010	$4,781.10	$3.10	$2,815.50	($152.90)	$2,225.90	($133.90)	$23.40
Beginning balance, common stock (in shares) at Dec. 31, 2010	'	307,500,000	'	'	'	'	'
Beginning balance, treasury stock (in shares) at Dec. 31, 2010	'	'	'	'	'	-2,000,000	'
Net earnings	938.1	'	'	'	934.5	'	3.6
Other comprehensive income (loss)	-89.7	'	'	-88.5	'	'	-1.2
Dividends ($0.20 per share)	-61.1	'	'	'	-61.1	'	'
Stock options exercised (in shares)	5,496,000	'	'	'	'	5,500,000	'
Stock options exercised	264	'	0.7	'	-131.2	394.5	'
Excess tax benefits from share-based compensation	37.7	'	37.7	'	'	'	'
Activity under other stock plans	6	'	0.1	'	-0.4	6.3	'
Purchase of treasury stock (in shares)	'	'	'	'	'	-6,000,000	'
Purchase of treasury stock	-461.7	'	'	'	'	-461.7	'
Stock-based award activity (in shares)	'	'	'	'	'	200,000	'
Stock-based award activity	80.2	'	67	'	1.6	11.6	'
Repurchase of equity component of convertible borrowings	-159.2	'	-159.2	'	'	'	'
Dividends to noncontrolling interest	-3	'	'	'	'	'	-3
Ending balance at Dec. 31, 2011	5,332.40	3.1	2,761.80	-241.4	2,969.30	-183.2	22.8
Ending balance, common stock (in shares) at Dec. 31, 2011	'	307,500,000	'	'	'	'	'
Ending balance, treasury stock (in shares) at Dec. 31, 2011	'	'	'	'	'	-2,300,000	'
Net earnings	1,102.50	'	'	'	1,098.80	'	3.7
Other comprehensive income (loss)	-1.9	'	'	-3.2	'	'	1.3
Dividends ($0.20 per share)	-60.4	'	'	'	-60.4	'	'
Stock options exercised (in shares)	4,928,000	'	'	'	'	4,900,000	'
Stock options exercised	246.2	'	0.6	'	-177.3	422.9	'
Excess tax benefits from share-based compensation	45.7	'	45.7	'	'	'	'
Activity under other stock plans (in shares)	'	'	'	'	'	100,000	'
Activity under other stock plans	6.4	'	-0.2	'	'	6.6	'
Purchase of treasury stock (in shares)	'	'	'	'	'	-10,000,000	'
Purchase of treasury stock	-909	'	'	'	'	-909	'
Stock-based award activity (in shares)	'	'	'	'	'	100,000	'
Stock-based award activity	103	'	92.7	'	1.7	8.6	'
Dividends to noncontrolling interest	-2.3	'	'	'	'	'	-2.3
Ending balance at Dec. 31, 2012	5,862.60	3.1	2,900.60	-244.6	3,832.10	-654.1	25.5
Ending balance, common stock (in shares) at Dec. 31, 2012	307,537,860	307,500,000	'	'	'	'	'
Ending balance, treasury stock (in shares) at Dec. 31, 2012	-7,213,757	'	'	'	'	-7,200,000	'
Net earnings	988.7	'	'	'	985.1	'	3.6
Other comprehensive income (loss)	13.9	'	'	14.7	'	'	-0.8
Dividends ($0.20 per share)	-59.5	'	'	'	-59.5	'	'
Stock options exercised (in shares)	3,187,000	100,000	'	'	'	3,200,000	'
Stock options exercised	182.3	'	0.7	'	-109.9	291.5	'
Excess tax benefits from share-based compensation	37.7	'	37.7	'	'	'	'
Activity under other stock plans (in shares)	'	'	'	'	'	100,000	'
Activity under other stock plans	6.3	'	-0.6	'	-0.7	7.6	'
Purchase of treasury stock (in shares)	'	'	'	'	'	-6,100,000	'
Purchase of treasury stock	-650.7	'	'	'	'	-650.7	'
Stock-based award activity (in shares)	'	'	'	'	'	100,000	'
Stock-based award activity	108.2	'	95.7	'	-0.4	12.9	'
Purchase of noncontrolling interest in a subsidiary	-18	'	'	'	'	'	-20
Purchase of noncontrolling interest in a subsidiary	'	'	-1.3	3.3	'	'	'
Dividends to noncontrolling interest	-2	'	'	'	'	'	-2
Ending balance at Dec. 31, 2013	$6,469.50	$3.10	$3,032.80	($226.60)	$4,646.70	($992.80)	$6.30
Ending balance, common stock (in shares) at Dec. 31, 2013	307,554,060	307,600,000	'	'	'	'	'
Ending balance, treasury stock (in shares) at Dec. 31, 2013	-9,947,345	'	'	'	'	-9,900,000	'

CONSOLIDATED_STATEMENTS_OF_EQU1

CONSOLIDATED STATEMENTS OF EQUITY (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Statement of Stockholders' Equity [Abstract]	'	'	'
Dividends per share	$0.20	$0.20	$0.20

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:	'	'	'
Net earnings	$988.70	$1,102.50	$938.10
Non-cash items included in net earnings:	'	'	'
Depreciation and amortization	254.6	256.6	253.4
Amortization of original issue discount and debt issuance costs	2.6	1.9	9.7
Amortization of net realized gain on interest rate swaps	-14.4	-7.7	-1.3
Deferred income tax benefit	-192.2	-88.3	-68.9
Loss on disposal and impairment of assets	5.8	5.7	0
Unrealized (gain) loss on derivative instruments	-10.4	15.3	-11.1
Expense of share-based compensation plans	114.4	109.1	86.3
Loss on sale of discontinued operations	408.2	0	0
Impairment of intangible assets and related costs	11.4	22.3	20.4
Expense from changes in fair value of contingent consideration	70.7	5.4	11.9
Restructuring charges	5.5	5.7	4.6
Loss on investments, net	3.7	0	1.3
Changes in operating assets and liabilities:	'	'	'
Trade receivables	-139.6	-34.3	-105.6
Inventories	-26.9	-7.3	-24
Other current assets	-0.8	-16	-33.1
Other non-current assets	-15.5	44.1	-13.4
Accounts payable	37.4	32.7	-19.3
Accrued expenses	110.2	73.1	39.1
Income taxes	64.9	52.4	-19.8
Other liabilities	17.1	26.7	13.6
Net cash provided by operating activities	1,695.40	1,599.90	1,081.90
Cash flows from investing activities:	'	'	'
Purchases of short-term investments	-1,025.60	-865.2	-571.1
Acquisitions, net of cash acquired	-892.1	-349.2	-101.4
Additions to property, plant and equipment	-171.9	-143.3	-118.6
Additions to capitalized software	-11.8	-13.9	-11.2
Additions to intangible assets	-0.3	-4.1	-0.3
Proceeds from maturities of short-term investments	683.2	784.6	1,140.30
Proceeds from sale of business	42.7	0	0
Proceeds from sale of equity investments	0	0	1.9
Proceeds from sale of property, plant and equipment	0.5	1.8	1.2
Net cash (used in) provided by investing activities	-1,375.30	-589.3	340.8
Cash flows from financing activities:	'	'	'
Repayments of convertible borrowings	0	0	-808.9
Dividends to stockholders	-59.4	-60.4	-61.1
Payments to acquire treasury stock	-650.7	-909	-461.7
Purchase of noncontrolling interest in a subsidiary	-18	0	0
Payments of contingent consideration	-61.2	-5.1	-3
Net borrowings (repayments) of notes payable	6.8	-35.1	30.7
Debt issuance costs	-4.8	0	0
Proceeds from issuance of senior notes, net of discount	598.5	0	0
Sale of stock to employees	179.3	246.4	264
Excess tax benefits from share-based compensation	37.7	45.7	37.7
Net cash provided by (used in) financing activities	28.2	-717.5	-1,002.30
Effect of exchange rate changes on cash and equivalents	-4	2.6	-5.5
Net increase in cash and equivalents	344.3	295.7	414.9
Cash and equivalents at beginning of period	2,701.80	2,406.10	1,991.20
Cash and equivalents at end of period	3,046.10	2,701.80	2,406.10
Cash paid for:	'	'	'
Interest, net of amount capitalized	83.3	64.2	64.5
Income taxes, net of refunds	$455.30	$407	$399.30

CONSOLIDATED_STATEMENTS_OF_CAS1

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]	'
Sale of obesity intervention business, minority equity interest received as part of the total consideration	$15

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	Note 1:  Summary of Significant Accounting Policies
	The consolidated financial statements include the accounts of Allergan, Inc. (“Allergan” or the “Company”) and all of its subsidiaries. All significant intercompany transactions and balances among the consolidated entities have been eliminated from the consolidated financial statements.
	Use of Estimates
	The financial statements have been prepared in conformity with accounting principles generally accepted in the United States and, as such, include amounts based on informed estimates and judgments of management. Actual results could differ materially from those estimates.
	Foreign Currency Translation
	The financial position and results of operations of the Company’s foreign subsidiaries are generally determined using local currency as the functional currency. Assets and liabilities of these subsidiaries are translated at the exchange rate in effect at each year end. Income statement accounts are translated at the average rate of exchange prevailing during the year. Adjustments arising from the use of differing exchange rates from period to period are included in accumulated other comprehensive loss in equity. Aggregate net realized and unrealized (losses) gains resulting from foreign currency transactions and derivative contracts of approximately $(7.4) million, $(23.4) million and $0.3 million for the years ended December 31, 2013, 2012 and 2011, respectively, are included in “Other, net” in the Company’s consolidated statements of earnings.
	Cash and Equivalents
	The Company considers cash in banks, repurchase agreements, commercial paper, money-market funds and deposits with financial institutions with maturities of three months or less when purchased and that can be liquidated without prior notice or penalty, to be cash and equivalents.
	Short-Term Investments
	Short-term investments consist primarily of investment grade commercial paper and time deposits with financial institutions with maturities from three months to one year when purchased and are classified as available-for-sale. Short-term investments are valued at cost, which approximates fair value due to their short-term maturities.
	Investments
	The Company has non-marketable equity investments in conjunction with its various collaboration arrangements. The non-marketable equity investments represent investments in start-up companies and are recorded at cost. The non-marketable equity investments are evaluated periodically for impairment. If it is determined that a decline of any investment is other than temporary, then the investment basis would be written down to fair value and the write-down would be included in earnings as a loss.
	Inventories
	Inventories are valued at the lower of cost or market (net realizable value). Cost is determined by the first-in, first-out method.
	Long-Lived Assets
	Property, plant and equipment are stated at cost. Additions, major renewals and improvements are capitalized, while maintenance and repairs are expensed. Upon disposition, the net book value of assets is relieved and resulting gains or losses are reflected in earnings. For financial reporting purposes, depreciation is generally provided on the straight-line method over the useful life of the related asset. The useful lives for buildings, including building improvements, range from seven years to 40 years and, for machinery and equipment, three years to 15 years.
	Leasehold improvements are amortized over the shorter of their economic lives or lease terms. Accelerated depreciation methods are generally used for income tax purposes.
	All long-lived assets are reviewed for impairment in value when changes in circumstances dictate, based upon undiscounted future operating cash flows, and appropriate losses are recognized and reflected in current earnings, to the extent the carrying amount of an asset exceeds its estimated fair value determined by the use of appraisals, discounted cash flow analyses or comparable fair values of similar assets.
	Goodwill and Intangible Assets
	Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill has an indefinite useful life and is not amortized, but instead tested for impairment annually. Intangible assets include developed technology, customer relationships, licensing agreements, trademarks, core technology and other rights, which are being amortized over their estimated useful lives ranging from two years to 21 years, and in-process research and development assets with indefinite useful lives that are not amortized, but instead tested for impairment until the successful completion and commercialization or abandonment of the associated research and development efforts, at which point the in-process research and development assets are either amortized over their estimated useful lives or written-off immediately.
	Treasury Stock
	Treasury stock is accounted for by the cost method. The Company maintains an evergreen stock repurchase program. The evergreen stock repurchase program authorizes management to repurchase the Company’s common stock for the primary purpose of funding its stock-based benefit plans. Under the stock repurchase program, the Company may maintain up to 18.4 million repurchased shares in its treasury account at any one time. As of December 31, 2013 and 2012, the Company held approximately 9.9 million and 7.2 million treasury shares, respectively, under this program.
	Revenue Recognition
	The Company recognizes revenue from product sales when goods are shipped and title and risk of loss transfer to its customers. A portion of the Company’s revenue is generated from consigned inventory of breast implants maintained at physician, hospital and clinic locations. These customers are contractually obligated to maintain a specific level of inventory and to notify the Company upon use. Revenue for consigned inventory is recognized at the time the Company is notified by the customer that the product has been used. Notification is usually through the replenishing of the inventory, and the Company periodically reviews consignment inventories to confirm the accuracy of customer reporting.
	The Company generally offers cash discounts to customers for the early payment of receivables. Those discounts are recorded as a reduction of revenue and accounts receivable in the same period that the related sale is recorded. The amounts reserved for cash discounts were $6.3 million and $4.2 million at December 31, 2013 and 2012, respectively. The Company permits returns of product from most product lines by any class of customer if such product is returned in a timely manner, in good condition and from normal distribution channels. Return policies in certain international markets and for certain medical device products, primarily breast implants, provide for more stringent guidelines in accordance with the terms of contractual agreements with customers. Estimated allowances for sales returns are based upon the Company’s historical patterns of product returns matched against sales, and management’s evaluation of specific factors that may increase the risk of product returns. The amount of allowances for sales returns recognized in the Company’s consolidated balance sheets at December 31, 2013 and 2012 were $84.4 million and $77.9 million, respectively, and are recorded in “Other accrued expenses” and “Trade receivables, net” in the Company’s consolidated balance sheets. (See Note 5, “Composition of Certain Financial Statement Captions.”) Actual historical allowances for cash discounts and product returns have been consistent with the amounts reserved or accrued.
	The Company participates in various U.S. federal and state government rebate programs, the largest of which are Medicaid, Medicare and the U.S. Department of Veterans Affairs. The Company also has contracts with various managed care and group purchasing organizations that provide for sales rebates and other contractual discounts. In the United States, the Company also incurs chargebacks, which are reimbursements to wholesalers for honoring contracted prices to third parties. Outside of the United States, the Company incurs sales allowances based on contractual provisions and legislative mandates. The Company also offers rebate and other incentive programs directly to customers for its aesthetic products and certain therapeutic products, including Botox® Cosmetic, the Juvéderm® franchise, Latisse®, Natrelle®, Acuvail®, Aczone®, Sanctura XR® and Restasis®, and for certain other skin care products. Sales rebates and incentive accruals reduce revenue in the same period that the related sale is recorded and are included in “Other accrued expenses” in the Company's consolidated balance sheets. (See Note 5, “Composition of Certain Financial Statement Captions.”) The amounts accrued for sales rebates and other incentive programs were $279.3 million and $269.6 million at December 31, 2013 and 2012, respectively.
	The Company’s procedures for estimating amounts accrued for sales rebates and other incentive programs at the end of any period are based on available quantitative data and are supplemented by management’s judgment with respect to many factors, including but not limited to, current market dynamics, changes in contract terms, changes in sales trends, an evaluation of current laws and regulations and product pricing. Quantitatively, the Company uses historical sales, product utilization and rebate data and applies forecasting techniques in order to estimate the Company’s liability amounts. Qualitatively, management’s judgment is applied to these items to modify, if appropriate, the estimated liability amounts. Additionally, there is a significant time lag between the date the Company determines the estimated liability and when the Company actually pays the liability. Due to this time lag, the Company records adjustments to its estimated liabilities over several periods, which can result in a net increase to earnings or a net decrease to earnings in those periods.
	The Company recognizes license fees, royalties and reimbursement income for services provided as other revenues based on the facts and circumstances of each contractual agreement. In general, the Company recognizes income upon the signing of a contractual agreement that grants rights to products or technology to a third party if the Company has no further obligation to provide products or services to the third party after entering into the contract. The Company recognizes contingent consideration earned from the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved. The Company defers income under contractual agreements when it has further obligations that indicate that a separate earnings process has not been completed.
	Contingent Consideration
	Contingent consideration liabilities represent future amounts the Company may be required to pay in conjunction with various business combinations. The ultimate amount of future payments is based on specified future criteria, such as sales performance and the achievement of certain future development, regulatory and sales milestones and other contractual performance conditions. The Company estimates the fair value of the contingent consideration liabilities related to sales performance using the income approach, which involves forecasting estimated future net cash flows and discounting the net cash flows to their present value using a risk-adjusted rate of return. The Company estimates the fair value of the contingent consideration liabilities related to the achievement of future development and regulatory milestones by assigning an achievement probability to each potential milestone and discounting the associated cash payment to its present value using a risk-adjusted rate of return. The Company estimates the fair value of the contingent consideration liabilities associated with sales milestones by employing Monte Carlo simulations to estimate the volatility and systematic relative risk of revenues subject to sales milestone payments and discounting the associated cash payment amounts to their present values using a credit-risk-adjusted interest rate. The fair value of other contractual performance conditions is measured by assigning an achievement probability to each payment and discounting the payment to its present value using the Company's estimated cost of borrowing. The Company evaluates its estimates of the fair value of contingent consideration liabilities on a periodic basis. Any changes in the fair value of contingent consideration liabilities are recorded through earnings as “Selling, general and administrative” in the Company’s consolidated statements of earnings. The total estimated fair value of contingent consideration liabilities was $225.2 million and $224.3 million at December 31, 2013 and 2012, respectively, and was included in "Other accrued expenses" and "Other liabilities" in the consolidated balance sheets.
	Share-Based Compensation
	The Company recognizes compensation expense for all share-based awards made to employees and directors. The fair value of share-based awards is estimated at the grant date and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period. The fair value of stock option awards that vest based on a service condition is estimated using the Black-Scholes option-pricing model. The fair value of share-based awards that contain a market condition is generally estimated using a Monte Carlo simulation model, and the fair value of modifications to share-based awards is generally estimated using a lattice model.
	Advertising Expenses
	Advertising expenses relating to production costs are expensed as incurred and the costs of television time, radio time and space in publications are expensed when the related advertising occurs. Advertising expenses were approximately $179.7 million, $158.5 million and $168.6 million in 2013, 2012 and 2011, respectively.
	Product Liability Self-Insurance
	As of June 1, 2012, the Company is largely self-insured for future product liability losses related to all of its products. The Company has historically been and continues to be self-insured for any product liability losses related to its breast implant products. The Company maintains third party insurance coverage that it believes is adequate to cover potential product liability losses for injuries alleged to have occurred prior to June 1, 2011 related to Botox® and Botox® Cosmetic and prior to June 1, 2012 related to all of its other products. Future product liability losses are, by their nature, uncertain and are based upon complex judgments and probabilities. The factors to consider in developing product liability reserves include the merits and jurisdiction of each claim, the nature and the number of other similar current and past claims, the nature of the product use and the likelihood of settlement. In addition, the Company accrues for certain potential product liability losses estimated to be incurred, but not reported, to the extent they can be reasonably estimated. The Company estimates these accruals for potential losses based primarily on historical claims experience and data regarding product usage.
	Income Taxes
	The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities along with net operating loss and tax credit carryovers. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.
	Valuation allowances against the Company’s deferred tax assets were $48.9 million and $22.6 million at December 31, 2013 and December 31, 2012, respectively. Changes in the valuation allowances are generally recognized in the provision for income taxes as a component of the estimated annual effective tax rate.
	The Company has not provided for withholding and U.S. taxes for the unremitted earnings of certain non-U.S. subsidiaries because it has currently reinvested these earnings indefinitely in these foreign operations. At December 31, 2013, the Company had approximately $3,828.0 million in unremitted earnings outside the United States for which withholding and U.S. taxes were not provided. Income tax expense would be incurred if these earnings were remitted to the United States. It is not practicable to estimate the amount of the deferred tax liability on such unremitted earnings. Upon remittance, certain foreign countries impose withholding taxes that are then available, subject to certain limitations, for use as credits against the Company’s U.S. tax liability, if any.
	Acquisitions
	The accounting for acquisitions requires extensive use of estimates and judgments to measure the fair value of the identifiable tangible and intangible assets acquired, including in-process research and development, and liabilities assumed. Additionally, the Company must determine whether an acquired entity is considered to be a business or a set of net assets, because the excess of the purchase price over the fair value of net assets acquired can only be recognized as goodwill in a business combination.
	On February 1, 2012, the Company purchased the commercial assets related to the selling and distribution of the Company's products from its distributor in Russia for $3.1 million in cash, net of a $6.6 million pre-existing net receivable from the distributor, and estimated contingent consideration of $4.7 million as of the acquisition date. On December 19, 2012, the Company acquired SkinMedica, Inc. for $348.9 million in cash and contingent consideration with an estimated fair value of $2.2 million as of the acquisition date. On March 1, 2013, the Company acquired MAP Pharmaceuticals, Inc. for an aggregate purchase price of approximately $871.7 million, net of cash acquired. On April 12, 2013, the Company acquired Exemplar Pharma, LLC for an aggregate purchase price of approximately $16.1 million, net of cash acquired. The Company accounted for these acquisitions as business combinations. The tangible and intangible assets acquired and liabilities assumed in connection with these acquisitions were recognized based on their estimated fair values at the acquisition dates. The determination of estimated fair values requires significant estimates and assumptions including, but not limited to, determining the timing and estimated costs to complete the in-process projects, projecting regulatory approvals, estimating future cash flows and developing appropriate discount rates. The Company believes the estimated fair values assigned to the assets acquired and liabilities assumed are based on reasonable assumptions.
	Comprehensive Income (Loss)
	Comprehensive income (loss) encompasses all changes in equity other than those with stockholders and consists of net earnings (losses), foreign currency translation adjustments, certain pension and other postretirement benefit plan adjustments, unrealized gains or losses on marketable equity investments and unrealized and realized gains or losses on derivative instruments, if applicable. The Company does not recognize U.S. income taxes on foreign currency translation adjustments since it does not provide for such taxes on undistributed earnings of foreign subsidiaries.
	Reclassifications
	Certain reclassifications of prior year amounts have been made to conform with the current year presentation.
	On December 2, 2013, the Company completed the sale of its obesity intervention business. Accordingly, the Company has reported the financial results from that business unit as discontinued operations in the consolidated statements of earnings for the year ended December 31, 2013 and the remaining assets related to that business unit as assets of discontinued operations in the consolidated balance sheet as of December 31, 2013. Additionally, the Company has retrospectively revised the consolidated statements of earnings for the years ended December 31, 2012 and 2011 and the consolidated balance sheet as of December 31, 2012 to reflect the financial results from the obesity intervention business unit and the related assets and liabilities as discontinued operations.
	Recently Adopted Accounting Standards
	In February 2013, the Financial Accounting Standards Board (FASB) issued an accounting standards update that requires an entity to report the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amounts are required to be reclassified in their entirety to net income. For other amounts that are not required to be reclassified in their entirety to net income in the same reporting period, an entity is required to cross-reference to other disclosures that provide additional detail about those amounts. This guidance became effective for reporting periods beginning after December 15, 2012, with early adoption permitted. The Company adopted the provisions of the guidance in the first quarter of 2013. The adoption did not have a material impact on the Company’s consolidated financial statements.
	In July 2012, the FASB issued an accounting standards update that gives an entity the option to first assess qualitative factors to determine whether it is more likely than not that an indefinite-lived intangible asset is impaired. If, after assessing the totality of events and circumstances, an entity concludes that it is not more likely than not that the indefinite-lived intangible asset is impaired, then the entity is not required to take further action. This guidance became effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012, with early adoption permitted. The Company adopted the provisions of the guidance in the first quarter of 2013. The adoption did not have a material impact on the Company’s consolidated financial statements.
	New Accounting Standards Not Yet Adopted
	In July 2013, the FASB issued an accounting standards update that requires the netting of unrecognized tax benefits against a deferred tax asset for a loss or other carryforward that would apply in settlement of the uncertain tax positions. This guidance will be effective for fiscal years beginning after December 15, 2013, which will be the Company's fiscal year 2014, with early adoption permitted. The Company currently does not expect the adoption of the guidance will have a material impact on the Company's consolidated financial statements.
	In March 2013, the FASB issued an accounting standards update that provides guidance on the accounting for the cumulative translation adjustment (CTA) upon derecognition of certain subsidiaries or groups of assets within a foreign entity or of an investment in a foreign entity. Under this guidance, an entity should recognize the CTA in earnings based on meeting certain criteria, including when it ceases to have a controlling financial interest in a subsidiary or group of assets within a consolidated foreign entity or upon a sale or transfer that results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets resides. This guidance will be effective for fiscal years beginning on or after December 15, 2013, which will be the Company's fiscal year 2014, with early adoption permitted. The Company currently does not expect the adoption of the guidance will have a material impact on the Company's consolidated financial statements.

Acquisitions_and_Collaboration

Acquisitions and Collaborations	12 Months Ended
	Dec. 31, 2013
Acquisitions and Collaborations [Abstract]	'
Acquisitions and Collaborations	'
	Note 2:  Acquisitions and Collaborations
	MAP Acquisition
	On March 1, 2013, the Company completed the acquisition of MAP Pharmaceuticals, Inc. (MAP), a biopharmaceutical company based in the United States focused on developing and commercializing new therapies in neurology, including Levadex®, an orally inhaled drug for the potential acute treatment of migraine in adults, for an aggregate purchase price of approximately $871.7 million, net of cash acquired. The acquisition was funded from a combination of current cash and equivalents and short-term investments.
	The Company recognized tangible and intangible assets acquired and liabilities assumed in connection with the MAP acquisition based on their estimated fair values at the acquisition date. The excess of the purchase price over the fair value of net assets acquired was recognized as goodwill. The goodwill acquired in the MAP acquisition is not deductible for federal income tax purposes. In connection with the acquisition, the Company acquired assets with a fair value of $1,233.6 million, consisting of current assets of $2.3 million, property, plant and equipment of $7.7 million, other non-current assets of $0.3 million, deferred tax assets of $132.7 million, intangible assets of $915.6 million and goodwill of $175.0 million, and assumed liabilities of $361.9 million, consisting of current liabilities of $27.3 million and deferred tax liabilities of $334.6 million.
	The intangible assets consist of an in-process research and development asset of $683.5 million associated with Levadex®, which is currently under review with the U.S. Food and Drug Administration (FDA), and a core technology asset of $232.1 million associated with MAP's proprietary Tempo® delivery system that has an estimated useful life of 15 years.
	Goodwill represents the excess of the MAP purchase price over the sum of the amounts assigned to assets acquired less liabilities assumed. The MAP acquisition broadens the Company's product offering for the treatment of migraine headaches and MAP's proprietary drug particle and inhalation technology provides the potential for new product development opportunities, which the Company believes support the amount of goodwill recognized as a result of the purchase price paid for MAP, in relation to other acquired tangible and intangible assets.
	Exemplar Acquisition
	On April 12, 2013, the Company completed the acquisition of Exemplar Pharma, LLC (Exemplar), a third party contract manufacturer for MAP's Tempo® delivery system, for an aggregate purchase price of approximately $16.1 million, net of cash acquired. Prior to the acquisition, the Company also had a $1.9 million payable to Exemplar, which was effectively settled upon the acquisition. In connection with the acquisition, the Company acquired assets with a fair value of $16.6 million, consisting of current assets of $0.5 million, property, plant and equipment of $2.1 million and goodwill of $14.0 million, and assumed current liabilities of $0.5 million. The goodwill acquired in the Exemplar acquisition is deductible for federal income tax purposes.
	SkinMedica Acquisition
	On December 19, 2012, the Company completed the acquisition of SkinMedica, Inc. (SkinMedica), a privately-held aesthetics skin care company based in the United States focused on developing and commercializing products that improve the appearance of skin, for an upfront payment of $348.9 million, net of cash acquired. The Company is also required to pay an additional $25.0 million contingent upon acquired products achieving certain sales milestones. The estimated fair value of the contingent consideration as of the acquisition date was $2.2 million. The acquisition was funded from current cash and equivalents balances.
	The Company recognized tangible and intangible assets acquired, liabilities assumed and the contingent consideration liability in connection with the SkinMedica acquisition based on their estimated fair values at the acquisition date. The excess of the purchase price over the fair value of net assets acquired was recognized as goodwill. The goodwill acquired in the SkinMedica acquisition is not deductible for federal income tax purposes. In connection with the acquisition, the Company acquired assets with a fair value of $438.6 million, consisting of current assets of $30.2 million, property, plant and equipment of $6.6 million, deferred tax assets of $40.6 million, intangible assets of $200.9 million and goodwill of $160.3 million, and assumed liabilities of $87.5 million, consisting of current liabilities of $11.5 million and deferred tax liabilities of $76.0 million. As of December 31, 2013, the total estimated fair value of the contingent consideration of $2.2 million was included in “Other liabilities.”
	The intangible assets consist of developed technology, customer relationships, trademarks and an in-process research and development asset. Acquired developed technology assets consist of the currently marketed SkinMedica® family of products, including the TNS® product line, Vaniqa®, Lytera® and scar recovery gel. The amounts assigned to each class of intangible assets and the related weighted average amortization periods are summarized in the following table:
		Value of Intangible Assets Acquired		Weighted
				Average
				Amortization
				Period
		(in millions)		(in years)
	Developed technology	$	87.5	10.6
	Customer relationships	50.6		2.7
	Trademarks	62.5		15
	In-process research and development	0.3		—
		$	200.9
	Goodwill represents the excess of the SkinMedica purchase price over the sum of the amounts assigned to assets acquired less liabilities assumed. The SkinMedica acquisition complements the Company's existing facial aesthetics business and enables the Company to take a leadership position in the growing physician-dispensed topical aesthetics skin care market and to create certain sales and marketing operating synergies, which the Company believes support the amount of goodwill recognized as a result of the purchase price paid for SkinMedica, in relation to other acquired tangible and intangible assets.
	Purchase of Distributor’s Business in Russia
	On February 1, 2012, the Company terminated its existing distributor agreement in Russia and completed the purchase from its distributor of all assets related to the selling and distribution of the Company’s products in Russia. The termination of the existing distributor agreement and purchase of the commercial assets enabled the Company to initiate direct operations for its medical aesthetics and neurosciences businesses in Russia.
	The purchase of the commercial assets was accounted for as a business combination. In connection with the purchase of the assets, the Company paid $3.1 million, net of a $6.6 million pre-existing net receivable from the distributor, and is also required to pay additional contingent consideration based on certain contractual obligations of the former distributor over a two year period from the acquisition date. The estimated fair value of the contingent consideration as of the acquisition date was $4.7 million. The Company acquired assets with a fair value of $14.4 million, consisting of inventories of $2.0 million, intangible assets of $8.6 million and goodwill of $3.8 million. No liabilities were assumed in connection with the purchase. The intangible assets relate to customer relationships that have an estimated useful life of three years and other contractual rights that have an estimated useful life of two years. As of December 31, 2013, the total estimated fair value of the contingent consideration of $2.0 million was included in "Other accrued expenses."
	The Company believes that the fair values assigned to the assets acquired, liabilities assumed and the contingent consideration liabilities were based on reasonable assumptions. The Company’s fair value estimates may change during the allowable measurement period, which is up to one year from the acquisition date, if additional information becomes available.
	Purchase of Noncontrolling Interest in a Subsidiary
	In November 2013, the Company purchased a noncontrolling interest in a subsidiary from a minority shareholder for $18.0 million. The Company accounted for the purchase as an equity transaction and recorded the difference between the cash consideration and the carrying amount of the noncontrolling interest, including its share of accumulated other comprehensive income, as a decrease in additional paid-in capital of $1.3 million.
	Molecular Partners AG Collaboration
	On August 21, 2012, the Company announced that it entered into two separate agreements with Molecular Partners AG to discover, develop, and commercialize proprietary therapeutic DARPin® products for the treatment of serious ophthalmic diseases. The first agreement is an exclusive license agreement for the design, development and commercialization of a potent dual anti-VEGF-A/PDGF-B DARPin® (AGN-151200) and its corresponding backups for the treatment of exudative (wet) age-related macular degeneration and related conditions. The second agreement is an exclusive discovery alliance agreement under which the parties are collaborating to design and develop DARPin® products against selected targets that are implicated in causing serious diseases of the eye. Under the terms of the agreements, the Company made combined upfront payments of $62.5 million to Molecular Partners AG in August 2012, which were recorded as research and development (R&D) expense in the third quarter of 2012 because the technology has not yet achieved regulatory approval. The terms of the agreements also include potential future development, regulatory and sales milestone payments to Molecular Partners AG of up to $1.4 billion, as well as potential future royalty payments.
	On May 4, 2011, the Company announced a license agreement with Molecular Partners AG pursuant to which the Company obtained exclusive global rights in the field of ophthalmology for AGN-150998, a Phase II proprietary therapeutic anti-VEGF DARPin® protein under investigation for the treatment of retinal diseases. Under the terms of the agreement, the Company made a $45.0 million upfront payment to Molecular Partners AG in May 2011, which was recorded as R&D expense in the second quarter of 2011 because the technology has not yet achieved regulatory approval. The terms of the agreement also include potential future development, regulatory and sales milestone payments to Molecular Partners AG of up to $375.0 million, as well as potential future royalty payments.
	Under the exclusive license agreements, subject to certain limited exceptions, the Company is responsible for and incurs all expenses related to the conduct of all development activities; the preparation, filing and maintaining of all regulatory materials; the planning and implementation of all commercial activities; and all manufacturing activities. Under the exclusive discovery alliance agreement, during the research term each party will bear all expenses it incurs to conduct its respective activities, subject to certain limited exceptions. Milestone payments made by the Company to Molecular Partners AG pursuant to these agreements prior to the achievement of regulatory approval are immediately recognized and recorded as R&D expense. Milestone payments, if any, that are made upon, or subsequent to, regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining commercial life of the underlying technology.
	MAP Collaboration
	On January 28, 2011, the Company entered into a collaboration agreement and a co-promotion agreement with MAP for the exclusive development and commercialization by the Company and MAP of Levadex® within the United States to certain headache specialist physicians for the acute treatment of migraine in adults, migraine in adolescents and other indications that may be approved by the parties. Under the terms of the agreements, the Company made a $60.0 million upfront payment to MAP in February 2011, which was recorded as selling, general and administrative (SG&A) expense in the first quarter of 2011. In August 2011, the Company made a $20.0 million milestone payment to MAP for the FDA acceptance of its New Drug Application for Levadex®, which was recorded as SG&A expense in the third quarter of 2011. The upfront and milestone payments were expensed because Levadex® has not yet achieved regulatory approval. On March 1, 2013, the Company completed the acquisition of MAP and has no remaining obligations under the collaboration and co-promotion agreements.
	Medytox Collaboration
	On September 25, 2013, the Company announced that it had entered into a license agreement with Medytox, Inc. (Medytox), contingent on obtaining certain government approvals. In January 2014, the Company closed the transaction. Under the terms of the agreement, the Company made an upfront payment to Medytox of $65.0 million in January 2014 and Medytox granted the Company exclusive rights, worldwide outside of Korea, to develop and, if approved, commercialize certain neurotoxin product candidates currently in development, including a potential liquid-injectable product. The upfront payment of $65.0 million will be recorded as R&D expense in the first quarter of 2014 because the technology has not yet achieved regulatory approval. The terms of the agreement also include potential future development milestone payments of up to $116.5 million and potential future sales milestone payments of up to $180.5 million, as well as potential future royalty payments.
	Other Collaborations
	On September 10, 2013, the Company entered into a license and collaboration agreement with a third party pursuant to which the Company obtained exclusive global rights to research, manufacture and commercialize certain technologies for the treatment of ocular disease. Under the terms of the agreement, the Company made a $6.5 million upfront payment, which was recorded as R&D expense in the third quarter of 2013 because the technology has not yet achieved regulatory approval. The terms of the agreement also include potential future payments to the third party related to the Company’s achievement of development, regulatory and sales milestone events, as well as potential future royalty payments.
	In March 2010, the Company and Serenity Pharmaceuticals, LLC (Serenity) entered into an agreement for the license, development and commercialization of a Phase III investigational drug currently in clinical development for the treatment of nocturia, a common urological disorder in adults characterized by frequent urination at night time. In conjunction with the agreement, the Company made an upfront payment to Serenity of $43.0 million. In December 2010, the Company and Serenity executed a letter agreement which specified terms and conditions governing additional development activities for a new Phase III trial which were not set forth in the original agreement. Under the letter agreement, the Company agreed to share 50% of the cost of additional development activities for the new Phase III trial. Since the Company is providing a significant amount of the funding for the new Phase III trial, it determined that Serenity is a variable interest entity (VIE). However, the Company determined that it is not the primary beneficiary of the VIE because it does not possess the power to direct Serenity’s research and development activities, which are the activities that most significantly impact Serenity’s economic performance. The Company’s maximum future exposure to loss is the Company's share of additional development activities.
	In connection with various business development transactions where the Company has outlicensed its technology to third parties, the Company has aggregate potential future milestone receipts of approximately $55.7 million as of December 31, 2013, none of which are individually significant. Of that amount, approximately $3.5 million relates to achievement of certain development milestones, approximately $17.0 million relates to achievement of certain regulatory milestones, and approximately $35.2 million relates to achievement of certain commercial sales milestones. Due to the challenges associated with developing and obtaining approval for pharmaceutical products, there is substantial uncertainty whether any of the future milestones will be achieved. The Company evaluates whether milestone payments are substantive based on the facts and circumstances associated with each milestone payment.

Discontinued_Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2013
Discontinued Operations and Disposal Groups [Abstract]	'
Discontinued Operations	'
	Note 3:  Discontinued Operations
	On February 1, 2013, the Company formally committed to pursue a sale of its obesity intervention business unit, including the assets related to the Lap-Band® gastric band system and the Orbera™ intra-gastric balloon system. On December 2, 2013, the Company completed the sale of its obesity intervention business to Apollo Endosurgery, Inc. (Apollo) for cash consideration of $75.0 million, subject to certain adjustments, and certain additional consideration, including a minority equity interest in Apollo with an estimated fair value of $15.0 million and contingent consideration of up to $20.0 million to be paid upon the achievement of certain regulatory and sales milestones.
	At the closing date, the cash consideration was reduced by the amount of inventories held outside of the United States of $7.6 million and net trade accounts receivable and payable of $19.4 million, which the Company retained pursuant to the sale and transition services agreements with Apollo. The remaining balance of retained inventories at December 31, 2013 is included in continuing operations and will be sold to Apollo pursuant to the transition services agreements. The Company expects to realize the value of these retained assets in the normal course of business within one year from the closing date.
	As a result of the sale of the obesity intervention business unit, the Company has reported the financial results from that business unit as discontinued operations in the consolidated statements of earnings for the year ended December 31, 2013 and the remaining assets related to that business unit as assets of discontinued operations in the consolidated balance sheet as of December 31, 2013. Additionally, the Company has retrospectively revised the consolidated statements of earnings for the years ended December 31, 2012 and 2011 and the consolidated balance sheet as of December 31, 2012 to reflect the financial results from the obesity intervention business unit and the related assets and liabilities as discontinued operations.
	In 2013, the Company also reported a pre-tax loss of $408.2 million ($297.9 million after tax) on the disposal of the obesity intervention business unit net assets. The pre-tax loss includes transaction costs of approximately $2.6 million, consisting primarily of investment banking fees. The net assets of the obesity intervention unit included a portion of the Company's medical devices reporting unit's goodwill allocated to the obesity intervention business based on the relative fair value as of February 1, 2013 of that business unit to the portion of the medical devices reporting unit that the Company will retain. During 2013, the Company tested the remaining goodwill of the medical devices reporting unit for impairment and concluded that no impairment was indicated.
	The results of operations from discontinued operations presented below include certain allocations that management believes fairly reflect the utilization of services provided to the obesity intervention business. The allocations do not include amounts related to general corporate administrative expenses or interest expense. Therefore, the results of operations from the obesity intervention business unit do not necessarily reflect what the results of operations would have been had the business operated as a stand-alone entity.
	The following table summarizes the results of discontinued operations:
		2013			2012			2011
		(in millions)
	Product net sales	$	114.4		$	159.5		$	203.1
	Operating costs and expenses:
	Cost of sales (excludes amortization of intangible assets)	20.2			24.3			30.7
	Selling, general and administrative	57.9			75.3			88.3
	Research and development	5			12.3			31.3
	Amortization of intangible assets	10.3			41.1			41.5
	Impairment of intangible assets	—			—			16.1
	Restructuring charges	—			4.2			4.7
	Earnings (loss) from discontinued operations before income taxes	21			2.3			(9.5		)
	Provision for income taxes	(6.9		)	(0.5		)	(2.0		)
	Earnings (loss) from discontinued operations, net of income taxes	$	14.1		$	1.8		$	(11.5	)
	Loss on sale of discontinued operations before income taxes	$	(408.2	)	$	—		$	—
	Income tax benefit on sale of discontinued operations	110.3			—			—
	Loss on sale of discontinued operations, net of income taxes	$	(297.9	)	$	—		$	—
	Discontinued operations	$	(283.8	)	$	1.8		$	(11.5	)
	The following table summarizes the assets and liabilities of discontinued operations as of December 31, 2013 and 2012 related to the Company's obesity intervention business unit:
		2013			2012
		(in millions)
	Assets:
	Trade receivables, net	$	9		$	25.2
	Inventories	—			10.6
	Property, plant and equipment, net	—			1.4
	Goodwill	—			105.7
	Intangibles, net	—			369
	Other assets	—			0.7
	Total assets of discontinued operations	$	9		$	512.6
	Liabilities:
	Accounts payable	$	—		$	0.9
	Accrued expenses	—			4.1
	Other liabilities	—			0.3
	Total liabilities of discontinued operations	$	—		$	5.3
	In connection with the sale of the obesity intervention business, the Company also entered into certain transitional service agreements designed to facilitate the orderly transfer of business operations to Apollo. These agreements primarily relate to administrative services in the United States and distribution services outside of the United States, all of which are generally to be provided for a period of up to 12 months. The Company will also manufacture and supply products to Apollo for a transitional period not to exceed 24 months in order to allow Apollo adequate time to obtain regulatory approval for licenses and manufacturing facilities. The continuing cash flows from these agreements are not significant. Net sales made pursuant to the manufacturing and distribution agreements are recorded as product net sales in the Company's consolidated statements of earnings and are reflected as other medical devices product net sales.

Restructuring_Charges_and_Inte

Restructuring Charges and Integration Costs	12 Months Ended
	Dec. 31, 2013
Restructuring and Related Activities [Abstract]	'
Restructuring Charges and Integration Costs	'
	Note 4:  Restructuring Charges and Integration Costs
	In connection with the March 2013 acquisition of MAP, the April 2013 acquisition of Exemplar and the December 2012 acquisition of SkinMedica, the Company initiated restructuring activities to integrate the operations of the acquired businesses with the Company's operations and to capture synergies through the centralization of certain research and development, manufacturing, general and administrative and commercial functions. In 2013, the Company recorded $4.5 million of restructuring charges, primarily consisting of employee severance and other one-time termination benefits for approximately 111 people.
	Included in 2013 and 2012 are $1.0 million and $0.7 million, respectively, of restructuring charges for employee severance and other one-time termination benefits related to the realignment of various business functions. Included in 2012 and 2011 are $0.8 million of restructuring charges and a $0.1 million restructuring charge reversal, respectively, related to restructuring activities initiated in prior years.
	Included in 2013 are $0.1 million of cost of sales and $20.6 million of SG&A expenses related to transaction and integration costs associated with the purchase of various businesses and collaboration agreements. The SG&A expenses primarily consist of investment banking and legal fees. Included in 2012 are $0.1 million of cost of sales and $2.3 million of SG&A expenses related to transaction and integration costs associated with the purchase of various businesses and collaboration agreements. Included in 2011 are $2.6 million of SG&A expenses related to transaction and integration costs associated with the purchase of various businesses and collaboration agreements.
	In addition, the Company incurred $1.7 million of SG&A expenses and $1.1 million of R&D expenses related to the realignment of various business functions in 2013 and $1.5 million of SG&A expenses and $0.3 million of R&D expenses in 2012, respectively. The SG&A and R&D expenses related to the realignment of various business functions primarily consist of one-time termination benefits earned based on specified retention periods and losses on the disposal of fixed assets.

Composition_of_Certain_Financi

Composition of Certain Financial Statement Captions	12 Months Ended
	Dec. 31, 2013
Composition of Certain Financial Statement Captions [Abstract]	'
Composition of Certain Financial Statement Captions	'
	Note 5:  Composition of Certain Financial Statement Captions
		December 31,
		2013			2012
		(in millions)
	Trade receivables, net
	Trade receivables	$	935.4		$	791.4
	Less allowance for sales returns — medical device products	(27.9		)	(28.2		)
	Less allowance for doubtful accounts	(24.2		)	(24.2		)
		$	883.3		$	739
	Inventories
	Finished products	$	180		$	179.9
	Work in process	44.1			41.3
	Raw materials	61.2			51.1
		$	285.3		$	272.3
	Other current assets
	Prepaid expenses	$	157.1		$	149.2
	Deferred taxes	277.9			249.1
	Other	58			50.3
		$	493		$	448.6
	Investments and other assets
	Deferred executive compensation investments	$	100.7		$	81.7
	Capitalized software	36.8			47.3
	Prepaid pensions	5.6			5.7
	Debt issuance costs	10.8			8
	Non-marketable equity investments	20.8			9
	Other	38.5			40.4
		$	213.2		$	192.1
		December 31,
		2013			2012
		(in millions)
	Property, plant and equipment, net
	Land	$	62.2		$	61.9
	Buildings	962.8			884.4
	Machinery and equipment	784.8			708.5
		1,809.80			1,654.80
	Less accumulated depreciation	(886.6		)	(803.3		)
		$	923.2		$	851.5
	Other accrued expenses
	Sales rebates and other incentive programs	$	279.3		$	269.6
	Royalties	26.2			26
	Interest	22			18.2
	Sales returns — specialty pharmaceutical products	56.5			49.7
	Product warranties — breast implant products	7.6			6.7
	Contingent consideration	9.9			59
	Other	196			157.6
		$	597.5		$	586.8
	Other liabilities
	Postretirement benefit plan	$	44.3		$	46.6
	Qualified and non-qualified pension plans	194.5			218.3
	Deferred executive compensation	105.3			85.3
	Deferred income	67			75.1
	Contingent consideration	215.3			165.3
	Product warranties — breast implant products	26			27.7
	Unrecognized tax benefit liabilities	67.7			53.8
	Other	42.1			36.7
		$	762.2		$	708.8
	Accumulated other comprehensive loss
	Foreign currency translation adjustments	$	(29.7	)	$	(25.2	)
	Deferred holding gains on derivative instruments, net of taxes of $1.2 million and $1.7 million for 2013 and 2012, respectively	1.8			2.6
	Actuarial losses not yet recognized as a component of pension and postretirement benefit plan costs, net of taxes of $83.5 million and $106.6 million for 2013 and 2012, respectively	(198.7		)	(222.0		)
		$	(226.6	)	$	(244.6	)
	At December 31, 2013 and 2012, approximately $11.7 million and $9.9 million, respectively, of the Company’s finished goods inventories, primarily breast implants, were held on consignment at a large number of doctors’ offices, clinics and hospitals worldwide. The value and quantity at any one location are not significant. At December 31, 2013 and 2012, approximately $10.3 million and $14.8 million, respectively, of specific reserves for sales returns related to certain genericized eye care pharmaceuticals and urologics products are included in accrued sales returns – specialty pharmaceutical products.

Intangibles_and_Goodwill

Intangibles and Goodwill	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangibles and Goodwill	'
	Note 6:  Intangibles and Goodwill
	Intangibles
	At December 31, 2013 and 2012, the components of intangibles and certain other related information were as follows:
		31-Dec-13								31-Dec-12
		Gross			Accumulated			Weighted		Gross		Accumulated			Weighted
		Amount			Amortization			Average		Amount		Amortization			Average
								Amortization							Amortization
								Period							Period
		(in millions)						(in years)		(in millions)					(in years)
	Amortizable Intangible Assets:
	Developed technology	$	647.7		$	(343.8	)	11.1		$	644.2	$	(284.5	)	11.1
	Customer relationships	54.7			(21.8		)	2.7		54.5		(1.2		)	2.7
	Licensing	185.8			(164.8		)	9.3		185.9		(157.8		)	9.3
	Trademarks	89.6			(29.7		)	12.4		87.9		(25.3		)	12.3
	Core technology	327.5			(66.9		)	14.8		93.8		(46.5		)	14.4
	Other	30.7			(12.8		)	7.6		43.9		(14.1		)	6.4
		1,336.00			(639.8		)	11.4		1,110.20		(529.4		)	10.6
	Unamortizable Intangible Assets:
	In-process research and development	953.8			—					279.3		—
		$	2,289.80		$	(639.8	)			$	1,389.50	$	(529.4	)
	Developed technology consists primarily of current product offerings, primarily breast aesthetics products, dermal fillers, skin care products and eye care products acquired in connection with business combinations, asset acquisitions and initial licensing transactions for products previously approved for marketing. Customer relationship assets consist of the estimated value of relationships with customers acquired in connection with business combinations. Licensing assets consist primarily of capitalized payments to third party licensors related to the achievement of regulatory approvals to commercialize products in specified markets and up-front payments associated with royalty obligations for products that have achieved regulatory approval for marketing. Core technology consists of a drug delivery technology acquired in connection with the Company's 2013 acquisition of MAP, proprietary technology associated with silicone gel breast implants acquired in connection with the Company's 2006 acquisition of Inamed Corporation, dermal filler technology acquired in connection with the Company’s 2007 acquisition of Groupe Cornéal Laboratoires and a drug delivery technology acquired in connection with the Company’s 2003 acquisition of Oculex Pharmaceuticals, Inc. Other intangible assets consist primarily of acquired product registration rights, distributor relationships, distribution rights, government permits, non-compete agreements and a defensive asset associated with developed technology that has been commercialized. The in-process research and development assets consist primarily of an orally inhaled drug for the potential acute treatment of migraine in adults acquired in connection with the Company's 2013 acquisition of MAP and a novel compound to treat erythema associated with rosacea acquired in connection with the Company’s 2011 acquisition of Vicept Therapeutics, Inc. (Vicept) that is currently under development.
	In the fourth quarter of 2013, the Company recorded a pre-tax charge of $11.4 million related to the impairment of an intangible asset for distribution rights acquired in connection with the Company's 2011 acquisition of Precision Light, Inc. as a result of the Company's decision to discontinue the sale of products related to those distribution rights.
	In the fourth quarter of 2012, the Company recorded a pre-tax charge of $17.0 million related to the partial impairment of the in-process research and development asset acquired in connection with the Company’s 2011 acquisition of Vicept. The impairment charge was recognized because the carrying amount of the asset was determined to be in excess of its estimated fair value.
	In the third quarter of 2011, the Company recorded a pre-tax charge of $4.3 million related to the impairment of an in-process research and development asset associated with a tissue reinforcement technology that has not yet achieved regulatory approval acquired in connection with the Company’s 2010 acquisition of Serica Technologies, Inc. The impairment charge was recognized because estimates of the anticipated future undiscounted cash flows of the asset were not sufficient to recover its carrying amount.
	The following table provides amortization expense by major categories of intangible assets for the years ended December 31, 2013, 2012 and 2011, respectively:
		2013			2012			2011
		(in millions)
	Developed technology	$	57.2		$	53.4		$	53.7
	Customer relationships	20.5			1.1			—
	Licensing	7.4			20.4			20.4
	Trademarks	4.4			0.4			1.4
	Core technology	19.4			6.5			6.7
	Other	7.8			8.4			3.9
		$	116.7		$	90.2		$	86.1
	Amortization expense related to intangible assets generally benefits multiple business functions within the Company, such as the Company’s ability to sell, manufacture, research, market and distribute products, compounds and intellectual property. The amount of amortization expense excluded from cost of sales consists primarily of amounts amortized with respect to developed technology and licensing intangible assets.
	Estimated amortization expense is $110.3 million for 2014, $96.7 million for 2015, $76.4 million for 2016, $57.9 million for 2017 and $55.9 million for 2018.
	Goodwill
	Changes in the carrying amount of goodwill by operating segment for the years ended December 31, 2013 and 2012 were as follows:
		Specialty			Medical			Total
		Pharmaceuticals			Devices
		(in millions)
	Balance at December 31, 2011	$	150.1		$	1,832.60		$	1,982.70
	SkinMedica acquisition	142.7			—			142.7
	Purchase of distributor’s business in Russia	3.8			—			3.8
	Foreign exchange translation effects and other	3.2			1.4			4.6
	Balance at December 31, 2012	299.8			1,834.00			2,133.80
	MAP acquisition	175			—			175
	Exemplar acquisition	14			—			14
	SkinMedica acquisition adjustments	17.6			—			17.6
	Foreign exchange translation effects and other	(5.2		)	4.2			(1.0		)
	Balance at December 31, 2013	$	501.2		$	1,838.20		$	2,339.40
	The SkinMedica acquisition adjustments primarily relate to adjusting the assigned fair values associated with deferred tax assets and deferred tax liabilities and a contractual purchase price adjustment of $2.8 million. The Company does not consider the adjustments to be material.

Notes_Payable_and_LongTerm_Deb

Notes Payable and Long-Term Debt	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Notes Payable and Long-Term Debt	'
	Note 7: Notes Payable and Long-Term Debt
		2013		31-Dec-13		2012		31-Dec-12
		Average				Average
		Effective				Effective
		Interest				Interest
		Rate				Rate
				(in millions)				(in millions)
	Bank loans	6.07	%	$	55.6	6.06	%	$	48.8
	Real estate mortgage; maturing 2017	5.65	%	20		5.65	%	20
	Senior notes due 2016	3.94	%	831		3.94	%	843.9
	Senior notes due 2018	1.39	%	249.5		—		—
	Senior notes due 2020	3.41	%	648.7		3.41	%	648.5
	Senior notes due 2023	2.83	%	349.1		—		—
				2,153.90				1,561.20
	Less current maturities			55.6				48.8
	Total long-term debt			$	2,098.30			$	1,512.40
	At December 31, 2013, the Company had a committed long-term credit facility, a commercial paper program, a shelf registration statement that allows the Company to issue additional securities, including debt securities, in one or more offerings from time to time, a real estate mortgage and various foreign bank facilities. The committed long-term credit facility will expire in October 2016. The termination date can be further extended from time to time upon the Company’s request and acceptance by the issuer of the facility for a period of one year from the last scheduled termination date for each request accepted. The committed long-term credit facility allows for borrowings of up to $800.0 million. The commercial paper program also provides for up to $800.0 million in borrowings. However, the combined borrowings under the committed long-term credit facility and the commercial paper program may not exceed $800.0 million in the aggregate. Borrowings under the committed long-term credit facility are subject to certain financial and operating covenants that include, among other provisions, maximum leverage ratios. Certain covenants also limit subsidiary debt. The Company was in compliance with these covenants at December 31, 2013. As of December 31, 2013, the Company had no borrowings under its committed long-term credit facility, $20.0 million in borrowings outstanding under the real estate mortgage, $55.6 million in borrowings outstanding under various foreign bank facilities and no borrowings under the commercial paper program. Commercial paper, when outstanding, is issued at current short-term interest rates. Additionally, any future borrowings that are outstanding under the long-term credit facility may be subject to a floating interest rate. The Company may from time to time seek to retire or purchase its outstanding debt.
	On March 12, 2013, the Company issued concurrently in a registered offering $250.0 million in aggregate principal amount of 1.35% Senior Notes due 2018 (2018 Notes) and $350.0 million in aggregate principal amount of 2.80% Senior Notes due 2023 (2023 Notes).
	The 2018 Notes, which were sold at 99.793% of par value with an effective interest rate of 1.39%, are unsecured and pay interest semi-annually on the principal amount of the notes at a rate of 1.35% per annum, and are redeemable at any time at the Company's option, subject to a make-whole provision based on the present value of remaining interest payments at the time of the redemption. The aggregate outstanding principal amount of the 2018 Notes will be due and payable on March 15, 2018, unless earlier redeemed by the Company. The original discount of approximately $0.5 million and the deferred debt issuance costs associated with the 2018 Notes are being amortized using the effective interest method over the stated term of 5 years.
	The 2023 Notes, which were sold at 99.714% of par value with an effective interest rate of 2.83%, are unsecured and pay interest semi-annually on the principal amount of the notes at a rate of 2.80% per annum, and are redeemable at any time at the Company's option, subject to a make-whole provision based on the present value of remaining interest payments at the time of the redemption, if the redemption occurs prior to December 15, 2022 (three months prior to the maturity of the 2023 Notes). If the redemption occurs on or after December 15, 2022, then such redemption is not subject to the make-whole provision. The aggregate outstanding principal amount of the 2023 Notes will be due and payable on March 15, 2023, unless earlier redeemed by the Company. The original discount of approximately $1.0 million and the deferred debt issuance costs associated with the 2023 Notes are being amortized using the effective interest method over the stated term of 10 years.
	On September 14, 2010, the Company issued its 3.375% Senior Notes due 2020 (2020 Notes) in a registered offering for an aggregate principal amount of $650.0 million. The 2020 Notes, which were sold at 99.697% of par value with an effective interest rate of 3.41%, are unsecured and pay interest semi-annually on the principal amount of the notes at a rate of 3.375% per annum, and are redeemable at any time at the Company’s option, subject to a make-whole provision based on the present value of remaining interest payments at the time of the redemption. The aggregate outstanding principal amount of the 2020 Notes will be due and payable on September 15, 2020, unless earlier redeemed by the Company. The original discount of approximately $2.0 million and the deferred debt issuance costs associated with the 2020 Notes are being amortized using the effective interest method over the stated term of 10 years.
	On April 12, 2006, the Company completed the private placement of its 5.75% Senior Notes due 2016 (2016 Notes) for an aggregate principal amount of $800.0 million. The 2016 Notes, which were sold at 99.717% of par value with an effective interest rate of 5.79%, are unsecured and pay interest semi-annually on the principal amount of the notes at a rate of 5.75% per annum, and are redeemable at any time at the Company’s option, subject to a make-whole provision based on the present value of remaining interest payments at the time of the redemption. The aggregate outstanding principal amount of the 2016 Notes will be due and payable on April 1, 2016, unless earlier redeemed by the Company. The original discount of approximately $2.3 million and the deferred debt issuance costs associated with the 2016 Notes are being amortized using the effective interest method over the stated term of 10 years.
	On January 31, 2007, the Company entered into a nine-year, two month interest rate swap with a $300.0 million notional amount. The swap received interest at a fixed rate of 5.75% and paid interest at a variable interest rate equal to 3-month LIBOR plus 0.368%, and effectively converted $300.0 million of the 2016 Notes to a variable interest rate. Based on the structure of the hedging relationship, the hedge met the criteria for using the short-cut method for a fair value hedge. In September 2012, the Company terminated the interest rate swap and received $54.7 million, which included accrued interest of $3.7 million. Upon termination of the interest rate swap, the Company added the net fair value received of $51.0 million to the carrying value of the 2016 Notes. The amount received for the termination of the interest rate swap is being amortized as a reduction to interest expense over the remaining life of the debt, which effectively fixes the interest rate for the remaining term of the 2016 Notes at 3.94%. As of December 31, 2013 and 2012, the unamortized amount of the terminated interest rate swap included in the carrying value of the 2016 Notes was $31.5 million and $44.6 million, respectively. During 2013, 2012 and 2011, the Company recognized $13.1 million, $13.8 million and $15.0 million, respectively, as a reduction of interest expense due to the effect of the interest rate swap.
	In February 2006, the Company entered into interest rate swap contracts based on 3-month LIBOR with an aggregate notional amount of $800.0 million, a swap period of 10 years and a starting swap rate of 5.198%. The Company entered into these swap contracts as a cash flow hedge to effectively fix the future interest rate for the 2016 Notes. In April 2006, the Company terminated the interest rate swap contracts and received approximately $13.0 million. The total gain was recorded to accumulated other comprehensive loss and is being amortized as a reduction to interest expense over a 10 year period to match the term of the 2016 Notes. During 2013, 2012 and 2011, the Company recognized $1.3 million, respectively, as a reduction of interest expense due to the amortization of deferred holding gains on derivatives designated as cash flow hedges. These amounts were reclassified from accumulated other comprehensive loss. As of December 31, 2013, the remaining unrecognized gain of $3.0 million ($1.8 million, net of tax) is recorded as a component of accumulated other comprehensive loss. The Company expects to reclassify an estimated pre-tax amount of $1.3 million from accumulated other comprehensive loss as a reduction in interest expense during fiscal year 2014 due to the amortization of deferred holding gains on derivatives designated as cash flow hedges.
	The aggregate maturities of total debt obligations, excluding the unamortized amount related to the terminated interest rate swap of $31.5 million, for each of the next five years and thereafter are as follows: $55.6 million in 2014; zero in 2015, $799.5 million in 2016, $20.0 million in 2017, $249.5 million in 2018 and $997.8 million thereafter. Interest incurred of $1.8 million in 2013, $0.9 million in 2012 and $1.0 million in 2011 has been capitalized and included in property, plant and equipment.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Note 8:  Income Taxes
	The components of earnings from continuing operations before income taxes were:
		Year Ended December 31,
		2013				2012				2011
		(in millions)
	U.S.	$	890.1			$	846.8			$	705.5
	Non-U.S.	840.7				684.2				603.7
	Total	$	1,730.80			$	1,531.00			$	1,309.20
	The provision for income taxes consists of the following:
		Year Ended December 31,
		2013				2012				2011
		(in millions)
	Current
	U.S. federal	$	342.4			$	378.3			$	298.2
	U.S. state	24.7				20.4				32.7
	Non-U.S.	152.7				103.9				83.6
	Total current	519.8				502.6				414.5
	Deferred
	U.S. federal	(34.8		)		(72.7		)		(45.8		)
	U.S. state	(12.6		)		0.1				(18.2		)
	Non-U.S.	(14.1		)		0.3				9.1
	Total deferred	(61.5		)		(72.3		)		(54.9		)
	Total	$	458.3			$	430.3			$	359.6
	The current provision for income taxes does not reflect the tax benefit of $37.7 million, $45.7 million and $37.7 million for the years ended December 31, 2013, 2012 and 2011, respectively, related to excess tax benefits from share-based compensation recorded directly to “Additional paid-in capital” in the consolidated balance sheets.
	The reconciliations of the U.S. federal statutory tax rate to the combined effective tax rate follow:
		2013			2012			2011
	Statutory rate of tax expense	35	%		35	%		35	%
	State taxes, net of U.S. tax benefit	0.9			1.1			1.6
	Tax differential on foreign earnings	(9.0	)		(8.8	)		(9.4	)
	Other credits (R&D)	(3.0	)		(0.9	)		(2.0	)
	Tax audit settlements/adjustments	0.8			1.3			1.5
	Other	1.8			0.4			0.8
	Effective tax rate	26.5	%		28.1	%		27.5	%
	On January 2, 2013, the President of the United States signed into law The American Taxpayer Relief Act of 2012. Under prior U.S. law, a taxpayer was entitled to a research tax credit for qualifying amounts paid or incurred on or before December 31, 2011. The 2012 Taxpayer Relief Act extends the research tax credit for two years to December 31, 2013. The extension of the research tax credit is retroactive to January 1, 2012 and includes amounts paid or incurred after December 31, 2011. In fiscal year 2013, the Company has recognized a retroactive benefit of $15.1 million for the U.S. R&D tax credit for fiscal year 2012.
	Withholding and U.S. taxes have not been provided on approximately $3,828.0 million of unremitted earnings of certain non-U.S. subsidiaries because the Company has currently reinvested these earnings indefinitely in such operations, or the U.S. taxes on such earnings will be offset by appropriate credits for foreign income taxes paid. Such earnings would become taxable upon the sale or liquidation of these non-U.S. subsidiaries or upon the remittance of dividends. It is not practicable to estimate the amount of the deferred tax liability on such unremitted earnings. Upon remittance, certain foreign countries impose withholding taxes that are then available, subject to certain limitations, for use as credits against the Company’s U.S. tax liability, if any.
	During the second quarter of 2010 the Company partially settled its U.S. federal income tax audit with the Internal Revenue Service (IRS) for tax years 2003 to 2006 for the Company’s acquired subsidiary, Inamed, which resulted in a total settlement amount of $1.2 million. The Company disagreed with certain positions taken by the IRS in the partially settled audit. The Company proceeded to the IRS administrative Appeals process where final settlement was reached in the second quarter of 2012 for tax years 2003, 2004 and 2006 and partial settlement was reached for tax year 2005 resulting in a total settlement of $1.1 million. During the third quarter of 2013, the Company reached a preliminary settlement for tax year 2005 with the IRS that is pending final review and approval by the U.S. Tax Court. The impact of this settlement is not expected to be material.
	The Company and its domestic subsidiaries file a consolidated U.S. federal income tax return. During the second quarter of 2010, the Company partially settled its U.S. federal income tax audit with the IRS for tax years 2005 and 2006 which resulted in a total settlement amount of $33.5 million, all of which was paid in 2009 as an advanced payment. The Company disagreed with certain positions taken by the IRS in the partially settled audit. The Company proceeded to the IRS administrative Appeals process where resolution was reached and a final determination was received during the third quarter of 2012 resulting in a total settlement of $1.5 million. During the fourth quarter of 2013, the Company signed an agreement with the U.S. and Canadian competent authorities for certain transfer pricing issues covering tax years 2005 through 2011. As a result, all positions have been resolved between the Company and the IRS for tax years 2005 and 2006. However, tax year 2006 will remain open for certain tax attribute carryforwards from the Inamed U.S. federal income tax audit for tax year 2005 mentioned above.
	With respect to the Company's U.S. federal income tax audit with the IRS for tax years 2007 and 2008, all positions have been tentatively resolved between the Company and the IRS with the exception of one position where the Company is pursuing Mutual Agreement Procedures with the U.S. and French competent authorities to seek relief from double taxation. In the fourth quarter of 2013, the Company paid a tax deposit of $19.5 million to the IRS for positions tentatively resolved for these years.
	The Company and its consolidated subsidiaries are currently under examination by the IRS for tax years 2009 and 2010. The Company believes that it has provided adequate accruals for any tax deficiencies or reductions in tax benefits that could result from all open audit years.
	The Company has been pursuing an Advanced Pricing Agreement with the IRS for certain transfer pricing issues covering tax years 2009 through 2013. A tentative agreement has been reached and the Company does not expect any tax benefits from the resolution to be material.
	At December 31, 2013, the Company has net operating loss carryforwards, with various expiration dates, in certain non-U.S. subsidiaries of approximately $76.1 million. The majority of the non-U.S. net operating loss carryforwards is not likely to be realized and has been reduced by a valuation allowance. The Company has U.S. federal and state net operating loss carryforwards of approximately $893.6 million. The state net operating loss carryforwards include $483.9 million that is not likely to be realized and has been reduced by a valuation allowance. Certain of our U.S. net operating losses are subject to limitations under section 382 of the Internal Revenue Code. If not utilized, the U.S. federal and state net operating loss carryforwards will expire between 2014 and 2033.
	At December 31, 2013, the Company has U.S. tax credit carryforwards of approximately $35.6 million and has provided a valuation allowance for $6.9 million of those U.S. tax credit carryforwards. If not utilized, the U.S. tax credit carryforwards will expire between 2014 and 2033.
	The Company has a subsidiary in Costa Rica operating under a local country tax incentive, which provides that the subsidiary will be exempt from income tax until the current tax incentive expires during 2014. The Company expects to qualify for future incentives and tax credits which are anticipated to be comparable to the current incentives for the eight year period from 2014 to 2022.
	Temporary differences and carryforwards/carrybacks which give rise to a significant portion of deferred tax assets and liabilities at December 31, 2013 and 2012 are as follows:
		2013				2012
		(in millions)
	Deferred tax assets
	Net operating losses	$	179.7			$	66.6
	Accrued expenses	130				114.4
	Capitalized expenses	176.5				182.3
	Deferred compensation	47.4				41.7
	Medicare, Medicaid and other accrued health care rebates	80				85
	Postretirement medical benefits	16.6				17.8
	Capitalized intangible assets	38.9				45
	Deferred revenue	19.2				22.3
	Inventory reserves and adjustments	14.5				18.7
	Share-based compensation awards	101.6				90.2
	Unbilled costs	28.3				23
	Pension plans	52.6				66.5
	R&D credits	26.2				12.7
	All other	46.3				30.1
		957.8				816.3
	Less: valuation allowance	(48.9		)		(22.6		)
Total deferred tax assets	908.9				793.7
Deferred tax liabilities
Depreciation	0.1				9.6
Developed and core technology intangible assets	153.5				227.3
In-process R&D	348.6				100.8
Total deferred tax liabilities	502.2				337.7
Net deferred tax assets	$	406.7			$	456
The balances of net current deferred tax assets and net non-current deferred tax assets at December 31, 2013 were $277.9 million and $128.8 million, respectively. The balances of net current deferred tax assets and net non-current deferred tax assets at December 31, 2012 were $249.1 million and $206.9 million, respectively. Net current deferred tax assets are included in “Other current assets” in the Company’s consolidated balance sheets.
The increase in the amount of valuation allowance at December 31, 2013 compared to December 31, 2012 is primarily due to valuation allowances related to net operating loss carryforwards and R&D tax credit carryforwards acquired in the SkinMedica and MAP acquisitions.
Based on the Company's historical pre-tax earnings, management believes it is more likely than not that the Company will realize the benefit of the existing total deferred tax assets at December 31, 2013. Management believes the existing net deductible temporary differences will reverse during periods in which the Company generates net taxable income; however, there can be no assurance that the Company will generate any earnings or any specific level of continuing earnings in future years. Certain tax planning or other strategies could be implemented, if necessary, to supplement income from operations to fully realize recorded tax benefits.
Disclosures for Uncertainty in Income Taxes
The Company classifies interest expense related to uncertainty in income taxes in the consolidated statements of earnings as interest expense. Income tax penalties are recorded in income tax expense, and are not material.
A tabular reconciliation of the total amounts of unrecognized tax benefits at the beginning and end of 2013, 2012 and 2011 is as follows:
	2013				2012				2011
	(in millions)
Balance, beginning of year	$	61.9			$	53			$	32.5
Gross increase as a result of positions taken in a prior year	8.7				20.9				21.8
Gross decrease as a result of positions taken in a prior year	(14.6		)		(12.7		)		(8.5		)
Gross increase as a result of positions taken in current year	23.3				3.4				16.9
Gross decrease as a result of positions taken in current year	—				—				(6.0		)
Decreases related to settlements	(2.0		)		(2.7		)		(3.7		)
Balance, end of year	$	77.3			$	61.9			$	53
The total amount of unrecognized tax benefits at December 31, 2013, 2012 and 2011 that, if recognized, would affect the effective tax rate is $70.5 million, $55.2 million and $44.5 million, respectively.
The total amount of interest expense related to uncertainty in income taxes recognized in the Company’s consolidated statements of earnings is $4.3 million, $2.2 million and $0.5 million for the years ended December 31, 2013, 2012 and 2011, respectively. The total amount of accrued interest expense related to uncertainty in income taxes included in the Company’s consolidated balance sheets is $9.8 million and $10.0 million at December 31, 2013 and 2012, respectively.
The Company expects that during the next 12 months it is reasonably possible that unrecognized tax benefit liabilities related to various audit issues will decrease by approximately $4.0 million to $5.0 million primarily due to settlements of income tax audits and Competent Authority negotiations.
The following tax years remain subject to examination:
Major Jurisdictions	Open Years
U.S. Federal	2005 - 2012
California	2000 - 2012
Brazil	2008 - 2012
Canada	2005 - 2012
France	2011 - 2012
Germany	2012
Italy	2008 - 2012
Ireland	2006 - 2012
Spain	2009 - 2012
United Kingdom	2011 - 2012

Employee_Retirement_and_Other_

Employee Retirement and Other Benefit Plans	12 Months Ended
	Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]	'
Employee Retirement and Other Benefit Plans	'
	Note 9:  Employee Retirement and Other Benefit Plans
	Pension and Postretirement Benefit Plans
	The Company sponsors various qualified defined benefit pension plans covering a substantial portion of its employees. In addition, the Company sponsors two supplemental nonqualified plans covering certain management employees and officers. U.S. pension benefits are based on years of service and compensation during the five highest consecutive earnings years. Foreign pension benefits are based on various formulas that consider years of service, average or highest earnings during specified periods of employment and other criteria.
	The Company also has one retiree health plan that covers U.S. retirees and dependents. Retiree contributions are required depending on the year of retirement and the number of years of service at the time of retirement. Disbursements exceed retiree contributions and the plan currently has no assets. The accounting for the retiree health care plan anticipates future cost-sharing changes to the written plan that are consistent with the Company’s past practice and management’s intent to manage plan costs. The Company’s history of retiree medical plan modifications indicates a consistent approach to increasing the cost sharing provisions of the plan.
	Accounting for Defined Benefit Pension and Other Postretirement Plans
	The Company recognizes on its balance sheet an asset or liability equal to the over- or under-funded benefit obligation of each defined benefit pension and other postretirement plan. Actuarial gains or losses and prior service costs or credits that arise during the period but are not recognized as components of net periodic benefit cost are recognized, net of tax, as a component of other comprehensive income.
	Included in accumulated other comprehensive loss as of December 31, 2013 and 2012 are unrecognized actuarial losses of $288.7 million and $330.0 million, respectively, related to the Company’s pension plans. Of the December 31, 2013 amount, the Company expects to recognize approximately $19.0 million in net periodic benefit cost during 2014. Also included in accumulated other comprehensive loss at December 31, 2013 and 2012 are unrecognized prior service credits of $17.0 million and $19.7 million, respectively, and unrecognized actuarial losses of $12.1 million and $19.0 million, respectively, related to the Company’s retiree health plan. Of the December 31, 2013 amounts, the Company expects to recognize $2.7 million of the unrecognized prior service credits and $0.8 million of the unrecognized actuarial losses in net periodic benefit cost during 2014.
	Components of net periodic benefit cost, change in projected benefit obligation, change in plan assets, funded status, funding policy, fair value of plan assets, assumptions used to determine net periodic benefit cost and estimated future benefit payments are summarized below for the Company’s U.S. and major non-U.S. pension plans and retiree health plan.
	Net Periodic Benefit Cost
	Components of net periodic benefit cost for the years ended 2013, 2012 and 2011 were as follows:
		Pension Benefits											Other Postretirement Benefits
		2013				2012				2011			2013				2012			2011
		(in millions)
	Service cost	$	28.5			$	25.7			$	23.7		$	1.8			$	1.7		$	1.9
	Interest cost	46.2				43.8				42.6			2				1.9			2.6
	Expected return on plan assets	(45.0		)		(43.4		)		(44.3		)	—				—			—
	Amortization of prior service costs (credits)	—				—				0.1			(2.7		)		(2.7		)	(1.6		)
	Recognized net actuarial losses	31				27				17.3			1.4				1.3			1.1
	Net periodic benefit cost	$	60.7			$	53.1			$	39.4		$	2.5			$	2.2		$	4
	Benefit Obligation, Change in Plan Assets and Funded Status
	The table below presents components of the change in projected benefit obligation, change in plan assets and funded status at December 31, 2013 and 2012.
		Pension Benefits								Other Postretirement Benefits
		2013				2012				2013			2012
		(in millions)
	Change in Projected Benefit Obligation
	Projected benefit obligation, beginning of year	$	1,084.60			$	933.2			$	47.9		$	42.5
	Service cost	28.5				25.7				1.8			1.7
	Interest cost	46.2				43.8				2			1.9
	Participant contributions	1.5				1.5				—			—
	Plan changes	(1.0		)		(1.6		)		—			—
	Actuarial (gains) losses	(25.7		)		93.3				(5.4		)	2.5
	Benefits paid	(19.8		)		(17.9		)		(0.5		)	(0.7		)
	Impact of foreign currency translation	11.3				6.6				—			—
	Projected benefit obligation, end of year	1,125.60				1,084.60				45.8			47.9
	Change in Plan Assets
	Fair value of plan assets, beginning of year	869.3				729.9				—			—
	Actual return on plan assets	31.3				103				—			—
	Company contributions	42.3				47.1				0.5			0.7
	Participant contributions	1.5				1.5				—			—
	Benefits paid	(19.8		)		(17.9		)		(0.5		)	(0.7		)
	Impact of foreign currency translation	9.3				5.7				—			—
	Fair value of plan assets, end of year	933.9				869.3				—			—
	Funded status of plans	$	(191.7	)		$	(215.3	)		$	(45.8	)	$	(47.9	)
	In June 2011, the Company made certain changes to its U.S. retiree health plan to incorporate health reimbursement arrangement accounts, transition plan participants to individual plans and cap future medical premium subsidies. In connection with the changes, the Company remeasured its retiree health plan liability resulting in a net reduction of accrued benefit costs associated with the plan of $20.5 million, including the impact of plan changes and a change in actuarial assumptions, a decrease in related deferred tax assets of $7.4 million, and an increase in net other comprehensive income of $13.1 million.
	Net accrued benefit costs for pension plans and other postretirement benefits are reported in the following components of the Company’s consolidated balance sheet at December 31, 2013 and 2012:
		Pension Benefits								Other Postretirement Benefits
		2013				2012				2013			2012
		(in millions)
	Investments and other assets	$	5.6			$	5.7			$	—		$	—
	Accrued compensation	(2.8		)		(2.7		)		(1.5		)	(1.3		)
	Other liabilities	(194.5		)		(218.3		)		(44.3		)	(46.6		)
	Net accrued benefit costs	$	(191.7	)		$	(215.3	)		$	(45.8	)	$	(47.9	)
	The accumulated benefit obligation for the Company’s U.S. and major non-U.S. pension plans was $1,018.0 million and $987.3 million at December 31, 2013 and 2012, respectively.
	The projected benefit obligation, accumulated benefit obligation and fair value of plan assets for pension plans with a projected benefit obligation in excess of the fair value of plan assets and pension plans with accumulated benefit obligations in excess of the fair value of plan assets at December 31, 2013 and 2012 were as follows:
		Projected Benefit								Accumulated
		Obligation								Benefit
		Exceeds								Obligation
		the Fair Value of								Exceeds the Fair
		Plan Assets								Value of
										Plan Assets
		2013				2012				2013			2012
		(in millions)
	Projected benefit obligation	$	1,098.40			$	1,061.60			$	327.5		$	980.9
Accumulated benefit obligation	992.3				965.8				283.5			900.7
Fair value of plan assets	901.1				840.6				156.6			762.7
The Company’s funding policy for its funded pension plans is based upon the greater of: (i) annual service cost, administrative expenses and a seven year amortization of any funded deficit or surplus relative to the projected pension benefit obligations or (ii) local statutory requirements. The Company’s funding policy is subject to certain statutory regulations with respect to annual minimum and maximum company contributions. Plan benefits for the nonqualified plans are paid as they come due. In 2014, the Company expects to pay contributions of between $30.0 million and $40.0 million for its U.S. and non-U.S. pension plans and between $1.0 million and $2.0 million for its other postretirement plan (unaudited).
Fair Value of Plan Assets
The Company measures the fair value of plan assets based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy described in Note 12, “Fair Value Measurements.”
The table below presents total plan assets by investment category as of December 31, 2013 and 2012 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value:
	December 31, 2013
	Total				Level 1				Level 2			Level 3
	(in millions)
Cash and Equivalents	$	16.9			$	—			$	16.9		$	—
Equity Securities
U.S. small-cap growth	26.1				26.1				—			—
U.S. large-cap index	65.3				65.3				—			—
International equities	212.7				212.7				—			—
Fixed Income Securities
U.S. Treasury bonds	86.5				—				86.5			—
Global corporate bonds	385.1				—				385.1			—
International bond funds	91.4				—				91.4			—
Global corporate bond funds	20.4				20.4				—			—
International government bond funds	29.5				29.5				—			—
	$	933.9			$	354			$	579.9		$	—
	December 31, 2012
	Total				Level 1				Level 2			Level 3
	(in millions)
Cash and Equivalents	$	16.2			$	—			$	16.2		$	—
Equity Securities
U.S. small-cap growth	26.5				26.5				—			—
U.S. large-cap index	74				74				—			—
International equities	201.4				201.4				—			—
Fixed Income Securities
U.S. Treasury bonds	87.3				—				87.3			—
Global corporate bonds	345.4				—				345.4			—
International bond funds	82.6				—				82.6			—
Global corporate bond funds	14.6				14.6				—			—
International government bond funds	21.3				21.3				—			—
	$	869.3			$	337.8			$	531.5		$	—
The Company’s target asset allocation for both its U.S. and non-U.S. pension plans’ assets is 30% equity securities and 70% fixed income securities. Risk tolerance on invested pension plan assets is established through careful consideration of plan liabilities, plan funded status and corporate financial condition. Investment risk is measured and monitored on an ongoing basis through annual liability measures, periodic asset/liability studies and quarterly investment portfolio reviews.
Assumptions
The weighted-average assumptions used to determine net periodic benefit cost and projected benefit obligation were as follows:
	Pension Benefits									Other
										Postretirement Benefits
	2013			2012			2011			2013		2012			2011
For Determining Net Periodic Benefit Cost
U.S. Plans:
Discount rate	4.23	%		4.63	%		5.51	%		4.21	%	4.6	%		5.56	%
Expected return on plan assets	6.25	%		6.75	%		7.25	%		—		—			—
Rate of compensation increase	4	%		4	%		4	%		—		—			—
Non-U.S. Pension Plans:
Discount rate	4.55	%		5.14	%		5.57	%
Expected return on plan assets	4.36	%		4.8	%		5.7	%
Rate of compensation increase	2.89	%		3.04	%		3.1	%
For Determining Projected Benefit Obligation
U.S. Plans:
Discount rate	5.05	%		4.23	%					5.02	%	4.21	%
Rate of compensation increase	4	%		4	%					—		—
Non-U.S. Pension Plans:
Discount rate	4.19	%		4.55	%
Rate of compensation increase	2.94	%		2.89	%
Under the current terms of the U.S. retiree health plan, the annual increase in the Company's subsidy to each retiree is capped at the lesser of 3.0% or the rate of medical inflation. The assumed annual increase in medical inflation is 3.0% for the duration of the plan. A one percentage point decrease in the assumed medical inflation rate would result in a $5.7 million reduction in postretirement benefit obligation and a $0.5 million reduction in service and interest cost components of the net periodic benefit cost for postretirement benefits.
For the U.S. qualified pension plan and the non-U.S. funded pension plans, the expected return on plan assets was determined using a building block approach that considers diversification and rebalancing for a long-term portfolio of invested assets. Historical market returns are studied and long-term historical relationships between equities and fixed income are preserved in a manner consistent with the widely-accepted capital market principle that assets with higher volatility generate a greater return over the long run. Current market factors such as inflation and interest rates are also evaluated before long-term capital market assumptions are determined. The Company’s pension plan assets are managed by outside investment managers using a total return investment approach whereby a mix of equities and debt securities investments are used to maximize the long-term rate of return on plan assets, and the Company utilizes a liability driven investment strategy to reduce financial volatility in the funded pension plans over time. The Company’s overall expected long-term rate of return on assets for 2014 is 6.25% for its U.S. funded pension plan and 4.56% for its non-U.S. funded pension plans.
Estimated Future Benefit Payments
Estimated benefit payments over the next 10 years for the Company’s U.S. and major non-U.S. pension plans and retiree health plan are as follows:
	Pension				Other
	Benefits				Postretirement
					Benefits
	(in millions)
2014	$	27.1			$	1.5
2015	30.1				1.7
2016	33.4				2
2017	37.3				2.3
2018	40.7				2.5
2019 – 2023	261.6				15.9
	$	430.2			$	25.9
Savings and Investment Plan
The Company has a Savings and Investment Plan, which allows all U.S. employees to become participants upon employment. In 2013, 2012 and 2011, participants’ contributions, up to 4% of compensation, generally qualified for a 100% Company match. Company contributions are used to purchase various investment funds at the participants’ discretion. The Company’s cost of the plan was $23.0 million, $19.9 million and $18.7 million in 2013, 2012 and 2011, respectively.
In addition, the Company has a Company sponsored retirement contribution program under the Savings and Investment Plan, which provides all U.S. employees hired after September 30, 2002 with at least six months of service and certain other employees who previously elected to participate in the Company sponsored retirement contribution program under the Savings and Investment Plan, a Company provided retirement contribution of 5% of annual pay if they are employed on the last day of each calendar year. Participating employees who receive the 5% Company retirement contribution do not accrue benefits under the Company’s defined benefit pension plan. The Company’s cost of the retirement contribution program under the Savings and Investment Plan was $25.6 million, $23.0 million and $19.6 million in 2013, 2012 and 2011, respectively.

Employee_Stock_Plans

Employee Stock Plans	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Employee Stock Plans	'
	Note 10:  Employee Stock Plans
	The Company has an incentive award plan that provides for the granting of non-qualified stock options, incentive stock options, stock appreciation rights, performance shares, restricted stock and restricted stock units to officers, key employees and non-employee directors.
	Stock option grants to officers and key employees under the incentive award plan are generally granted at an exercise price equal to the fair market value at the date of grant, generally expire ten years after their original date of grant and generally become vested and exercisable at a rate of 25% per year beginning twelve months after the date of grant. Restricted share awards to officers and key employees generally become fully vested and free of restrictions four years from the date of grant, except for restricted stock grants pursuant to the Company’s executive bonus plan, which generally become fully vested and free of restrictions two years from the date of grant.
	Restricted share awards to non-employee directors generally vest and become free of restrictions twelve months after the date of grant.
	At December 31, 2013, the aggregate number of shares available for future grant under the incentive award plan for stock options and restricted share awards was approximately 19.5 million shares.
	Share-Based Award Activity and Balances
	The following table summarizes the Company’s stock option activity:
		2013							2012					2011
		Number			Weighted				Number			Weighted		Number		Weighted
		of			Average				of			Average		of		Average
		Shares			Exercise				Shares			Exercise		Shares		Exercise
					Price							Price				Price
		(in thousands, except option exercise price and fair value data)
	Outstanding, beginning of year	21,567			$	65			22,651			$	57.47	23,856		$	51.5
	Options granted	4,511			105.38				4,372			88.01		5,007		75.95
	Options exercised	(3,187	)		57.36				(4,928	)		50.02		(5,496	)	48.01
	Options cancelled	(874	)		89.29				(528	)		72.39		(716	)	60.35
	Outstanding, end of year	22,017			73.41				21,567			65		22,651		57.47
	Exercisable, end of year	12,051			59.52				10,906			56.25		12,414		53.05
	Weighted average per share fair value of options granted during the year				$	27.58						$	22.45			$	23.3
	The aggregate intrinsic value of stock options exercised in 2013, 2012 and 2011 was $149.7 million, $202.4 million and $172.5 million, respectively.
	As of December 31, 2013, the weighted average remaining contractual life of options outstanding and options exercisable are 6.3 years and 4.7 years, respectively, and based on the Company’s closing year-end stock price of $111.08 at December 31, 2013, the aggregate intrinsic value of options outstanding and options exercisable are $829.4 million and $621.4 million, respectively. Upon exercise of stock options, the Company generally issues shares from treasury stock.
	The following table summarizes the Company’s restricted share activity:
		2013							2012					2011
		Number			Weighted				Number			Weighted		Number		Weighted
		of			Average				of			Average		of		Average
		Shares			Grant-Date				Shares			Grant-Date		Shares		Grant-Date
					Fair Value							Fair Value				Fair Value
		(in thousands, except fair value data)
	Restricted share awards, beginning of year	1,165			$	67.08			1,035			$	57.38	886		$	51.2
	Shares granted	178			104.66				360			88.75		277		76.52
	Shares vested	(406	)		48.2				(198	)		57.22		(87	)	56.12
	Shares cancelled	(62	)		78.69				(32	)		59.87		(41	)	54.45
	Restricted share awards, end of year	875			76.59				1,165			67.08		1,035		57.38
	Restricted share awards granted in 2012 include a grant to the Company's Chief Executive Officer of restricted stock units that have both market-based and service-based vesting conditions. The terms of the award allow for up to 165,000 shares of the Company's common stock to be earned if the Company's stock price meets certain thresholds and the Chief Executive Officer remains employed with the Company for five years from the date of grant.
	The total fair value of restricted shares that vested was $43.0 million in 2013, $17.9 million in 2012 and $6.9 million in 2011, respectively.
	Valuation and Expense Recognition of Share-Based Awards
	The Company accounts for the measurement and recognition of compensation expense for all share-based awards made to the Company’s employees and directors based on the estimated fair value of the awards.
	The following table summarizes share-based compensation expense by award type for the years ended December 31, 2013, 2012 and 2011, respectively:
		2013				2012				2011
		(in millions)
	Employee and director stock options	$	90.1			$	81.1			$	64.3
	Employee and director restricted share awards	16.4				19.4				14.8
	Stock contributed to employee benefit plans	6.2				6.1				5.7
	Pre-tax share-based compensation expense	112.7				106.6				84.8
	Income tax benefit	(35.8		)		(34.6		)		(28.0		)
	Net share-based compensation expense	$	76.9			$	72			$	56.8
	The following table summarizes pre-tax share-based compensation expense by expense category for the years ended December 31, 2013, 2012 and 2011, respectively:
		2013				2012				2011
		(in millions)
	Cost of sales	$	9.4			$	9			$	7.8
	Selling, general and administrative	74.1				70.1				55.3
	Research and development	29.2				27.5				21.7
	Pre-tax share-based compensation expense	$	112.7			$	106.6			$	84.8
	The fair value of stock option awards that vest based solely on a service condition is estimated using the Black-Scholes option-pricing model. The fair value of share-based awards that contain a market condition is generally estimated using a Monte Carlo simulation model, and the fair value of modifications to share-based awards is generally estimated using a lattice model.
	The determination of fair value using the Black-Scholes, Monte Carlo simulation and lattice models is affected by the Company’s stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk-free interest rate, expected dividends and projected employee stock option exercise behaviors. Stock options granted during 2013, 2012 and 2011 were valued using the Black-Scholes option-pricing model with the following weighted-average assumptions:
		2013			2012			2011
	Expected volatility	26.22	%		25.65	%		27.82	%
	Risk-free interest rate	1.05	%		1.07	%		2.54	%
	Expected dividend yield	0.2	%		0.26	%		0.32	%
	Expected option life (in years)	5.73			5.73			5.85
	The Company estimates its stock price volatility based on an equal weighting of the Company’s historical stock price volatility and the average implied volatility of at-the-money options traded in the open market. The risk-free interest rate assumption is based on observed interest rates for the appropriate term of the Company’s stock options. The Company does not target a specific dividend yield for its dividend payments but is required to assume a dividend yield as an input to the Black-Scholes option-pricing model. The dividend yield assumption is based on the Company’s history and an expectation of future dividend amounts. The expected option life assumption is estimated based on actual historical exercise activity and assumptions regarding future exercise activity of unexercised, outstanding options.
	Share-based compensation expense is recognized only for those awards that are ultimately expected to vest. An estimated forfeiture rate has been applied to unvested awards for the purpose of calculating compensation cost. Forfeitures were estimated based on historical experience. These estimates are revised, if necessary, in future periods if actual forfeitures differ from the estimates. Changes in forfeiture estimates impact compensation cost in the period in which the change in estimate occurs. Compensation expense for share-based awards based on a service condition is recognized over the vesting period using the straight-line single option method.
As of December 31, 2013, total compensation cost related to non-vested stock options and restricted stock not yet recognized was approximately $202.2 million, which is expected to be recognized over the next 46 months (30 months on a weighted-average basis). The Company has not capitalized as part of inventory any share-based compensation costs because such costs were negligible as of December 31, 2013, 2012 and 2011.

Financial_Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Financial Instruments	'
	Note 11:  Financial Instruments
	In the normal course of business, operations of the Company are exposed to risks associated with fluctuations in interest rates and foreign currency exchange rates. The Company addresses these risks through controlled risk management that includes the use of derivative financial instruments to economically hedge or reduce these exposures. The Company does not enter into derivative financial instruments for trading or speculative purposes.
	The Company has not experienced any losses to date on its derivative financial instruments due to counterparty credit risk.
	The Company assesses the adequacy and effectiveness of its interest rate and foreign exchange hedge positions by continually monitoring its interest rate swap and foreign exchange forward and option positions both on a stand-alone basis and in conjunction with its underlying interest rate and foreign currency exposures, from an accounting and economic perspective.
	However, given the inherent limitations of forecasting and the anticipatory nature of the exposures intended to be hedged, the Company cannot assure that such programs will offset more than a portion of the adverse financial impact resulting from unfavorable movements in either interest or foreign exchange rates. In addition, the timing of the accounting for recognition of gains and losses related to mark-to-market instruments for any given period may not coincide with the timing of gains and losses related to the underlying economic exposures and, therefore, may adversely affect the Company’s consolidated operating results and financial position.
	Interest Rate Risk Management
	The Company’s interest income and expense are more sensitive to fluctuations in the general level of U.S. interest rates than to changes in rates in other markets. Changes in U.S. interest rates affect the interest earned on cash and equivalents and short-term investments and interest expense on debt, as well as costs associated with foreign currency contracts. For a discussion of the Company’s interest rate swap activities, see Note 7, “Notes Payable and Long-Term Debt.”
	Foreign Exchange Risk Management
	Overall, the Company is a net recipient of currencies other than the U.S. dollar and, as such, benefits from a weaker dollar and is adversely affected by a stronger dollar relative to major currencies worldwide. Accordingly, changes in exchange rates, and in particular a strengthening of the U.S. dollar, may negatively affect the Company’s consolidated revenues or operating costs and expenses as expressed in U.S. dollars.
	From time to time, the Company enters into foreign currency option and forward contracts to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on its core business issues. Accordingly, the Company enters into various contracts which change in value as foreign exchange rates change to economically offset the effect of changes in the value of foreign currency assets and liabilities, commitments and anticipated foreign currency denominated sales and operating expenses. The Company enters into foreign currency option and forward contracts in amounts between minimum and maximum anticipated foreign exchange exposures, generally for periods not to exceed 24 months. The Company does not designate these derivative instruments as accounting hedges.
	The Company uses foreign currency option contracts, which provide for the sale or purchase of foreign currencies to economically hedge the currency exchange risks associated with probable but not firmly committed transactions that arise in the normal course of the Company’s business. Probable but not firmly committed transactions are comprised primarily of sales of products and purchases of raw material in currencies other than the U.S. dollar. The foreign currency option contracts are entered into to reduce the volatility of earnings generated in currencies other than the U.S. dollar. While these instruments are subject to fluctuations in value, such fluctuations are anticipated to offset changes in the value of the underlying exposures.
	Changes in the fair value of open foreign currency option contracts and any realized gains (losses) on settled contracts are recorded through earnings as “Other, net” in the accompanying consolidated statements of earnings. During 2013, 2012 and 2011, the Company recognized realized gains on settled foreign currency option contracts of $6.4 million, $14.2 million and $2.2 million, respectively, and net unrealized gains (losses) on open foreign currency option contracts of $10.4 million, $(15.3) million and $11.1 million, respectively. The premium costs of purchased foreign exchange option contracts are recorded in “Other current assets” and amortized to “Other, net” over the life of the options.
	All of the Company’s outstanding foreign exchange forward contracts are entered into to offset the change in value of certain intercompany receivables or payables that are subject to fluctuations in foreign currency exchange rates. The realized and unrealized gains and losses from foreign currency forward contracts and the revaluation of the foreign denominated intercompany receivables or payables are recorded through “Other, net” in the accompanying consolidated statements of earnings. During 2013, 2012 and 2011, the Company recognized total realized and unrealized gains (losses) from foreign exchange forward contracts of $5.3 million, $(0.9) million and $(2.5) million, respectively.
	The fair value of outstanding foreign exchange option and forward contracts, collectively referred to as foreign currency derivative financial instruments, are recorded in “Other current assets” and “Accounts payable.” At December 31, 2013 and 2012, foreign currency derivative assets associated with the foreign exchange option contracts of $20.2 million and $9.9 million, respectively, were included in “Other current assets.” At December 31, 2013 and 2012, net foreign currency derivative assets associated with the foreign exchange forward contracts of $0.2 million and $0.3 million, respectively, were included in “Other current assets.”
	At December 31, 2013 and 2012, the notional principal and fair value of the Company’s outstanding foreign currency derivative financial instruments were as follows:
		2013				2012
		Notional		Fair		Notional		Fair
		Principal		Value		Principal		Value
		(in millions)
	Foreign currency forward exchange contracts	$	35	$	0.1	$	44.6	$	0.3
	(Receive U.S. dollar/pay foreign currency)
	Foreign currency forward exchange contracts	41.3		0.1		39.6		—
	(Pay U.S. dollar/receive foreign currency)
	Foreign currency sold — put options	560.8		20.2		501.6		9.9
	The notional principal amounts provide one measure of the transaction volume outstanding as of December 31, 2013 and 2012, and do not represent the amount of the Company’s exposure to market loss. The estimates of fair value are based on applicable and commonly used pricing models using prevailing financial market information as of December 31, 2013 and 2012. The amounts ultimately realized upon settlement of these financial instruments, together with the gains and losses on the underlying exposures, will depend on actual market conditions during the remaining life of the instruments.
	Other Financial Instruments
	At December 31, 2013 and 2012, the Company’s other financial instruments included cash and equivalents, short-term investments, trade receivables, non-marketable equity investments, accounts payable and borrowings. The carrying amount of cash and equivalents, short-term investments, trade receivables and accounts payable approximates fair value due to the short-term maturities of these instruments. The fair value of non-marketable equity investments, which represent investments in start-up companies, are estimated based on information provided by these companies. The fair value of notes payable and long-term debt are estimated based on quoted market prices and interest rates.
	The carrying amount and estimated fair value of the Company’s other financial instruments at December 31, 2013 and 2012 were as follows:
		2013				2012
		Carrying		Fair		Carrying		Fair
		Amount		Value		Amount		Value
		(in millions)
	Cash and equivalents	$	3,046.10	$	3,046.10	$	2,701.80	$	2,701.80
	Short-term investments	603		603		260.6		260.6
	Non-current non-marketable equity investments	20.8		20.8		9		9
	Notes payable	55.6		55.6		48.8		48.8
	Long-term debt	2,098.30		2,163.80		1,512.40		1,673.00
	In 2013 and 2011, the Company recorded impairment charges of $3.7 million and $3.2 million, respectively, included in "Other, net" non-operating expense due to the other than temporary decline in value of a non-marketable equity investment.
	Concentration of Credit Risk
	Financial instruments that potentially subject the Company to credit risk principally consist of trade receivables. Wholesale distributors, major retail chains and managed care organizations account for a substantial portion of trade receivables. This risk is limited due to the number of customers comprising the Company’s customer base, and their geographic dispersion. At December 31, 2013, no single customer represented more than 10% of trade receivables, net. Ongoing credit evaluations of customers’ financial condition are performed and, generally, no collateral is required. The Company has purchased an insurance policy intended to reduce the Company’s exposure to potential credit risks associated with certain U.S. customers. To date, no claims have been made against the insurance policy. The Company maintains reserves for potential credit losses and such losses, in the aggregate, have not historically exceeded management’s estimates.

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	Note 12:  Fair Value Measurements
	The Company measures fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.
	Assets and Liabilities Measured at Fair Value on a Recurring Basis
	As of December 31, 2013 and 2012, the Company has certain assets and liabilities that are required to be measured at fair value on a recurring basis. These include cash equivalents, short-term investments, foreign exchange derivatives, deferred executive compensation investments and liabilities and contingent consideration liabilities. These assets and liabilities are classified in the table below in one of the three categories of the fair value hierarchy described above.
		December 31, 2013
		Total			Level 1			Level 2		Level 3
		(in millions)
	Assets
	Commercial paper	$	2,016.80		$	—		$	2,016.80	$	—
	Foreign time deposits	370.3			—			370.3		—
	Other cash equivalents	1,080.40			—			1,080.40		—
	Foreign exchange derivative assets	20.4			—			20.4		—
	Deferred executive compensation investments	100.7			80.4			20.3		—
		$	3,588.60		$	80.4		$	3,508.20	$	—
	Liabilities
	Deferred executive compensation liabilities	$	93		$	72.7		$	20.3	$	—
	Contingent consideration liabilities	225.2			—			—		225.2
		$	318.2		$	72.7		$	20.3	$	225.2
		December 31, 2012
		Total			Level 1			Level 2		Level 3
		(in millions)
	Assets
	Commercial paper	$	1,709.00		$	—		$	1,709.00	$	—
	Foreign time deposits	341.7			—			341.7		—
	Other cash equivalents	685			—			685		—
	Foreign exchange derivative assets	10.2			—			10.2		—
	Deferred executive compensation investments	81.7			66.8			14.9		—
		$	2,827.60		$	66.8		$	2,760.80	$	—
	Liabilities
	Deferred executive compensation liabilities	73.5			58.6			14.9		—
	Contingent consideration liabilities	224.3			—			—		224.3
		$	297.8		$	58.6		$	14.9	$	224.3
	Cash equivalents consist of commercial paper, foreign time deposits and other cash equivalents. Other cash equivalents consist primarily of money-market fund investments. Short-term investments consist of commercial paper and foreign time deposits. Cash equivalents and short-term investments are valued at cost, which approximates fair value due to the short-term maturities of these instruments. Foreign currency derivative assets and liabilities are valued using quoted forward foreign exchange prices and option volatility at the reporting date. The Company believes the fair values assigned to its derivative instruments as of December 31, 2013 and 2012 are based upon reasonable estimates and assumptions. Assets and liabilities related to deferred executive compensation consist of actively traded mutual funds classified as Level 1 and money-market funds classified as Level 2.
	Contingent consideration liabilities represent future amounts the Company may be required to pay in conjunction with various business combinations. The ultimate amount of future payments is based on specified future criteria, such as sales performance and the achievement of certain future development, regulatory and sales milestones and other contractual performance conditions. The Company evaluates its estimates of the fair value of contingent consideration liabilities on a periodic basis. Any changes in the fair value of contingent consideration liabilities are recorded as SG&A expense.
	The Company estimates the fair value of the contingent consideration liabilities related to sales performance using the income approach, which involves forecasting estimated future net cash flows and discounting the net cash flows to their present value using a risk-adjusted rate of return. The Company estimates the fair value of the contingent consideration liabilities related to the achievement of future development and regulatory milestones by assigning an achievement probability to each potential milestone and discounting the associated cash payment to its present value using a risk-adjusted rate of return. The Company estimates the fair value of the contingent consideration liabilities associated with sales milestones by employing Monte Carlo simulations to estimate the volatility and systematic relative risk of revenues subject to sales milestone payments and discounting the associated cash payment amounts to their present values using a credit-risk-adjusted interest rate. The fair value of other contractual performance conditions is measured by assigning an achievement probability to each payment and discounting the payment to its present value using the Company's estimated cost of borrowing. The unobservable inputs to the valuation models that have the most significant effect on the fair value of the Company's contingent consideration liabilities are the probabilities that certain in-process development projects will meet specified development milestones, including ultimate approval by the FDA. The Company currently estimates that the probabilities of success in meeting the specified development milestones are between 65% and 75%.
	The following table provides a reconciliation of the change in the contingent consideration liabilities for the years ended December 31, 2013 and 2012:
		2013			2012
		(in million)
	Balance, beginning of year	$	224.3		$	214.6
	Additions during the period related to business combinations	—			6.9
	Change in the estimated fair value of the contingent consideration liabilities	70.7			5.4
	Payments made during the period	(61.2		)	(5.1		)
	Foreign exchange translation effects	(8.6		)	2.5
	Balance, end of year	$	225.2		$	224.3
	The change in estimated fair value of contingent consideration liabilities during 2013 is primarily related to positive results from a Phase II clinical trial for the Company's novel compound to treat erythema associated with rosacea that was acquired in connection with the 2011 acquisition of Vicept Therapeutics, Inc. The successful completion of this Phase II clinical trial increased the technology's probability of success in meeting future specified development milestones and, accordingly, increased the Company's estimated fair value of the related contingent consideration liability.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Note 13:  Commitments and Contingencies
	Legal Proceedings
	In the ordinary course of business, the Company is involved in various legal actions, government investigations and environmental proceedings, and we anticipate that additional actions will be brought against us in the future. The most significant of these actions, proceedings and investigations are described below.
	The Company’s legal proceedings range from cases brought by a single plaintiff to a class action with thousands of putative class members. These legal proceedings, as well as other matters, involve various aspects of the Company’s business and a variety of claims (including but not limited to patent infringement, marketing, product liability, pricing and trade practices and securities law), some of which present novel factual allegations and/or unique legal theories. Complex legal proceedings frequently extend for several years, and a number of the matters pending against the Company are at very early stages of the legal process. As a result, some pending matters have not yet progressed sufficiently through discovery and/or development of important factual information and legal issues to enable the Company to determine whether the proceeding is material to the Company or to estimate a range of possible loss, if any. Unless otherwise disclosed, the Company is unable to estimate the possible loss or range of loss for the legal proceedings described below. Litigation is unpredictable and, while it is not possible to accurately predict or determine the eventual outcomes of these items, an adverse determination in one or more of these items currently pending could have a material adverse effect on the Company’s consolidated results of operations, financial position or cash flows.
	Stockholder Derivative Litigation
	Botox® Settlement-Related Actions
	In 2010, Daniel Himmel, Willa Rosenbloom, the Pompano Beach Police & Firefighters’ Retirement System and the Western Washington Laborers-Employers Pension Trust separately filed stockholder derivative complaints against the Company’s then-current Board of Directors as of September 2010 and Allergan, Inc. in the U.S. District Court for the Central District of California alleging violations of federal securities laws, breaches of fiduciary duties, abuse of control, gross mismanagement, and corporate waste and seeks, among other things, damages, corporate governance reforms, attorneys’ fees and costs. The actions were subsequently consolidated. In 2012, the U.S. District Court entered an order granting the Company’s and the individual defendants’ motion to dismiss the first amended verified consolidated complaint and dismissed the consolidated action with prejudice. The plaintiffs filed a notice of appeal to the U.S. Court of Appeals for the Ninth Circuit and their opening appellate brief. The Company and the individual defendants have filed an answering appellate brief.
	2011 Incentive Award Plan Action
	The New Jersey Building Laborers Pension Fund filed a stockholder derivative complaint against members of the Company’s Board, three current officers of Allergan, Inc., one former officer of Allergan, Inc., and Allergan, Inc. in the U.S. District Court for the District of Delaware alleging claims for breach of fiduciary duty, waste of corporate assets, unjust enrichment, and wrongful acts and omissions under federal securities laws and seeks, among other things, an order voiding the stockholders’ vote and Allergan, Inc.’s 2011 Incentive Award Plan, damages, attorneys’ fees and costs. Plaintiff dismissed its claims against the former officer of Allergan, Inc. In June 2012, the U.S. District Court heard oral argument on the motions to dismiss filed by the Company and the individual defendants and took the matter under submission.
	Government Investigations
	In May 2012, the Company received service of process of a Subpoena Duces Tecum from the Department of Health and Human Services, Office of the Inspector General. The subpoena requests the production of documents relating to Lap-Band®. In February 2013, the Company received a Civil Investigative Demand from the U.S. Department of Justice requesting information relating to the Lap-Band®.
	Patent Litigation
	We are involved in patent litigation matters, including certain paragraph 4 invalidity and non-infringement claims brought under the Hatch-Waxman Act in the United States described below.
	Combigan®
	Combigan® I. After Sandoz, Inc. (Sandoz), Alcon Research, Ltd. and its affiliates (Alcon), Hi-Tech, Apotex, Watson Pharma, Inc. and Watson Pharmaceuticals, Inc. (Watson, and collectively, the Combigan Defendants) each filed an ANDA seeking approval of generic forms of Combigan®, a brimonidine tartrate 0.2%, timolol 0.5% ophthalmic solution, the Company received paragraph 4 invalidity and noninfringement certifications from the Combigan Defendants contending that U.S. Patent Numbers 7,030,149, 7,320,976, 7,323,463 and 7,642,258 (the Combigan Patents) are invalid or not infringed by the proposed generic products. The Company filed a complaint against the Combigan Defendants in the U.S. District Court for the Eastern District of Texas, Marshall Division, alleging infringement of the Combigan Patents. Before trial, the Company settled with Hi-Tech. In 2011, the U.S. District Court held a bench trial and issued its opinion holding that the Combigan Patents are not invalid and are infringed by defendants’ proposed products, and entered a final judgment and injunction in the Company’s favor. In May 2013, the U.S. Court of Appeals for the Federal Circuit affirmed the ruling of the U.S. District Court finding that U.S. Patent Number 7,030,149 is not invalid, affirmed the District Court’s claim construction ruling and reversed the District Court’s ruling finding that the asserted claims of U.S. Patent Number 7,323,463 are not invalid; the Court of Appeals declined to address the claims regarding U.S. Patent Numbers 7,320,976 and 7,642,258. In January 2014, Sandoz and Alcon filed a Petition for Writ of Certiorari to the U.S. Supreme Court appealing this Court of Appeals ruling. In September and October 2013, Sandoz, Alcon, and Apotex filed a motion seeking to modify the permanent injunction issued by the U.S. District Court for the Eastern District of Texas. In December 2013, the U.S. District Court for the Eastern District of Texas denied Sandoz, Alcon, and Apotex’s motion to modify the permanent injunction. In February 2014, Sandoz, Alcon and Apotex filed a Notice of Appeal to the U.S. Court of Appeals for the Federal Circuit appealing this District Court ruling.
	Combigan® II. In 2012, the Company filed a complaint against Sandoz, Alcon, Apotex and Watson in the U.S. District Court for the Eastern District of Texas, Marshall Division, alleging that their proposed products infringe U.S. Patent Number 8,133,890 (‘890 Patent), and subsequently amended their complaint to assert infringement of U.S. Patent Number 8,354,409. In March 2013, the Company received a paragraph 4 invalidity and noninfringement certification from Sandoz, contending that the ‘890 Patent is invalid and not infringed by the proposed generic product. In October 2013, the Company filed a motion to stay and administratively close the Combigan II matter, which was granted.
	Latisse®. After Apotex, Sandoz, Hi-Tech and Watson each filed an ANDA seeking approval of a generic form of Latisse® 0.03% bimatoprost ophthalmic solution, the Company received paragraph 4 invalidity and noninfringement certifications from Apotex, Sandoz, Hi-Tech and Watson contending that U.S. Patent Numbers 7,351,404 (‘404 Patent), 7,388,029 (‘029 Patent), 8,038,988 (‘988 Patent) and 8,101,161 (‘161 Patent) are invalid or not infringed by the proposed generic products. The Company, with Duke University, filed complaints against Sandoz, Alcon, Apotex and Watson in the U.S. District Court for the Middle District of North Carolina alleging that their proposed products infringe the ‘404, ‘029, ‘988 and ‘161 Patents.
	In 2012, the U.S. District Court commenced a bench trial on the ‘404 and ‘029 Patents in the Apotex, Sandoz, and Hi-Tech actions. In January 2013, the U.S. District Court issued its opinion holding that the ‘404 and ‘029 Patents are not invalid and are infringed by Apotex, Sandoz, and Hi-Tech’s proposed products and entered a final judgment in the Company’s favor and against these defendants. In February 2013, the U.S. District Court issued judgment for the Company and Duke University against Watson, finding that the ‘404 and ‘029 Patents are not invalid and are infringed by Watson’s proposed product. In February 2013, the Company and Duke filed motions for permanent injunction as to Apotex, Sandoz, Hi-Tech and Watson. In February 2013, Apotex, Sandoz and Hi-Tech filed a Notice of Appeal. The U.S. District Court has not yet set a trial date for the actions on the ‘988 and ‘161 Patents.
	In January 2013, the Company filed a complaint against Apotex, Sandoz, Hi-Tech and Watson in the U.S. District Court for the Middle District of North Carolina alleging that the defendants’ proposed products infringe U.S. Patent Number 8,263,054. No trial date has been set. In April 2013, the U.S. District Court granted the Company and Duke University’s motions for permanent injunction as to Apotex, Sandoz, Hi-Tech, and Watson. In April 2013, the U.S. District Court for the Middle District of North Carolina entered a permanent injunction against Apotex, Sandoz, Hi-Tech, and Watson. In May 2013, the U.S. Court of Appeals for the Federal Circuit denied the Company’s motion to dismiss Apotex, Sandoz, and Hi-Tech’s appeal, but granted it with respect to Watson. In May 2013, Watson filed an amended notice of appeal and its appeal was consolidated with that of Apotex, Sandoz, and Hi-Tech. In February 2014, the U.S. Court of Appeals for the Federal Circuit heard oral argument on Apotex, Sandoz, Hi-Tech, and Watson’s appeal regarding the ‘404 and ‘029 Patents and took the matter under submission.
	Lumigan® 0.01%. After Sandoz, Lupin, Hi-Tech and Watson (the Lumigan Defendants) each filed an ANDA seeking approval of a generic form of Lumigan® 0.01% bimatoprost ophthalmic solution, the Company received paragraph 4 invalidity and noninfringement certifications contending that U.S. Patent Numbers 7,851,504 and 5,688,819 (Lumigan Patents) are invalid or not infringed by the proposed generic products. The Company filed complaints against the Lumigan Defendants in the U.S. District Court for the Eastern District of Texas alleging that their proposed products infringe the Lumigan Patents. In January 2013, the Company filed an amended complaint against the Lumigan Defendants alleging that, in addition to the Lumigan Patents, the defendants’ proposed generic products infringe U.S. Patent Numbers 8,278,353, 8,299,118, 8,309,605, and 8,338,479 (Additional Lumigan Patents). In July 2013, a bench trial was held and the U.S. District Court for the Eastern District of Texas took the matter under submission. In 2013, after Lupin and Watson separately filed an ANDA with the FDA seeking approval to market a generic version of Lumigan® 0.01%, the Company received paragraph 4 invalidity and noninfringement certifications from Lupin and Watson, contending that the Additional Lumigan Patents are invalid and not infringed by the proposed generic product. In January 2014, the U.S. District Court issued its opinion holding that the Lumigan Patents and Additional Lumigan Patents (excluding U.S. Patent Number 5,688,819, which claim was previously dismissed by the Company) are not invalid and are infringed by the Lumigan Defendants’ proposed products and entered a final judgment and injunction in the Company’s favor and against the Lumigan Defendants. In February 2014, the Lumigan Defendants filed a Notice of Appeal to the U.S. Court of Appeals for the Federal Circuit.
	Other Litigation
	Allergan, Inc. v. Cayman Chemical Company, et al. The Company, with Duke University (Duke) and Murray A. Johnstone, M,D. (Johnstone), filed complaints against several defendants, including Athena Cosmetics, Inc. (Athena), Cosmetic Alchemy, LLC (Cosmetic Alchemy), LifeTech Resources, LLC (LifeTech), and Rocasuba, Inc. (Rocasuba), in the U.S. District Court for the Central District of California alleging that the defendants are in violation of the California unfair competition statute and infringing the ‘404 Patent and U.S. Patent Numbers 6,262,105 (‘105 Patent) and 7,388,029 ( ‘029 Patent). In 2012, the U.S. District Court granted the Company’s motion for partial summary judgment on our unfair competition claim against Athena, Cosmetic Alchemy, LifeTech and Rocasuba. In 2012, the U.S. District Court granted the motion by the Company and Duke to dismiss the claims on the ‘029 patent. The U.S. District Court set trial on the patent claims for May 7, 2013. In January 2013, Athena filed a motion for summary judgment of invalidity of the ‘404 Patent, the Company filed a motion for permanent injunction against Athena, Cosmetic Alchemy, LifeTech and Rocasuba, and the Company and Johnstone filed a motion for partial summary judgment against Cosmetic Alchemy on their patent infringement and contributory infringement claims regarding the ‘105 Patent. In 2013, the Company reached a settlement with LifeTech and Rocasuba and they were dismissed from the case. In February and March 2013, the U.S. District Court for the Central District of California denied Athena motion for summary judgment of invalidity of the ‘404 Patent, granted the Company’s motion for permanent injunction against Athena, Cosmetic Alchemy, LifeTech, and Rocasuba, and granted the Company and Johnstone’s motion for partial summary judgment against Cosmetic Alchemy on its patent infringement and contributory infringement claims regarding the ‘105 Patent. In March 2013, Cosmetic Alchemy was dismissed from the case. In March 2013, Athena filed a Notice of Appeal to the U.S. Court of Appeals for the Federal Circuit. In March 2013, the U.S. District Court dismissed all claims and counterclaims except the Company’s unfair competition claim against Athena. In October 2013, the U.S. Court of Appeals for the Federal Circuit heard oral argument on Athena’s appeal and took the matter under submission. In December 2013, the U.S. Court of Appeals for the Federal Circuit affirmed the U.S. District Court’s grant of summary judgment that Athena violated the California unfair competition statute, vacated the injunction entered by the U.S. District Court, and remanded to the U.S. District Court to limit the scope of the injunction to regulate conduct occurring within California.
	Contingencies
	In 2009, the Company established a reserve for a contingent liability associated with regulation changes resulting from a final rule issued by the U.S. Department of Defense (DoD) that placed retroactive and prospective pricing limits on certain branded pharmaceuticals under the TRICARE Retail Pharmacy Program, even though such branded pharmaceuticals have not historically been subject to a contract with the Company. As of December 31, 2012, the reserve for the contingent liability was $21.7 million and was included in “Other accrued expenses.” In January 2013, the United States Court of Appeals for the District of Columbia Circuit affirmed an earlier decision by the United States District Court for the District of Columbia in favor of the DoD, and the Company subsequently paid all outstanding contingent TRICARE Retail Pharmacy Program claims.
	As of June 1, 2012 the Company is largely self-insured for future product liability losses related to all of its products. Future product liability losses are, by their nature, uncertain and are based upon complex judgments and probabilities. The Company accrues for certain potential product liability losses estimated to be incurred, but not reported, to the extent they can be reasonably estimated. The Company estimates these accruals for potential losses based primarily on historical claims experience and data regarding product usage. The total value of self-insured product liability claims settled in 2013, 2012 and 2011, respectively, and the value of known and reasonably estimable incurred but unreported self-insured product liability claims pending as of December 31, 2013 and 2012 are not material.
	The Company has provided reserves for contingencies related to various lawsuits, claims and contractual disputes that management believes are probable and reasonably estimable. The amounts reserved for these contingencies as of December 31, 2013 and 2012 are not material.
	Operating Lease Obligations
	The Company leases certain facilities, office equipment and automobiles and provides for payment of taxes, insurance and other charges on certain of these leases. Rental expense was $79.0 million in 2013, $67.0 million in 2012 and $58.1 million in 2011.
	Future minimum rental payments under non-cancelable operating lease commitments with a term of more than one year as of December 31, 2013 are as follows: $67.8 million in 2014, $47.6 million in 2015, $31.1 million in 2016, $17.1 million in 2017, $11.4 million in 2018 and $57.1 million thereafter.

Guarantees

Guarantees	12 Months Ended
	Dec. 31, 2013
Guarantees [Abstract]	'
Guarantees	'
	Note 14:  Guarantees
	The Company’s Amended and Restated Certificate of Incorporation provides that the Company will indemnify, to the fullest extent permitted by the Delaware General Corporation Law, each person that is involved in or is, or is threatened to be, made a party to any action, suit or proceeding by reason of the fact that he or she, or a person of whom he or she is the legal representative, is or was a director or officer of the Company or was serving at the request of the Company as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust or other enterprise. The Company has also entered into contractual indemnity agreements with each of its directors and executive officers pursuant to which, among other things, the Company has agreed to indemnify such directors and executive officers against any payments they are required to make as a result of a claim brought against such executive officer or director in such capacity, excluding claims (i) relating to the action or inaction of a director or executive officer that resulted in such director or executive officer gaining illegal personal profit or advantage, (ii) for an accounting of profits made from the purchase or sale of securities of the Company within the meaning of Section 16(b) of the Securities Exchange Act of 1934, as amended, or similar provisions of any state law or (iii) that are based upon or arise out of such director’s or executive officer’s knowingly fraudulent, deliberately dishonest or willful misconduct. The maximum potential amount of future payments that the Company could be required to make under these indemnification provisions is unlimited. However, the Company has purchased directors’ and officers’ liability insurance policies intended to reduce the Company’s monetary exposure and to enable the Company to recover a portion of any future amounts paid. The Company has not previously paid any material amounts to defend lawsuits or settle claims as a result of these indemnification provisions, but makes no assurance that such amounts will not be paid in the future. The Company currently believes the estimated fair value of these indemnification arrangements is minimal.
	The Company customarily agrees in the ordinary course of its business to indemnification provisions in agreements with clinical trials investigators in its drug, biologics and medical device development programs, in sponsored research agreements with academic and not-for-profit institutions, in various comparable agreements involving parties performing services for the Company in the ordinary course of business, and in its real estate leases. The Company also customarily agrees to certain indemnification provisions in its acquisition agreements and discovery and development collaboration agreements. With respect to the Company’s clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of the Company’s contractual obligations arising out of the research or clinical testing of the Company’s products, compounds or drug candidates. With respect to real estate lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by the Company, to violations of law by the Company or to certain breaches of the Company’s contractual obligations. The indemnification provisions appearing in the Company’s acquisition agreements and collaboration agreements are similar, but in addition often provide indemnification for the collaborator in the event of third party claims alleging infringement of intellectual property rights. In each of the above cases, the terms of these indemnification provisions generally survive the termination of the agreement. The maximum potential amount of future payments that the Company could be required to make under these provisions is generally unlimited. The Company has purchased insurance policies covering personal injury, property damage and general liability intended to reduce the Company’s exposure for indemnification and to enable the Company to recover a portion of any future amounts paid. The Company has not previously paid any material amounts to defend lawsuits or settle claims as a result of these indemnification provisions. As a result, the Company believes the estimated fair value of these indemnification arrangements is minimal.

Product_Warranties

Product Warranties	12 Months Ended
	Dec. 31, 2013
Product Warranties Disclosures [Abstract]	'
Product Warranties	'
	Note 15:  Product Warranties
	The Company provides warranty programs for breast implant sales primarily in the United States, Europe and certain other countries. Management estimates the amount of potential future claims from these warranty programs based on actuarial analyses. Expected future obligations are determined based on the history of product shipments and claims and are discounted to a current value. The liability is included in both current and long-term liabilities in the Company’s consolidated balance sheets. The U.S. programs include the ConfidencePlus® and ConfidencePlus® Premier warranty programs. The ConfidencePlus® program, which is limited to saline breast implants, currently provides lifetime product replacement, $1,200 of financial assistance for surgical procedures within ten years of implantation and contralateral implant replacement. The ConfidencePlus® Premier program, which is standard for silicone gel implants and requires a low enrollment fee for saline breast implants, generally provides lifetime product replacement, $2,400 of financial assistance for saline breast implants and $3,500 of financial assistance for silicone gel breast implants for surgical procedures within ten years of implantation and contralateral implant replacement. The warranty programs in non-U.S. markets have similar terms and conditions to the U.S. programs. The Company does not warrant any level of aesthetic result and, as required by government regulation, makes extensive disclosures concerning the risks of the use of its products and breast implant surgery. Changes to actual warranty claims incurred and interest rates could have a material impact on the actuarial analysis and the Company’s estimated liabilities. A large majority of the product warranty liability arises from the U.S. warranty programs. The Company does not currently offer any similar warranty program on any other product.
	The following table provides a reconciliation of the change in estimated product warranty liabilities for the years ended December 31, 2013 and 2012:
		2013			2012
		(in millions)
	Balance, beginning of year	$	34.4		$	32.6
	Provision for warranties issued during the year	8			9.9
	Settlements made during the year	(8.1		)	(8.1		)
	Decreases in warranty estimates	(0.7		)	—
	Balance, end of year	$	33.6		$	34.4
	Current portion	$	7.6		$	6.7
	Non-current portion	26			27.7
	Total	$	33.6		$	34.4

Business_Segment_Information

Business Segment Information	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Business Segment Information	'
	Note 16:  Business Segment Information
	The Company operates its business on the basis of two reportable segments — specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces a broad range of pharmaceutical products, including: ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox® for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and other prescription and physician-dispensed skin care products; and urologics products. The medical devices segment produces a broad range of medical devices, including: breast implants for augmentation, revision and reconstructive surgery and tissue expanders; and facial aesthetics products. The Company provides global marketing strategy teams to ensure development and execution of a consistent marketing strategy for its products in all geographic regions that share similar distribution channels and customers.
	The Company evaluates segment performance on a product net sales and operating income basis exclusive of general and administrative expenses and other indirect costs, legal settlement expenses, impairment of intangible assets and related costs, restructuring charges, amortization of certain identifiable intangible assets related to business combinations, asset acquisitions and related capitalized licensing costs and certain other adjustments, which are not allocated to the Company’s segments for performance assessment by the Company’s chief operating decision maker. Other adjustments excluded from the Company’s segments for performance assessment represent income or expenses that do not reflect, according to established Company-defined criteria, operating income or expenses associated with the Company’s core business activities. Because operating segments are generally defined by the products they design and sell, they do not make sales to each other. The Company does not discretely allocate assets to its operating segments, nor does the Company’s chief operating decision maker evaluate operating segments using discrete asset information.
	Operating Segments
		2013		2012		2011
		(in millions)
	Product net sales:
	Specialty pharmaceuticals	$	5,339.00	$	4,784.60	$	4,432.00
	Medical devices	858.5		764.7		712
	Total product net sales	6,197.50		5,549.30		5,144.00
	Other revenues	102.9		97.3		72
	Total revenues	$	6,300.40	$	5,646.60	$	5,216.00
	Operating income:
	Specialty pharmaceuticals	$	2,282.00	$	1,997.70	$	1,763.30
	Medical devices	246.2		229.1		238.1
	Total segments	2,528.20		2,226.80		2,001.40
	General and administrative expenses, other indirect costs and other adjustments	594.6		525.3		556.7
	Amortization of intangible assets (a)	107.4		66.7		62.6
	Impairment of intangible assets and related costs	11.4		22.3		7.6
	Restructuring charges (reversal)	5.5		1.5		(0.1		)
	Total operating income	$	1,809.30	$	1,611.00	$	1,374.60
	——————————
	(a)	Represents amortization of certain identifiable intangible assets related to business combinations and asset acquisitions and related capitalized licensing costs, as applicable.
	Product net sales for the Company’s various global product portfolios are presented below. The Company’s principal geographic markets are the United States, Europe, Latin America and Asia Pacific. The U.S. information is presented separately as it is the Company’s headquarters country. U.S. sales represented 62.0%, 60.9% and 60.0% of the Company’s total consolidated product net sales in 2013, 2012 and 2011, respectively.
	Sales to two customers in the Company’s specialty pharmaceuticals segment each generated over 10% of the Company’s total consolidated product net sales. Sales to McKesson Drug Company for the years ended December 31, 2013, 2012 and 2011 were 15.0%, 14.6% and 13.1%, respectively, of the Company’s total consolidated product net sales. Sales to Cardinal Health, Inc. for the years ended December 31, 2013, 2012 and 2011 were 13.0%, 14.7% and 14.6%, respectively, of the Company’s total consolidated product net sales. No other country or single customer generates over 10% of the Company’s total consolidated product net sales. Other medical devices product net sales represent sales made pursuant to certain transitional manufacturing and distribution service agreements with Apollo related to the sale of the Company's obesity intervention business unit. Net sales for the Europe region also include sales to customers in Africa and the Middle East, and net sales in the Asia Pacific region include sales to customers in Australia and New Zealand.
	Product Net Sales by Product Line
		2013		2012		2011
		(in millions)
	Specialty Pharmaceuticals:
	Eye Care Pharmaceuticals	$	2,890.30	$	2,692.20	$	2,520.20
	Botox®/Neuromodulators	1,982.20		1,766.30		1,594.90
	Skin Care and Other	466.5		326.1		316.9
	Total Specialty Pharmaceuticals	5,339.00		4,784.60		4,432.00
	Medical Devices:
	Breast Aesthetics	377.9		377.1		349.3
	Facial Aesthetics	477.5		387.6		362.7
	Core Medical Devices	855.4		764.7		712
	Other	3.1		—		—
	Total Medical Devices	858.5		764.7		712
	Total product net sales	$	6,197.50	$	5,549.30	$	5,144.00
	Geographic Information
		Product Net Sales
		2013		2012		2011
		(in millions)
	United States	$	3,839.40	$	3,379.10	$	3,086.30
	Europe	1,237.80		1,095.50		1,057.40
	Latin America	383		386.3		377.3
	Asia Pacific	464.1		432.3		389.3
	Other	273.2		256.1		233.7
	Total product net sales	$	6,197.50	$	5,549.30	$	5,144.00
		Long-lived Assets				Depreciation and							Capital Expenditures
						Amortization
		2013		2012		2013			2012		2011		2013		2012		2011
		(in millions)
	United States	$	4,274.70	$	3,242.90	$	181.2		$	153.5	$	146.7	$	82.3	$	75.7	$	63.3
	Europe	569.9		538.6		49.6			48.1		49.7		79.7		59.5		45.6
	Latin America	52.2		55.2		7.7			8.1		9.4		7.6		6		6.3
	Asia Pacific	51.2		53.8		5			4.6		4.5		2.3		2		2.1
	Other	1.4		2.2		0.6			0.8		0.9		—		0.1		—
	Total	$	4,949.40	$	3,892.70	$	244.1		$	215.1	$	211.2	$	171.9	$	143.3	$	117.3
	The increase in long-lived assets located in the United States at December 31, 2013 compared to December 31, 2012 is primarily due to an increase in intangible assets and goodwill related to the acquisitions of MAP completed in the first quarter of 2013 and Exemplar completed in the second quarter of 2013.
	The increase in United States depreciation and amortization for the year ended December 31, 2013 compared to the year ended December 31, 2012 primarily relates to amortization of acquired intangible assets associated with the acquisitions of MAP in the first quarter of 2013 and SkinMedica in the fourth quarter of 2012.

Earnings_Per_Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Earnings Per Share	'
	Note 17:  Earnings Per Share
	The table below presents the computation of basic and diluted earnings per share:
		Year Ended December 31,
		2013			2012		2011
		(in millions, except per share amounts)
	Net earnings attributable to Allergan, Inc.:
	Earnings from continuing operations attributable to Allergan, Inc.:
	Earnings from continuing operations	$	1,272.50		$	1,100.70	$	949.6
	Less net earnings attributable to noncontrolling interest	3.6			3.7		3.6
	Earnings from continuing operations attributable to Allergan, Inc.	1,268.90			1,097.00		946
	(Loss) earnings from discontinued operations	(283.8		)	1.8		(11.5		)
	Net earnings attributable to Allergan, Inc.	$	985.1		$	1,098.80	$	934.5
	Weighted average number of shares outstanding	296.8			301.5		304.4
	Net shares assumed issued using the treasury stock method for options and non-vested equity shares and share units outstanding during each period based on average market price	5			5.6		5.5
	Dilutive effect of assumed conversion of convertible notes outstanding	—			—		0.3
	Diluted shares	301.8			307.1		310.2
	Basic earnings per share attributable to Allergan, Inc. stockholders:
	Continuing operations	$	4.28		$	3.64	$	3.11
	Discontinued operations	(0.96		)	—		(0.04		)
	Net basic earnings per share attributable to Allergan, Inc. stockholders	$	3.32		$	3.64	$	3.07
	Diluted earnings per share attributable to Allergan, Inc. stockholders:
	Continuing operations	$	4.2		$	3.57	$	3.05
	Discontinued operations	(0.94		)	0.01		(0.04		)
	Net diluted earnings per share attributable to Allergan, Inc. stockholders	$	3.26		$	3.58	$	3.01
	For the year ended December 31, 2013, options to purchase 5.5 million shares of common stock at exercise prices ranging from $81.06 to $113.55 per share were outstanding but were not included in the computation of diluted earnings per share because the effect from the assumed exercise of these options calculated under the treasury stock method would be anti-dilutive.
	For the year ended December 31, 2012, options to purchase 5.5 million shares of common stock at exercise prices ranging from $75.58 to $92.90 per share were outstanding but were not included in the computation of diluted earnings per share because the effect from the assumed exercise of these options calculated under the treasury stock method would be anti-dilutive.
	For the year ended December 31, 2011, options to purchase 4.8 million shares of common stock at exercise prices ranging from $62.71 to $84.40 per share were outstanding but were not included in the computation of diluted earnings per share because the effect from the assumed exercise of these options calculated under the treasury stock method would be anti-dilutive.

Subsequent_Event

Subsequent Event	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Event	'
	Note 18:  Subsequent Event
	In January 2014, the Company initiated a restructuring plan that will affect approximately 300 employees, including a reduction of approximately 150 positions. The restructuring plan includes certain sales force realignments and position eliminations, certain facility relocations and closures in the United States and Europe and the realignment of certain other business support functions. The Company currently estimates that the total costs related to this restructuring plan will be between $40 million and $45 million, which includes severance and other one-time termination benefits, lease exit and contract termination costs, accelerated depreciation and share-based compensation expenses, and relocation and duplicate operating expenses. The Company currently expects that the majority of the expenses will be incurred in 2014 and anticipates that certain expenses related to the relocation of a minor manufacturing facility will be incurred in 2015.

Schedule_II_VALUATION_AND_QUAL

Schedule II - VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Dec. 31, 2013
Valuation and Qualifying Accounts [Abstract]	'
Valuation and Qualifying Accounts	'
	SCHEDULE II
	ALLERGAN, INC.
	VALUATION AND QUALIFYING ACCOUNTS
	Years Ended December 31, 2013, 2012 and 2011
	Allowance for Doubtful Accounts Deducted from Trade Receivables		Balance at		Additions (a)		Deductions (b)			Balance
			Beginning							at End
			of Year							of Year
			(in millions)
	2013		$	24.2	$	6.2	$	(6.2	)	$	24.2
	2012		27.6		0.8		(4.2		)	24.2
	2011		25.3		6.6		(4.3		)	27.6
	——————————
	(a)	Provision charged to earnings.
	(b)	Accounts written off, net of recoveries.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Consolidation	'
	The consolidated financial statements include the accounts of Allergan, Inc. (“Allergan” or the “Company”) and all of its subsidiaries. All significant intercompany transactions and balances among the consolidated entities have been eliminated from the consolidated financial statements.
Use of Estimates	'
	Use of Estimates
	The financial statements have been prepared in conformity with accounting principles generally accepted in the United States and, as such, include amounts based on informed estimates and judgments of management. Actual results could differ materially from those estimates.
Foreign Currency Translation	'
	Foreign Currency Translation
	The financial position and results of operations of the Company’s foreign subsidiaries are generally determined using local currency as the functional currency. Assets and liabilities of these subsidiaries are translated at the exchange rate in effect at each year end. Income statement accounts are translated at the average rate of exchange prevailing during the year. Adjustments arising from the use of differing exchange rates from period to period are included in accumulated other comprehensive loss in equity. Aggregate net realized and unrealized (losses) gains resulting from foreign currency transactions and derivative contracts of approximately $(7.4) million, $(23.4) million and $0.3 million for the years ended December 31, 2013, 2012 and 2011, respectively, are included in “Other, net” in the Company’s consolidated statements of earnings.
Cash and Equivalents	'
	Cash and Equivalents
	The Company considers cash in banks, repurchase agreements, commercial paper, money-market funds and deposits with financial institutions with maturities of three months or less when purchased and that can be liquidated without prior notice or penalty, to be cash and equivalents.
Short-Term Investments	'
	Short-Term Investments
	Short-term investments consist primarily of investment grade commercial paper and time deposits with financial institutions with maturities from three months to one year when purchased and are classified as available-for-sale. Short-term investments are valued at cost, which approximates fair value due to their short-term maturities.
Investments	'
	Investments
	The Company has non-marketable equity investments in conjunction with its various collaboration arrangements. The non-marketable equity investments represent investments in start-up companies and are recorded at cost. The non-marketable equity investments are evaluated periodically for impairment. If it is determined that a decline of any investment is other than temporary, then the investment basis would be written down to fair value and the write-down would be included in earnings as a loss.
Inventories	'
	Inventories
	Inventories are valued at the lower of cost or market (net realizable value). Cost is determined by the first-in, first-out method.
Long-Lived Assets	'
	Long-Lived Assets
	Property, plant and equipment are stated at cost. Additions, major renewals and improvements are capitalized, while maintenance and repairs are expensed. Upon disposition, the net book value of assets is relieved and resulting gains or losses are reflected in earnings. For financial reporting purposes, depreciation is generally provided on the straight-line method over the useful life of the related asset. The useful lives for buildings, including building improvements, range from seven years to 40 years and, for machinery and equipment, three years to 15 years.
	Leasehold improvements are amortized over the shorter of their economic lives or lease terms. Accelerated depreciation methods are generally used for income tax purposes.
	All long-lived assets are reviewed for impairment in value when changes in circumstances dictate, based upon undiscounted future operating cash flows, and appropriate losses are recognized and reflected in current earnings, to the extent the carrying amount of an asset exceeds its estimated fair value determined by the use of appraisals, discounted cash flow analyses or comparable fair values of similar assets.
Goodwill and Intangible Assets	'
	Goodwill and Intangible Assets
	Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill has an indefinite useful life and is not amortized, but instead tested for impairment annually. Intangible assets include developed technology, customer relationships, licensing agreements, trademarks, core technology and other rights, which are being amortized over their estimated useful lives ranging from two years to 21 years, and in-process research and development assets with indefinite useful lives that are not amortized, but instead tested for impairment until the successful completion and commercialization or abandonment of the associated research and development efforts, at which point the in-process research and development assets are either amortized over their estimated useful lives or written-off immediately.
Treasury Stock	'
	Treasury Stock
	Treasury stock is accounted for by the cost method. The Company maintains an evergreen stock repurchase program. The evergreen stock repurchase program authorizes management to repurchase the Company’s common stock for the primary purpose of funding its stock-based benefit plans. Under the stock repurchase program, the Company may maintain up to 18.4 million repurchased shares in its treasury account at any one time. As of December 31, 2013 and 2012, the Company held approximately 9.9 million and 7.2 million treasury shares, respectively, under this program.
Revenue Recognition	'
	Revenue Recognition
	The Company recognizes revenue from product sales when goods are shipped and title and risk of loss transfer to its customers. A portion of the Company’s revenue is generated from consigned inventory of breast implants maintained at physician, hospital and clinic locations. These customers are contractually obligated to maintain a specific level of inventory and to notify the Company upon use. Revenue for consigned inventory is recognized at the time the Company is notified by the customer that the product has been used. Notification is usually through the replenishing of the inventory, and the Company periodically reviews consignment inventories to confirm the accuracy of customer reporting.
	The Company generally offers cash discounts to customers for the early payment of receivables. Those discounts are recorded as a reduction of revenue and accounts receivable in the same period that the related sale is recorded. The amounts reserved for cash discounts were $6.3 million and $4.2 million at December 31, 2013 and 2012, respectively. The Company permits returns of product from most product lines by any class of customer if such product is returned in a timely manner, in good condition and from normal distribution channels. Return policies in certain international markets and for certain medical device products, primarily breast implants, provide for more stringent guidelines in accordance with the terms of contractual agreements with customers. Estimated allowances for sales returns are based upon the Company’s historical patterns of product returns matched against sales, and management’s evaluation of specific factors that may increase the risk of product returns. The amount of allowances for sales returns recognized in the Company’s consolidated balance sheets at December 31, 2013 and 2012 were $84.4 million and $77.9 million, respectively, and are recorded in “Other accrued expenses” and “Trade receivables, net” in the Company’s consolidated balance sheets. (See Note 5, “Composition of Certain Financial Statement Captions.”) Actual historical allowances for cash discounts and product returns have been consistent with the amounts reserved or accrued.
	The Company participates in various U.S. federal and state government rebate programs, the largest of which are Medicaid, Medicare and the U.S. Department of Veterans Affairs. The Company also has contracts with various managed care and group purchasing organizations that provide for sales rebates and other contractual discounts. In the United States, the Company also incurs chargebacks, which are reimbursements to wholesalers for honoring contracted prices to third parties. Outside of the United States, the Company incurs sales allowances based on contractual provisions and legislative mandates. The Company also offers rebate and other incentive programs directly to customers for its aesthetic products and certain therapeutic products, including Botox® Cosmetic, the Juvéderm® franchise, Latisse®, Natrelle®, Acuvail®, Aczone®, Sanctura XR® and Restasis®, and for certain other skin care products. Sales rebates and incentive accruals reduce revenue in the same period that the related sale is recorded and are included in “Other accrued expenses” in the Company's consolidated balance sheets. (See Note 5, “Composition of Certain Financial Statement Captions.”) The amounts accrued for sales rebates and other incentive programs were $279.3 million and $269.6 million at December 31, 2013 and 2012, respectively.
	The Company’s procedures for estimating amounts accrued for sales rebates and other incentive programs at the end of any period are based on available quantitative data and are supplemented by management’s judgment with respect to many factors, including but not limited to, current market dynamics, changes in contract terms, changes in sales trends, an evaluation of current laws and regulations and product pricing. Quantitatively, the Company uses historical sales, product utilization and rebate data and applies forecasting techniques in order to estimate the Company’s liability amounts. Qualitatively, management’s judgment is applied to these items to modify, if appropriate, the estimated liability amounts. Additionally, there is a significant time lag between the date the Company determines the estimated liability and when the Company actually pays the liability. Due to this time lag, the Company records adjustments to its estimated liabilities over several periods, which can result in a net increase to earnings or a net decrease to earnings in those periods.
	The Company recognizes license fees, royalties and reimbursement income for services provided as other revenues based on the facts and circumstances of each contractual agreement. In general, the Company recognizes income upon the signing of a contractual agreement that grants rights to products or technology to a third party if the Company has no further obligation to provide products or services to the third party after entering into the contract. The Company recognizes contingent consideration earned from the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved. The Company defers income under contractual agreements when it has further obligations that indicate that a separate earnings process has not been completed.
Contingent Consideration	'
	Contingent Consideration
	Contingent consideration liabilities represent future amounts the Company may be required to pay in conjunction with various business combinations. The ultimate amount of future payments is based on specified future criteria, such as sales performance and the achievement of certain future development, regulatory and sales milestones and other contractual performance conditions. The Company estimates the fair value of the contingent consideration liabilities related to sales performance using the income approach, which involves forecasting estimated future net cash flows and discounting the net cash flows to their present value using a risk-adjusted rate of return. The Company estimates the fair value of the contingent consideration liabilities related to the achievement of future development and regulatory milestones by assigning an achievement probability to each potential milestone and discounting the associated cash payment to its present value using a risk-adjusted rate of return. The Company estimates the fair value of the contingent consideration liabilities associated with sales milestones by employing Monte Carlo simulations to estimate the volatility and systematic relative risk of revenues subject to sales milestone payments and discounting the associated cash payment amounts to their present values using a credit-risk-adjusted interest rate. The fair value of other contractual performance conditions is measured by assigning an achievement probability to each payment and discounting the payment to its present value using the Company's estimated cost of borrowing. The Company evaluates its estimates of the fair value of contingent consideration liabilities on a periodic basis. Any changes in the fair value of contingent consideration liabilities are recorded through earnings as “Selling, general and administrative” in the Company’s consolidated statements of earnings. The total estimated fair value of contingent consideration liabilities was $225.2 million and $224.3 million at December 31, 2013 and 2012, respectively, and was included in "Other accrued expenses" and "Other liabilities" in the consolidated balance sheets.
Share-Based Compensation	'
	Share-Based Compensation
	The Company recognizes compensation expense for all share-based awards made to employees and directors. The fair value of share-based awards is estimated at the grant date and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period. The fair value of stock option awards that vest based on a service condition is estimated using the Black-Scholes option-pricing model. The fair value of share-based awards that contain a market condition is generally estimated using a Monte Carlo simulation model, and the fair value of modifications to share-based awards is generally estimated using a lattice model.
Advertising Expenses	'
	Advertising Expenses
	Advertising expenses relating to production costs are expensed as incurred and the costs of television time, radio time and space in publications are expensed when the related advertising occurs. Advertising expenses were approximately $179.7 million, $158.5 million and $168.6 million in 2013, 2012 and 2011, respectively.
Product Liability Self-Insurance	'
	Product Liability Self-Insurance
	As of June 1, 2012, the Company is largely self-insured for future product liability losses related to all of its products. The Company has historically been and continues to be self-insured for any product liability losses related to its breast implant products. The Company maintains third party insurance coverage that it believes is adequate to cover potential product liability losses for injuries alleged to have occurred prior to June 1, 2011 related to Botox® and Botox® Cosmetic and prior to June 1, 2012 related to all of its other products. Future product liability losses are, by their nature, uncertain and are based upon complex judgments and probabilities. The factors to consider in developing product liability reserves include the merits and jurisdiction of each claim, the nature and the number of other similar current and past claims, the nature of the product use and the likelihood of settlement. In addition, the Company accrues for certain potential product liability losses estimated to be incurred, but not reported, to the extent they can be reasonably estimated. The Company estimates these accruals for potential losses based primarily on historical claims experience and data regarding product usage.
Income Taxes	'
	Income Taxes
	The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities along with net operating loss and tax credit carryovers. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.
	Valuation allowances against the Company’s deferred tax assets were $48.9 million and $22.6 million at December 31, 2013 and December 31, 2012, respectively. Changes in the valuation allowances are generally recognized in the provision for income taxes as a component of the estimated annual effective tax rate.
	The Company has not provided for withholding and U.S. taxes for the unremitted earnings of certain non-U.S. subsidiaries because it has currently reinvested these earnings indefinitely in these foreign operations. At December 31, 2013, the Company had approximately $3,828.0 million in unremitted earnings outside the United States for which withholding and U.S. taxes were not provided. Income tax expense would be incurred if these earnings were remitted to the United States. It is not practicable to estimate the amount of the deferred tax liability on such unremitted earnings. Upon remittance, certain foreign countries impose withholding taxes that are then available, subject to certain limitations, for use as credits against the Company’s U.S. tax liability, if any.
Acquisitions	'
	Acquisitions
	The accounting for acquisitions requires extensive use of estimates and judgments to measure the fair value of the identifiable tangible and intangible assets acquired, including in-process research and development, and liabilities assumed. Additionally, the Company must determine whether an acquired entity is considered to be a business or a set of net assets, because the excess of the purchase price over the fair value of net assets acquired can only be recognized as goodwill in a business combination.
	On February 1, 2012, the Company purchased the commercial assets related to the selling and distribution of the Company's products from its distributor in Russia for $3.1 million in cash, net of a $6.6 million pre-existing net receivable from the distributor, and estimated contingent consideration of $4.7 million as of the acquisition date. On December 19, 2012, the Company acquired SkinMedica, Inc. for $348.9 million in cash and contingent consideration with an estimated fair value of $2.2 million as of the acquisition date. On March 1, 2013, the Company acquired MAP Pharmaceuticals, Inc. for an aggregate purchase price of approximately $871.7 million, net of cash acquired. On April 12, 2013, the Company acquired Exemplar Pharma, LLC for an aggregate purchase price of approximately $16.1 million, net of cash acquired. The Company accounted for these acquisitions as business combinations. The tangible and intangible assets acquired and liabilities assumed in connection with these acquisitions were recognized based on their estimated fair values at the acquisition dates. The determination of estimated fair values requires significant estimates and assumptions including, but not limited to, determining the timing and estimated costs to complete the in-process projects, projecting regulatory approvals, estimating future cash flows and developing appropriate discount rates. The Company believes the estimated fair values assigned to the assets acquired and liabilities assumed are based on reasonable assumptions.
Comprehensive Income (Loss)	'
	Comprehensive Income (Loss)
	Comprehensive income (loss) encompasses all changes in equity other than those with stockholders and consists of net earnings (losses), foreign currency translation adjustments, certain pension and other postretirement benefit plan adjustments, unrealized gains or losses on marketable equity investments and unrealized and realized gains or losses on derivative instruments, if applicable. The Company does not recognize U.S. income taxes on foreign currency translation adjustments since it does not provide for such taxes on undistributed earnings of foreign subsidiaries.
Reclassifications	'
	Reclassifications
	Certain reclassifications of prior year amounts have been made to conform with the current year presentation.
New Accounting Pronouncements	'
	Recently Adopted Accounting Standards
	In February 2013, the Financial Accounting Standards Board (FASB) issued an accounting standards update that requires an entity to report the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amounts are required to be reclassified in their entirety to net income. For other amounts that are not required to be reclassified in their entirety to net income in the same reporting period, an entity is required to cross-reference to other disclosures that provide additional detail about those amounts. This guidance became effective for reporting periods beginning after December 15, 2012, with early adoption permitted. The Company adopted the provisions of the guidance in the first quarter of 2013. The adoption did not have a material impact on the Company’s consolidated financial statements.
	In July 2012, the FASB issued an accounting standards update that gives an entity the option to first assess qualitative factors to determine whether it is more likely than not that an indefinite-lived intangible asset is impaired. If, after assessing the totality of events and circumstances, an entity concludes that it is not more likely than not that the indefinite-lived intangible asset is impaired, then the entity is not required to take further action. This guidance became effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012, with early adoption permitted. The Company adopted the provisions of the guidance in the first quarter of 2013. The adoption did not have a material impact on the Company’s consolidated financial statements.
	New Accounting Standards Not Yet Adopted
	In July 2013, the FASB issued an accounting standards update that requires the netting of unrecognized tax benefits against a deferred tax asset for a loss or other carryforward that would apply in settlement of the uncertain tax positions. This guidance will be effective for fiscal years beginning after December 15, 2013, which will be the Company's fiscal year 2014, with early adoption permitted. The Company currently does not expect the adoption of the guidance will have a material impact on the Company's consolidated financial statements.
	In March 2013, the FASB issued an accounting standards update that provides guidance on the accounting for the cumulative translation adjustment (CTA) upon derecognition of certain subsidiaries or groups of assets within a foreign entity or of an investment in a foreign entity. Under this guidance, an entity should recognize the CTA in earnings based on meeting certain criteria, including when it ceases to have a controlling financial interest in a subsidiary or group of assets within a consolidated foreign entity or upon a sale or transfer that results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets resides. This guidance will be effective for fiscal years beginning on or after December 15, 2013, which will be the Company's fiscal year 2014, with early adoption permitted. The Company currently does not expect the adoption of the guidance will have a material impact on the Company's consolidated financial statements.

Acquisitions_and_Collaboration1

Acquisitions and Collaborations (Tables)	12 Months Ended
	Dec. 31, 2013
Acquisitions and Collaborations [Abstract]	'
Intangible Assets Acquired as Part of SkinMedica Acquisition	'
		Value of Intangible Assets Acquired		Weighted
				Average
				Amortization
				Period
		(in millions)		(in years)
	Developed technology	$	87.5	10.6
	Customer relationships	50.6		2.7
	Trademarks	62.5		15
	In-process research and development	0.3		—
		$	200.9

Discontinued_Operations_Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2013
Discontinued Operations and Disposal Groups [Abstract]	'
Results of Operations from Discontinued Operations	'
	The following table summarizes the results of discontinued operations:
		2013			2012			2011
		(in millions)
	Product net sales	$	114.4		$	159.5		$	203.1
	Operating costs and expenses:
	Cost of sales (excludes amortization of intangible assets)	20.2			24.3			30.7
	Selling, general and administrative	57.9			75.3			88.3
	Research and development	5			12.3			31.3
	Amortization of intangible assets	10.3			41.1			41.5
	Impairment of intangible assets	—			—			16.1
	Restructuring charges	—			4.2			4.7
	Earnings (loss) from discontinued operations before income taxes	21			2.3			(9.5		)
	Provision for income taxes	(6.9		)	(0.5		)	(2.0		)
	Earnings (loss) from discontinued operations, net of income taxes	$	14.1		$	1.8		$	(11.5	)
	Loss on sale of discontinued operations before income taxes	$	(408.2	)	$	—		$	—
	Income tax benefit on sale of discontinued operations	110.3			—			—
	Loss on sale of discontinued operations, net of income taxes	$	(297.9	)	$	—		$	—
	Discontinued operations	$	(283.8	)	$	1.8		$	(11.5	)
Assets and Liabilities Held for Sale	'
	The following table summarizes the assets and liabilities of discontinued operations as of December 31, 2013 and 2012 related to the Company's obesity intervention business unit:
		2013			2012
		(in millions)
	Assets:
	Trade receivables, net	$	9		$	25.2
	Inventories	—			10.6
	Property, plant and equipment, net	—			1.4
	Goodwill	—			105.7
	Intangibles, net	—			369
	Other assets	—			0.7
	Total assets of discontinued operations	$	9		$	512.6
	Liabilities:
	Accounts payable	$	—		$	0.9
	Accrued expenses	—			4.1
	Other liabilities	—			0.3
	Total liabilities of discontinued operations	$	—		$	5.3

Composition_of_Certain_Financi1

Composition of Certain Financial Statement Captions (Tables)	12 Months Ended
	Dec. 31, 2013
Composition of Certain Financial Statement Captions [Abstract]	'
Composition of Certain Financial Statement Captions	'
	Composition of Certain Financial Statement Captions
		December 31,
		2013			2012
		(in millions)
	Trade receivables, net
	Trade receivables	$	935.4		$	791.4
	Less allowance for sales returns — medical device products	(27.9		)	(28.2		)
	Less allowance for doubtful accounts	(24.2		)	(24.2		)
		$	883.3		$	739
	Inventories
	Finished products	$	180		$	179.9
	Work in process	44.1			41.3
	Raw materials	61.2			51.1
		$	285.3		$	272.3
	Other current assets
	Prepaid expenses	$	157.1		$	149.2
	Deferred taxes	277.9			249.1
	Other	58			50.3
		$	493		$	448.6
	Investments and other assets
	Deferred executive compensation investments	$	100.7		$	81.7
	Capitalized software	36.8			47.3
	Prepaid pensions	5.6			5.7
	Debt issuance costs	10.8			8
	Non-marketable equity investments	20.8			9
	Other	38.5			40.4
		$	213.2		$	192.1
		December 31,
		2013			2012
		(in millions)
	Property, plant and equipment, net
	Land	$	62.2		$	61.9
	Buildings	962.8			884.4
	Machinery and equipment	784.8			708.5
		1,809.80			1,654.80
	Less accumulated depreciation	(886.6		)	(803.3		)
		$	923.2		$	851.5
	Other accrued expenses
	Sales rebates and other incentive programs	$	279.3		$	269.6
	Royalties	26.2			26
	Interest	22			18.2
	Sales returns — specialty pharmaceutical products	56.5			49.7
	Product warranties — breast implant products	7.6			6.7
	Contingent consideration	9.9			59
	Other	196			157.6
		$	597.5		$	586.8
	Other liabilities
	Postretirement benefit plan	$	44.3		$	46.6
	Qualified and non-qualified pension plans	194.5			218.3
	Deferred executive compensation	105.3			85.3
	Deferred income	67			75.1
	Contingent consideration	215.3			165.3
	Product warranties — breast implant products	26			27.7
	Unrecognized tax benefit liabilities	67.7			53.8
	Other	42.1			36.7
		$	762.2		$	708.8
	Accumulated other comprehensive loss
	Foreign currency translation adjustments	$	(29.7	)	$	(25.2	)
	Deferred holding gains on derivative instruments, net of taxes of $1.2 million and $1.7 million for 2013 and 2012, respectively	1.8			2.6
	Actuarial losses not yet recognized as a component of pension and postretirement benefit plan costs, net of taxes of $83.5 million and $106.6 million for 2013 and 2012, respectively	(198.7		)	(222.0		)
		$	(226.6	)	$	(244.6	)

Intangibles_and_Goodwill_Table

Intangibles and Goodwill (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangibles	'
	Intangibles
	At December 31, 2013 and 2012, the components of intangibles and certain other related information were as follows:
		31-Dec-13								31-Dec-12
		Gross			Accumulated			Weighted		Gross		Accumulated			Weighted
		Amount			Amortization			Average		Amount		Amortization			Average
								Amortization							Amortization
								Period							Period
		(in millions)						(in years)		(in millions)					(in years)
	Amortizable Intangible Assets:
	Developed technology	$	647.7		$	(343.8	)	11.1		$	644.2	$	(284.5	)	11.1
	Customer relationships	54.7			(21.8		)	2.7		54.5		(1.2		)	2.7
	Licensing	185.8			(164.8		)	9.3		185.9		(157.8		)	9.3
	Trademarks	89.6			(29.7		)	12.4		87.9		(25.3		)	12.3
	Core technology	327.5			(66.9		)	14.8		93.8		(46.5		)	14.4
	Other	30.7			(12.8		)	7.6		43.9		(14.1		)	6.4
		1,336.00			(639.8		)	11.4		1,110.20		(529.4		)	10.6
	Unamortizable Intangible Assets:
	In-process research and development	953.8			—					279.3		—
		$	2,289.80		$	(639.8	)			$	1,389.50	$	(529.4	)
Amortization Expense of Intangible Assets	'
	The following table provides amortization expense by major categories of intangible assets for the years ended December 31, 2013, 2012 and 2011, respectively:
		2013			2012			2011
		(in millions)
	Developed technology	$	57.2		$	53.4		$	53.7
	Customer relationships	20.5			1.1			—
	Licensing	7.4			20.4			20.4
	Trademarks	4.4			0.4			1.4
	Core technology	19.4			6.5			6.7
	Other	7.8			8.4			3.9
		$	116.7		$	90.2		$	86.1
Goodwill	'
	Goodwill
	Changes in the carrying amount of goodwill by operating segment for the years ended December 31, 2013 and 2012 were as follows:
		Specialty			Medical			Total
		Pharmaceuticals			Devices
		(in millions)
	Balance at December 31, 2011	$	150.1		$	1,832.60		$	1,982.70
	SkinMedica acquisition	142.7			—			142.7
	Purchase of distributor’s business in Russia	3.8			—			3.8
	Foreign exchange translation effects and other	3.2			1.4			4.6
	Balance at December 31, 2012	299.8			1,834.00			2,133.80
	MAP acquisition	175			—			175
	Exemplar acquisition	14			—			14
	SkinMedica acquisition adjustments	17.6			—			17.6
	Foreign exchange translation effects and other	(5.2		)	4.2			(1.0		)
	Balance at December 31, 2013	$	501.2		$	1,838.20		$	2,339.40

Notes_Payable_and_LongTerm_Deb1

Notes Payable and Long-Term Debt (Tables)	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Notes Payable and Long-Term Debt	'
		2013		31-Dec-13		2012		31-Dec-12
		Average				Average
		Effective				Effective
		Interest				Interest
		Rate				Rate
				(in millions)				(in millions)
	Bank loans	6.07	%	$	55.6	6.06	%	$	48.8
	Real estate mortgage; maturing 2017	5.65	%	20		5.65	%	20
	Senior notes due 2016	3.94	%	831		3.94	%	843.9
	Senior notes due 2018	1.39	%	249.5		—		—
	Senior notes due 2020	3.41	%	648.7		3.41	%	648.5
	Senior notes due 2023	2.83	%	349.1		—		—
				2,153.90				1,561.20
	Less current maturities			55.6				48.8
	Total long-term debt			$	2,098.30			$	1,512.40

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Components of Earnings Before Income Taxes	'
	The components of earnings from continuing operations before income taxes were:
		Year Ended December 31,
		2013				2012				2011
		(in millions)
	U.S.	$	890.1			$	846.8			$	705.5
	Non-U.S.	840.7				684.2				603.7
	Total	$	1,730.80			$	1,531.00			$	1,309.20
Provision for Income Taxes	'
	The provision for income taxes consists of the following:
		Year Ended December 31,
		2013				2012				2011
		(in millions)
	Current
	U.S. federal	$	342.4			$	378.3			$	298.2
	U.S. state	24.7				20.4				32.7
	Non-U.S.	152.7				103.9				83.6
	Total current	519.8				502.6				414.5
	Deferred
	U.S. federal	(34.8		)		(72.7		)		(45.8		)
	U.S. state	(12.6		)		0.1				(18.2		)
	Non-U.S.	(14.1		)		0.3				9.1
	Total deferred	(61.5		)		(72.3		)		(54.9		)
	Total	$	458.3			$	430.3			$	359.6
Reconciliation of the US Federal Statutory Tax Rate to Effective Tax Rate	'
	The reconciliations of the U.S. federal statutory tax rate to the combined effective tax rate follow:
		2013			2012			2011
	Statutory rate of tax expense	35	%		35	%		35	%
	State taxes, net of U.S. tax benefit	0.9			1.1			1.6
	Tax differential on foreign earnings	(9.0	)		(8.8	)		(9.4	)
	Other credits (R&D)	(3.0	)		(0.9	)		(2.0	)
	Tax audit settlements/adjustments	0.8			1.3			1.5
	Other	1.8			0.4			0.8
	Effective tax rate	26.5	%		28.1	%		27.5	%
Significant Components of Deferred Tax Assets and Liabilities	'
	Temporary differences and carryforwards/carrybacks which give rise to a significant portion of deferred tax assets and liabilities at December 31, 2013 and 2012 are as follows:
		2013				2012
		(in millions)
	Deferred tax assets
	Net operating losses	$	179.7			$	66.6
	Accrued expenses	130				114.4
	Capitalized expenses	176.5				182.3
	Deferred compensation	47.4				41.7
	Medicare, Medicaid and other accrued health care rebates	80				85
	Postretirement medical benefits	16.6				17.8
	Capitalized intangible assets	38.9				45
	Deferred revenue	19.2				22.3
	Inventory reserves and adjustments	14.5				18.7
	Share-based compensation awards	101.6				90.2
	Unbilled costs	28.3				23
	Pension plans	52.6				66.5
	R&D credits	26.2				12.7
	All other	46.3				30.1
		957.8				816.3
	Less: valuation allowance	(48.9		)		(22.6		)
	Total deferred tax assets	908.9				793.7
	Deferred tax liabilities
	Depreciation	0.1				9.6
	Developed and core technology intangible assets	153.5				227.3
	In-process R&D	348.6				100.8
	Total deferred tax liabilities	502.2				337.7
	Net deferred tax assets	$	406.7			$	456
Reconciliation of Unrecognized Tax Benefits	'
	A tabular reconciliation of the total amounts of unrecognized tax benefits at the beginning and end of 2013, 2012 and 2011 is as follows:
		2013				2012				2011
		(in millions)
	Balance, beginning of year	$	61.9			$	53			$	32.5
	Gross increase as a result of positions taken in a prior year	8.7				20.9				21.8
	Gross decrease as a result of positions taken in a prior year	(14.6		)		(12.7		)		(8.5		)
	Gross increase as a result of positions taken in current year	23.3				3.4				16.9
	Gross decrease as a result of positions taken in current year	—				—				(6.0		)
	Decreases related to settlements	(2.0		)		(2.7		)		(3.7		)
	Balance, end of year	$	77.3			$	61.9			$	53
Tax Years Remaining Subject to Examination by Taxing Authorities	'
	The following tax years remain subject to examination:
	Major Jurisdictions	Open Years
	U.S. Federal	2005 - 2012
	California	2000 - 2012
	Brazil	2008 - 2012
	Canada	2005 - 2012
	France	2011 - 2012
	Germany	2012
	Italy	2008 - 2012
	Ireland	2006 - 2012
	Spain	2009 - 2012
	United Kingdom	2011 - 2012

Employee_Retirement_and_Other_1

Employee Retirement and Other Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]	'
Components of Net Periodic Benefit Cost	'
	Net Periodic Benefit Cost
	Components of net periodic benefit cost for the years ended 2013, 2012 and 2011 were as follows:
		Pension Benefits											Other Postretirement Benefits
		2013				2012				2011			2013				2012			2011
		(in millions)
	Service cost	$	28.5			$	25.7			$	23.7		$	1.8			$	1.7		$	1.9
	Interest cost	46.2				43.8				42.6			2				1.9			2.6
	Expected return on plan assets	(45.0		)		(43.4		)		(44.3		)	—				—			—
	Amortization of prior service costs (credits)	—				—				0.1			(2.7		)		(2.7		)	(1.6		)
	Recognized net actuarial losses	31				27				17.3			1.4				1.3			1.1
	Net periodic benefit cost	$	60.7			$	53.1			$	39.4		$	2.5			$	2.2		$	4
Change in Projected Benefit Obligation, Change in Plan Assets and Funded Status of Plans	'
	Benefit Obligation, Change in Plan Assets and Funded Status
	The table below presents components of the change in projected benefit obligation, change in plan assets and funded status at December 31, 2013 and 2012.
		Pension Benefits								Other Postretirement Benefits
		2013				2012				2013			2012
		(in millions)
	Change in Projected Benefit Obligation
	Projected benefit obligation, beginning of year	$	1,084.60			$	933.2			$	47.9		$	42.5
	Service cost	28.5				25.7				1.8			1.7
	Interest cost	46.2				43.8				2			1.9
	Participant contributions	1.5				1.5				—			—
	Plan changes	(1.0		)		(1.6		)		—			—
	Actuarial (gains) losses	(25.7		)		93.3				(5.4		)	2.5
	Benefits paid	(19.8		)		(17.9		)		(0.5		)	(0.7		)
	Impact of foreign currency translation	11.3				6.6				—			—
	Projected benefit obligation, end of year	1,125.60				1,084.60				45.8			47.9
	Change in Plan Assets
	Fair value of plan assets, beginning of year	869.3				729.9				—			—
	Actual return on plan assets	31.3				103				—			—
	Company contributions	42.3				47.1				0.5			0.7
	Participant contributions	1.5				1.5				—			—
	Benefits paid	(19.8		)		(17.9		)		(0.5		)	(0.7		)
	Impact of foreign currency translation	9.3				5.7				—			—
	Fair value of plan assets, end of year	933.9				869.3				—			—
	Funded status of plans	$	(191.7	)		$	(215.3	)		$	(45.8	)	$	(47.9	)
Net Accrued Benefit Costs Reported in the Consolidated Balance Sheet	'
	Net accrued benefit costs for pension plans and other postretirement benefits are reported in the following components of the Company’s consolidated balance sheet at December 31, 2013 and 2012:
		Pension Benefits								Other Postretirement Benefits
		2013				2012				2013			2012
		(in millions)
	Investments and other assets	$	5.6			$	5.7			$	—		$	—
	Accrued compensation	(2.8		)		(2.7		)		(1.5		)	(1.3		)
	Other liabilities	(194.5		)		(218.3		)		(44.3		)	(46.6		)
	Net accrued benefit costs	$	(191.7	)		$	(215.3	)		$	(45.8	)	$	(47.9	)
Benefit Obligations in Excess of Fair Value of Plan Assets	'
	The projected benefit obligation, accumulated benefit obligation and fair value of plan assets for pension plans with a projected benefit obligation in excess of the fair value of plan assets and pension plans with accumulated benefit obligations in excess of the fair value of plan assets at December 31, 2013 and 2012 were as follows:
		Projected Benefit								Accumulated
		Obligation								Benefit
		Exceeds								Obligation
		the Fair Value of								Exceeds the Fair
		Plan Assets								Value of
										Plan Assets
		2013				2012				2013			2012
		(in millions)
	Projected benefit obligation	$	1,098.40			$	1,061.60			$	327.5		$	980.9
	Accumulated benefit obligation	992.3				965.8				283.5			900.7
	Fair value of plan assets	901.1				840.6				156.6			762.7
Fair Values of the Plan Assets by Investment Category	'
	The table below presents total plan assets by investment category as of December 31, 2013 and 2012 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value:
		December 31, 2013
		Total				Level 1				Level 2			Level 3
		(in millions)
	Cash and Equivalents	$	16.9			$	—			$	16.9		$	—
	Equity Securities
	U.S. small-cap growth	26.1				26.1				—			—
	U.S. large-cap index	65.3				65.3				—			—
	International equities	212.7				212.7				—			—
	Fixed Income Securities
	U.S. Treasury bonds	86.5				—				86.5			—
	Global corporate bonds	385.1				—				385.1			—
	International bond funds	91.4				—				91.4			—
	Global corporate bond funds	20.4				20.4				—			—
	International government bond funds	29.5				29.5				—			—
		$	933.9			$	354			$	579.9		$	—
		December 31, 2012
		Total				Level 1				Level 2			Level 3
		(in millions)
	Cash and Equivalents	$	16.2			$	—			$	16.2		$	—
	Equity Securities
	U.S. small-cap growth	26.5				26.5				—			—
	U.S. large-cap index	74				74				—			—
	International equities	201.4				201.4				—			—
	Fixed Income Securities
	U.S. Treasury bonds	87.3				—				87.3			—
	Global corporate bonds	345.4				—				345.4			—
	International bond funds	82.6				—				82.6			—
	Global corporate bond funds	14.6				14.6				—			—
	International government bond funds	21.3				21.3				—			—
		$	869.3			$	337.8			$	531.5		$	—
Weighted-Average Assumptions Used to Determine Net Periodic Benefit Cost and Projected Benefit Obligations	'
	Assumptions
	The weighted-average assumptions used to determine net periodic benefit cost and projected benefit obligation were as follows:
		Pension Benefits									Other
											Postretirement Benefits
		2013			2012			2011			2013		2012			2011
	For Determining Net Periodic Benefit Cost
	U.S. Plans:
	Discount rate	4.23	%		4.63	%		5.51	%		4.21	%	4.6	%		5.56	%
	Expected return on plan assets	6.25	%		6.75	%		7.25	%		—		—			—
	Rate of compensation increase	4	%		4	%		4	%		—		—			—
	Non-U.S. Pension Plans:
	Discount rate	4.55	%		5.14	%		5.57	%
	Expected return on plan assets	4.36	%		4.8	%		5.7	%
	Rate of compensation increase	2.89	%		3.04	%		3.1	%
	For Determining Projected Benefit Obligation
	U.S. Plans:
	Discount rate	5.05	%		4.23	%					5.02	%	4.21	%
	Rate of compensation increase	4	%		4	%					—		—
	Non-U.S. Pension Plans:
	Discount rate	4.19	%		4.55	%
	Rate of compensation increase	2.94	%		2.89	%
Estimated Benefit Payments Over the Next 10 Years	'
	Estimated Future Benefit Payments
	Estimated benefit payments over the next 10 years for the Company’s U.S. and major non-U.S. pension plans and retiree health plan are as follows:
		Pension				Other
		Benefits				Postretirement
						Benefits
		(in millions)
	2014	$	27.1			$	1.5
	2015	30.1				1.7
	2016	33.4				2
	2017	37.3				2.3
	2018	40.7				2.5
	2019 – 2023	261.6				15.9
		$	430.2			$	25.9

Employee_Stock_Plans_Tables

Employee Stock Plans (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock Option Activity	'
	The following table summarizes the Company’s stock option activity:
		2013							2012					2011
		Number			Weighted				Number			Weighted		Number		Weighted
		of			Average				of			Average		of		Average
		Shares			Exercise				Shares			Exercise		Shares		Exercise
					Price							Price				Price
		(in thousands, except option exercise price and fair value data)
	Outstanding, beginning of year	21,567			$	65			22,651			$	57.47	23,856		$	51.5
	Options granted	4,511			105.38				4,372			88.01		5,007		75.95
	Options exercised	(3,187	)		57.36				(4,928	)		50.02		(5,496	)	48.01
	Options cancelled	(874	)		89.29				(528	)		72.39		(716	)	60.35
	Outstanding, end of year	22,017			73.41				21,567			65		22,651		57.47
	Exercisable, end of year	12,051			59.52				10,906			56.25		12,414		53.05
	Weighted average per share fair value of options granted during the year				$	27.58						$	22.45			$	23.3
Restricted Share Activity	'
	The following table summarizes the Company’s restricted share activity:
		2013							2012					2011
		Number			Weighted				Number			Weighted		Number		Weighted
		of			Average				of			Average		of		Average
		Shares			Grant-Date				Shares			Grant-Date		Shares		Grant-Date
					Fair Value							Fair Value				Fair Value
		(in thousands, except fair value data)
	Restricted share awards, beginning of year	1,165			$	67.08			1,035			$	57.38	886		$	51.2
	Shares granted	178			104.66				360			88.75		277		76.52
	Shares vested	(406	)		48.2				(198	)		57.22		(87	)	56.12
	Shares cancelled	(62	)		78.69				(32	)		59.87		(41	)	54.45
	Restricted share awards, end of year	875			76.59				1,165			67.08		1,035		57.38
Share-Based Compensation Expense by Award Type	'
	The following table summarizes share-based compensation expense by award type for the years ended December 31, 2013, 2012 and 2011, respectively:
		2013				2012				2011
		(in millions)
	Employee and director stock options	$	90.1			$	81.1			$	64.3
	Employee and director restricted share awards	16.4				19.4				14.8
	Stock contributed to employee benefit plans	6.2				6.1				5.7
	Pre-tax share-based compensation expense	112.7				106.6				84.8
	Income tax benefit	(35.8		)		(34.6		)		(28.0		)
	Net share-based compensation expense	$	76.9			$	72			$	56.8
Share-Based Compensation Expense by Expense Category	'
	The following table summarizes pre-tax share-based compensation expense by expense category for the years ended December 31, 2013, 2012 and 2011, respectively:
		2013				2012				2011
		(in millions)
	Cost of sales	$	9.4			$	9			$	7.8
	Selling, general and administrative	74.1				70.1				55.3
	Research and development	29.2				27.5				21.7
	Pre-tax share-based compensation expense	$	112.7			$	106.6			$	84.8
Share- Based Awards Fair Value Assumptions	'
	The determination of fair value using the Black-Scholes, Monte Carlo simulation and lattice models is affected by the Company’s stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk-free interest rate, expected dividends and projected employee stock option exercise behaviors. Stock options granted during 2013, 2012 and 2011 were valued using the Black-Scholes option-pricing model with the following weighted-average assumptions:
		2013			2012			2011
	Expected volatility	26.22	%		25.65	%		27.82	%
	Risk-free interest rate	1.05	%		1.07	%		2.54	%
	Expected dividend yield	0.2	%		0.26	%		0.32	%
	Expected option life (in years)	5.73			5.73			5.85

Financial_Instruments_Tables

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Notional Principal and Fair Value of Foreign Currency Derivative Instruments	'
	At December 31, 2013 and 2012, the notional principal and fair value of the Company’s outstanding foreign currency derivative financial instruments were as follows:
		2013				2012
		Notional		Fair		Notional		Fair
		Principal		Value		Principal		Value
		(in millions)
	Foreign currency forward exchange contracts	$	35	$	0.1	$	44.6	$	0.3
	(Receive U.S. dollar/pay foreign currency)
	Foreign currency forward exchange contracts	41.3		0.1		39.6		—
	(Pay U.S. dollar/receive foreign currency)
	Foreign currency sold — put options	560.8		20.2		501.6		9.9
Carrying Amount and Estimated Fair Value of Other Financial Instruments	'
	The carrying amount and estimated fair value of the Company’s other financial instruments at December 31, 2013 and 2012 were as follows:
		2013				2012
		Carrying		Fair		Carrying		Fair
		Amount		Value		Amount		Value
		(in millions)
	Cash and equivalents	$	3,046.10	$	3,046.10	$	2,701.80	$	2,701.80
	Short-term investments	603		603		260.6		260.6
	Non-current non-marketable equity investments	20.8		20.8		9		9
	Notes payable	55.6		55.6		48.8		48.8
	Long-term debt	2,098.30		2,163.80		1,512.40		1,673.00

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'
		December 31, 2013
		Total			Level 1			Level 2		Level 3
		(in millions)
	Assets
	Commercial paper	$	2,016.80		$	—		$	2,016.80	$	—
	Foreign time deposits	370.3			—			370.3		—
	Other cash equivalents	1,080.40			—			1,080.40		—
	Foreign exchange derivative assets	20.4			—			20.4		—
	Deferred executive compensation investments	100.7			80.4			20.3		—
		$	3,588.60		$	80.4		$	3,508.20	$	—
	Liabilities
	Deferred executive compensation liabilities	$	93		$	72.7		$	20.3	$	—
	Contingent consideration liabilities	225.2			—			—		225.2
		$	318.2		$	72.7		$	20.3	$	225.2
		December 31, 2012
		Total			Level 1			Level 2		Level 3
		(in millions)
	Assets
	Commercial paper	$	1,709.00		$	—		$	1,709.00	$	—
	Foreign time deposits	341.7			—			341.7		—
	Other cash equivalents	685			—			685		—
	Foreign exchange derivative assets	10.2			—			10.2		—
	Deferred executive compensation investments	81.7			66.8			14.9		—
		$	2,827.60		$	66.8		$	2,760.80	$	—
	Liabilities
	Deferred executive compensation liabilities	73.5			58.6			14.9		—
	Contingent consideration liabilities	224.3			—			—		224.3
		$	297.8		$	58.6		$	14.9	$	224.3
Reconciliation of the Change in the Contingent Consideration Liabilities	'
	The following table provides a reconciliation of the change in the contingent consideration liabilities for the years ended December 31, 2013 and 2012:
		2013			2012
		(in million)
	Balance, beginning of year	$	224.3		$	214.6
	Additions during the period related to business combinations	—			6.9
	Change in the estimated fair value of the contingent consideration liabilities	70.7			5.4
	Payments made during the period	(61.2		)	(5.1		)
	Foreign exchange translation effects	(8.6		)	2.5
	Balance, end of year	$	225.2		$	224.3

Product_Warranties_Tables

Product Warranties (Tables)	12 Months Ended
	Dec. 31, 2013
Product Warranties Disclosures [Abstract]	'
Change in Estimated Product Warranty Liabilities	'
	The following table provides a reconciliation of the change in estimated product warranty liabilities for the years ended December 31, 2013 and 2012:
		2013			2012
		(in millions)
	Balance, beginning of year	$	34.4		$	32.6
	Provision for warranties issued during the year	8			9.9
	Settlements made during the year	(8.1		)	(8.1		)
	Decreases in warranty estimates	(0.7		)	—
	Balance, end of year	$	33.6		$	34.4
	Current portion	$	7.6		$	6.7
	Non-current portion	26			27.7
	Total	$	33.6		$	34.4

Business_Segment_Information_T

Business Segment Information (Tables)	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Operating Segments	'
		2013		2012		2011
		(in millions)
	Product net sales:
	Specialty pharmaceuticals	$	5,339.00	$	4,784.60	$	4,432.00
	Medical devices	858.5		764.7		712
	Total product net sales	6,197.50		5,549.30		5,144.00
	Other revenues	102.9		97.3		72
	Total revenues	$	6,300.40	$	5,646.60	$	5,216.00
	Operating income:
	Specialty pharmaceuticals	$	2,282.00	$	1,997.70	$	1,763.30
	Medical devices	246.2		229.1		238.1
	Total segments	2,528.20		2,226.80		2,001.40
	General and administrative expenses, other indirect costs and other adjustments	594.6		525.3		556.7
	Amortization of intangible assets (a)	107.4		66.7		62.6
	Impairment of intangible assets and related costs	11.4		22.3		7.6
	Restructuring charges (reversal)	5.5		1.5		(0.1		)
	Total operating income	$	1,809.30	$	1,611.00	$	1,374.60
	——————————
	(a)	Represents amortization of certain identifiable intangible assets related to business combinations and asset acquisitions and related capitalized licensing costs, as applicable.
Product Net Sales by Product Line	'
		2013		2012		2011
		(in millions)
	Specialty Pharmaceuticals:
	Eye Care Pharmaceuticals	$	2,890.30	$	2,692.20	$	2,520.20
	Botox®/Neuromodulators	1,982.20		1,766.30		1,594.90
	Skin Care and Other	466.5		326.1		316.9
	Total Specialty Pharmaceuticals	5,339.00		4,784.60		4,432.00
	Medical Devices:
	Breast Aesthetics	377.9		377.1		349.3
	Facial Aesthetics	477.5		387.6		362.7
	Core Medical Devices	855.4		764.7		712
	Other	3.1		—		—
	Total Medical Devices	858.5		764.7		712
	Total product net sales	$	6,197.50	$	5,549.30	$	5,144.00
Geographic Information	'
	Geographic Information
		Product Net Sales
		2013		2012		2011
		(in millions)
	United States	$	3,839.40	$	3,379.10	$	3,086.30
	Europe	1,237.80		1,095.50		1,057.40
	Latin America	383		386.3		377.3
	Asia Pacific	464.1		432.3		389.3
	Other	273.2		256.1		233.7
	Total product net sales	$	6,197.50	$	5,549.30	$	5,144.00
		Long-lived Assets				Depreciation and							Capital Expenditures
						Amortization
		2013		2012		2013			2012		2011		2013		2012		2011
		(in millions)
	United States	$	4,274.70	$	3,242.90	$	181.2		$	153.5	$	146.7	$	82.3	$	75.7	$	63.3
	Europe	569.9		538.6		49.6			48.1		49.7		79.7		59.5		45.6
	Latin America	52.2		55.2		7.7			8.1		9.4		7.6		6		6.3
	Asia Pacific	51.2		53.8		5			4.6		4.5		2.3		2		2.1
	Other	1.4		2.2		0.6			0.8		0.9		—		0.1		—
	Total	$	4,949.40	$	3,892.70	$	244.1		$	215.1	$	211.2	$	171.9	$	143.3	$	117.3

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Computation of Basic and Diluted Earnings Per Share	'
	The table below presents the computation of basic and diluted earnings per share:
		Year Ended December 31,
		2013			2012		2011
		(in millions, except per share amounts)
	Net earnings attributable to Allergan, Inc.:
	Earnings from continuing operations attributable to Allergan, Inc.:
	Earnings from continuing operations	$	1,272.50		$	1,100.70	$	949.6
	Less net earnings attributable to noncontrolling interest	3.6			3.7		3.6
	Earnings from continuing operations attributable to Allergan, Inc.	1,268.90			1,097.00		946
	(Loss) earnings from discontinued operations	(283.8		)	1.8		(11.5		)
	Net earnings attributable to Allergan, Inc.	$	985.1		$	1,098.80	$	934.5
	Weighted average number of shares outstanding	296.8			301.5		304.4
	Net shares assumed issued using the treasury stock method for options and non-vested equity shares and share units outstanding during each period based on average market price	5			5.6		5.5
	Dilutive effect of assumed conversion of convertible notes outstanding	—			—		0.3
	Diluted shares	301.8			307.1		310.2
	Basic earnings per share attributable to Allergan, Inc. stockholders:
	Continuing operations	$	4.28		$	3.64	$	3.11
	Discontinued operations	(0.96		)	—		(0.04		)
	Net basic earnings per share attributable to Allergan, Inc. stockholders	$	3.32		$	3.64	$	3.07
	Diluted earnings per share attributable to Allergan, Inc. stockholders:
	Continuing operations	$	4.2		$	3.57	$	3.05
	Discontinued operations	(0.94		)	0.01		(0.04		)
	Net diluted earnings per share attributable to Allergan, Inc. stockholders	$	3.26		$	3.58	$	3.01

Schedule_II_VALUATION_AND_QUAL1

Schedule II - VALUATION AND QUALIFYING ACCOUNTS (Tables)	12 Months Ended
	Dec. 31, 2013
Valuation and Qualifying Accounts [Abstract]	'
Valuation and Qualifying Accounts	'
	VALUATION AND QUALIFYING ACCOUNTS
	Years Ended December 31, 2013, 2012 and 2011
	Allowance for Doubtful Accounts Deducted from Trade Receivables		Balance at		Additions (a)		Deductions (b)			Balance
			Beginning							at End
			of Year							of Year
			(in millions)
	2013		$	24.2	$	6.2	$	(6.2	)	$	24.2
	2012		27.6		0.8		(4.2		)	24.2
	2011		25.3		6.6		(4.3		)	27.6
	——————————
	(a)	Provision charged to earnings.
	(b)	Accounts written off, net of recoveries.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Details) (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Accounting Policies [Abstract]	'	'	'
Aggregate net realized and unrealized (losses) gains resulting from foreign currency transactions and derivative contracts	($7.40)	($23.40)	$0.30
Number of shares the Company may maintain in its treasury account at any one time under the evergreen stock repurchase program (in shares)	18,400,000	'	'
Number of treasury shares (in shares)	9,947,345	7,213,757	'
Amounts reserved for cash discounts	6.3	4.2	'
Amount of allowances for sales returns	84.4	77.9	'
Amounts accrued for sales rebates and other incentive programs	279.3	269.6	'
Advertising expenses	179.7	158.5	168.6
Deferred tax assets valuation allowances	48.9	22.6	'
Unremitted earnings outside the United States	$3,828	'	'
Building and Building Improvements [Member] | Minimum [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property, plant and equipment, useful life	'7 years	'	'
Building and Building Improvements [Member] | Maximum [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property, plant and equipment, useful life	'40 years	'	'
Machinery and Equipment [Member] | Minimum [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property, plant and equipment, useful life	'3 years	'	'
Machinery and Equipment [Member] | Maximum [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property, plant and equipment, useful life	'15 years	'	'

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Intangible Assets) (Details)	12 Months Ended
	Dec. 31, 2013
Minimum [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Finite-lived intangible asset, useful life	'2 years
Maximum [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Finite-lived intangible asset, useful life	'21 years

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Acquisitions) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Mar. 31, 2012	Dec. 31, 2013	Feb. 01, 2012	Dec. 31, 2012	Dec. 31, 2013	Dec. 19, 2012	Mar. 31, 2013	Jun. 30, 2013
In Millions, unless otherwise specified			Purchase of Distributors Business In Russia [Member]	Purchase of Distributors Business In Russia [Member]	Purchase of Distributors Business In Russia [Member]	SkinMedica Acquisition [Member]	SkinMedica Acquisition [Member]	SkinMedica Acquisition [Member]	MAP Acquisition [Member]	Exemplar Acquisition [Member]
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'	'	'
Date of acquisition	'	'	1-Feb-12	'	'	19-Dec-12	'	'	1-Mar-13	12-Apr-13
Business combination, cash payments to acquire businesses	'	'	$3.10	'	'	$348.90	'	'	'	'
Pre-existing receivable from the distributor	'	'	'	'	6.6	'	'	'	'	'
Fair value of contingent consideration	225.2	224.3	'	2	4.7	'	2.2	2.2	'	'
Business combination, total consideration	'	'	'	'	'	'	'	'	$871.70	$16.10

Acquisitions_and_Collaboration2

Acquisitions and Collaborations (Details) (USD $)

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

3 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

In Millions, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Mar. 31, 2013

Mar. 01, 2013

Dec. 31, 2013

Mar. 01, 2013

Mar. 01, 2013

Jun. 30, 2013

Apr. 12, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 19, 2012

Dec. 31, 2013

Dec. 19, 2012

Dec. 31, 2013

Dec. 19, 2012

Dec. 31, 2013

Dec. 19, 2012

Dec. 19, 2012

Mar. 31, 2012

Dec. 31, 2013

Feb. 01, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

MAP Acquisition [Member]

MAP Acquisition [Member]

MAP Acquisition [Member]

MAP Acquisition [Member]

MAP Acquisition [Member]

Exemplar Acquisition [Member]

Exemplar Acquisition [Member]

SkinMedica Acquisition [Member]

SkinMedica Acquisition [Member]

SkinMedica Acquisition [Member]

SkinMedica Acquisition [Member]

SkinMedica Acquisition [Member]

SkinMedica Acquisition [Member]

SkinMedica Acquisition [Member]

SkinMedica Acquisition [Member]

SkinMedica Acquisition [Member]

SkinMedica Acquisition [Member]

Purchase of Distributors Business In Russia [Member]

Purchase of Distributors Business In Russia [Member]

Purchase of Distributors Business In Russia [Member]

Purchase of Distributors Business In Russia [Member]

Purchase of Distributors Business In Russia [Member]

Purchase of Noncontrolling Interest in a Subsidiary [Member]

Core Technology [Member]

Core Technology [Member]

In Process Research and Development [Member]

Developed Technology [Member]

Developed Technology [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Trademarks [Member]

Trademarks [Member]

In Process Research and Development [Member]

Customer Relationships [Member]

Contractual Rights [Member]

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Date of acquisition

'

'

'

1-Mar-13

'

'

'

'

12-Apr-13

'

19-Dec-12

'

'

'

'

'

'

'

'

'

1-Feb-12

'

'

'

'

'

Business combination, total consideration

'

'

'

$871.70

'

'

'

'

$16.10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business combination, cash payments to acquire businesses

'

'

'

'

'

'

'

'

'

'

348.9

'

'

'

'

'

'

'

'

'

3.1

'

'

'

'

'

Contingent consideration potential cash payment

'

'

'

'

'

'

'

'

'

'

'

'

25

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of contingent consideration

225.2

224.3

'

'

'

'

'

'

'

'

'

2.2

2.2

'

'

'

'

'

'

'

'

2

4.7

'

'

'

Pre-existing payable to Exemplar

'

'

'

'

'

'

'

'

'

1.9

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Pre-existing receivable from the distributor

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6.6

'

'

'

Fair value of assets acquired

'

'

'

'

1,233.60

'

'

'

'

16.6

'

'

438.6

'

'

'

'

'

'

'

'

'

14.4

'

'

'

Current assets

'

'

'

'

2.3

'

'

'

'

0.5

'

'

30.2

'

'

'

'

'

'

'

'

'

'

'

'

'

Inventories

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

Property, plant, and equipment

'

'

'

'

7.7

'

'

'

'

2.1

'

'

6.6

'

'

'

'

'

'

'

'

'

'

'

'

'

Other non-current assets

'

'

'

'

0.3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred tax assets

'

'

'

'

132.7

'

'

'

'

'

'

'

40.6

'

'

'

'

'

'

'

'

'

'

'

'

'

Intangible assets

'

'

'

'

915.6

'

232.1

683.5

'

'

'

'

200.9

'

87.5

'

50.6

'

62.5

0.3

'

'

8.6

'

'

'

Goodwill

2,339.40

2,133.80

1,982.70

'

175

'

'

'

'

14

'

'

160.3

'

'

'

'

'

'

'

'

'

3.8

'

'

'

Liabilities assumed

'

'

'

'

361.9

'

'

'

'

'

'

'

87.5

'

'

'

'

'

'

'

'

'

'

'

'

'

Current liabilities

'

'

'

'

27.3

'

'

'

'

0.5

'

'

11.5

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred tax liabilities

'

'

'

'

334.6

'

'

'

'

'

'

'

76

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated useful life of the intangible asset

'11 years 5 months

'10 years 7 months

'

'

'

'15 years

'

'

'

'

'

'

'

'10 years 7 months

'

'2 years 8 months

'

'15 years

'

'

'

'

'

'3 years

'2 years

'

Date of purchase of noncontrolling interest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

30-Nov-13

Purchase of noncontrolling interest in a subsidiary

18

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

18

Decrease in APIC due to the purchase of noncontrolling interest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.30

Acquisitions_and_Collaboration3

Acquisitions and Collaborations (Collaborations) (Details) (USD $)

Dec. 31, 2013

Sep. 30, 2012

Dec. 31, 2013

Jun. 30, 2011

Dec. 31, 2013

Sep. 30, 2011

Mar. 31, 2011

Jan. 31, 2014

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2013

Mar. 31, 2010

Dec. 31, 2010

Dec. 31, 2013

In Millions, unless otherwise specified

Collaborative Arrangement II with Molecular Partners [Member]

Collaborative Arrangement II with Molecular Partners [Member]

Collaborative Arrangement I With Molecular Partners [Member]

Collaborative Arrangement I With Molecular Partners [Member]

Collaborative Arrangement With MAP [Member]

Collaborative Arrangement With MAP [Member]

Collaborative Arrangement with Medytox [Member]

Collaborative Arrangement with Medytox [Member]

Collaborative Arrangement with Medytox [Member]

Collaborative Arrangement With A Third Party [Member]

Collaborative Arrangement With Serenity [Member]

Collaborative Arrangement With Serenity [Member]

Collaborative Arrangement With Serenity [Member]

Business Collaborations [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Date of collaboration agreement

'

21-Aug-12

'

4-May-11

'

'

28-Jan-11

'

25-Sep-13

'

10-Sep-13

31-Mar-10

'

'

Upfront payment

'

$62.50

'

$45

'

'

$60

$65

'

'

$6.50

'

$43

'

Milestone payment

'

'

'

'

'

20

'

'

'

'

'

'

'

'

Potential future milestone payments

'

'

1,400

'

375

'

'

'

'

'

'

'

'

'

Potential future development milestone payments

'

'

'

'

'

'

'

'

'

116.5

'

'

'

'

Potential future sales milestone payments

'

'

'

'

'

'

'

'

'

180.5

'

'

'

'

Share of the cost of additional development activities (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

Potential future milestone receipts

55.7

'

'

'

'

'

'

'

'

'

'

'

'

'

Potential future development milestone receipts

3.5

'

'

'

'

'

'

'

'

'

'

'

'

'

Potential future regulatory milestone receipts

17

'

'

'

'

'

'

'

'

'

'

'

'

'

Potential future commercial sales milestone receipts

$35.20

'

'

'

'

'

'

'

'

'

'

'

'

'

Discontinued_Operations_Detail

Discontinued Operations (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 02, 2013
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'
Sale of discontinued operations, cash consideration	'	'	'	$75
Sale of discontinued operations, additional consideration - minority equity interest	'	'	'	15
Sale of discontinued operations, contingent consideration from the buyer	'	'	'	20
Inventories held outside of the United States that reduces the cash consideration	'	'	'	7.6
Net accounts receivable and payable that reduces the cash consideration	'	'	'	19.4
Transaction costs related to the sale of discontinued operations	'	'	'	2.6
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]	'	'	'	'
Product net sales	114.4	159.5	203.1	'
Costs of sales (excludes amortization of intangible assets)	20.2	24.3	30.7	'
Selling, general and administrative	57.9	75.3	88.3	'
Research and development	5	12.3	31.3	'
Amortization of intangible assets	10.3	41.1	41.5	'
Impairment of intangible assets	0	0	16.1	'
Restructuring charges	0	4.2	4.7	'
Earnings (loss) from discontinued operations before income taxes	21	2.3	-9.5	'
Provision for income taxes	-6.9	-0.5	-2	'
Earnings (loss) from discontinued operations, net of income taxes	14.1	1.8	-11.5	'
Loss on sale of discontinued operations before income taxes	-408.2	0	0	'
Income tax benefit on sale of discontinued operations	110.3	0	0	'
Loss on sale of discontinued operation, net of income taxes	-297.9	0	0	'
Discontinued operations	-283.8	1.8	-11.5	'
Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]	'	'	'	'
Trade receivables, net	9	25.2	'	'
Inventories	0	10.6	'	'
Property, plant, and equipment, net	0	1.4	'	'
Goodwill	0	105.7	'	'
Intangibles, net	0	369	'	'
Other assets	0	0.7	'	'
Total assets of discontinued operations	9	512.6	'	'
Accounts payable	0	0.9	'	'
Accrued expenses	0	4.1	'	'
Other liabilities	0	0.3	'	'
Total liabilities of discontinued operations	$0	$5.30	'	'
Transitional period to provide administrative and distribution services	'12 months	'	'	'
Transitional period to manufacture and supply products	'24 months	'	'	'

Restructuring_Charges_and_Inte1

Restructuring Charges and Integration Costs (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Restructuring and Related Cost [Line Items]	'	'	'
Restructuring charges (reversal)	$5.50	$1.50	($0.10)
Integration and transaction costs, cost of sales	0.1	0.1	'
Integration and transaction costs, SG&A expenses	20.6	2.3	2.6
Realignment of business functions, SG&A expenses	1.7	1.5	'
Realignment of business functions, R&D expenses	1.1	0.3	'
MAP, SkinMedica and Exemplar Acquisitions Restructuring [Member]	'	'	'
Restructuring and Related Cost [Line Items]	'	'	'
Restructuring charges (reversal)	4.5	'	'
Number of positions eliminated	111	'	'
Realignment of Business Functions [Member]	'	'	'
Restructuring and Related Cost [Line Items]	'	'	'
Restructuring charges (reversal)	1	0.7	'
Other Restructuring [Member]	'	'	'
Restructuring and Related Cost [Line Items]	'	'	'
Restructuring charges (reversal)	'	$0.80	($0.10)

Composition_of_Certain_Financi2

Composition of Certain Financial Statement Captions (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Trade receivables, net [Abstract]	'	'
Trade receivables	$935.40	$791.40
Less allowance for sales returns - medical device products	-27.9	-28.2
Less allowance for doubtful accounts	-24.2	-24.2
Trade receivables, net	883.3	739
Inventories [Abstract]	'	'
Finished products	180	179.9
Work in process	44.1	41.3
Raw materials	61.2	51.1
Inventories	285.3	272.3
Other currents assets [Abstract]	'	'
Prepaid expenses	157.1	149.2
Deferred taxes	277.9	249.1
Other	58	50.3
Other currents assets	493	448.6
Investments and other assets [Abstract]	'	'
Deferred executive compensation investments	100.7	81.7
Capitalized software	36.8	47.3
Prepaid pensions	5.6	5.7
Debt issuance costs	10.8	8
Non-marketable equity investments	20.8	9
Other	38.5	40.4
Investments and other assets	213.2	192.1
Property, plant and equipment, net [Abstract]	'	'
Land	62.2	61.9
Buildings	962.8	884.4
Machinery and equipment	784.8	708.5
Property, plant and equipment, gross	1,809.80	1,654.80
Less accumulated depreciation	-886.6	-803.3
Property, plant and equipment, net	923.2	851.5
Other accrued expenses [Abstract]	'	'
Sales rebates and other incentive programs	279.3	269.6
Royalties	26.2	26
Interest	22	18.2
Sales returns - specialty pharmaceutical products	56.5	49.7
Product warranties - breast implant products	7.6	6.7
Contingent consideration	9.9	59
Other	196	157.6
Other accrued expenses	597.5	586.8
Other liabilities [Abstract]	'	'
Postretirement benefit plan	44.3	46.6
Qualified and non-qualified pension plans	194.5	218.3
Deferred executive compensation	105.3	85.3
Deferred income	67	75.1
Contingent consideration	215.3	165.3
Product warranties - breast implant products	26	27.7
Unrecognized tax benefit liabilities	67.7	53.8
Other	42.1	36.7
Other liabilities	762.2	708.8
Accumulated other comprehensive loss [Abstract]	'	'
Foreign currency translation adjustments	-29.7	-25.2
Deferred holding gains on derivative instruments, net of taxes	1.8	2.6
Actuarial losses not yet recognized as a component of pension and postretirement benefit plan costs, net of taxes	-198.7	-222
Accumulated other comprehensive loss	-226.6	-244.6
Deferred holding gains on derivative instruments, taxes	1.2	1.7
Actuarial losses not yet recognized as a component of pension and postretirement benefit plan costs, taxes	83.5	106.6
Inventories under consignment	11.7	9.9
Reserves for sales returns related to certain eye care pharmaceutical products genericized	$10.30	$14.80

Intangibles_and_Goodwill_Detai

Intangibles and Goodwill (Details) (USD $)	3 Months Ended			12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Sep. 30, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Finite-Lived Intangible Assets, Net [Abstract]	'	'	'	'	'	'
Gross amount	$1,336	$1,110.20	'	$1,336	$1,110.20	'
Accumulated amortization	-639.8	-529.4	'	-639.8	-529.4	'
Weighted average amortization period	'	'	'	'11 years 5 months	'10 years 7 months	'
Intangible Assets, Net (Excluding Goodwill) (Abstract)	'	'	'	'	'	'
Total intangible assets - gross	2,289.80	1,389.50	'	2,289.80	1,389.50	'
Total intangible assets - accumulated amortization	-639.8	-529.4	'	-639.8	-529.4	'
Amortization expense [Abstract]	'	'	'	'	'	'
Amortization expense of intangible assets	'	'	'	116.7	90.2	86.1
Impairment of an intangible asset for distribution rights	11.4	'	'	'	'	'
Impairment of in-process research and development assets	'	17	4.3	'	'	'
Estimated amortization expense [Abstract]	'	'	'	'	'	'
Estimated amortization expense, 2014	110.3	'	'	110.3	'	'
Estimated amortization expense, 2015	96.7	'	'	96.7	'	'
Estimated amortization expense, 2016	76.4	'	'	76.4	'	'
Estimated amortization expense, 2017	57.9	'	'	57.9	'	'
Estimated amortization expense, 2018	55.9	'	'	55.9	'	'
Developed Technology [Member]	'	'	'	'	'	'
Finite-Lived Intangible Assets, Net [Abstract]	'	'	'	'	'	'
Gross amount	647.7	644.2	'	647.7	644.2	'
Accumulated amortization	-343.8	-284.5	'	-343.8	-284.5	'
Weighted average amortization period	'	'	'	'11 years 1 month	'11 years 1 month	'
Amortization expense [Abstract]	'	'	'	'	'	'
Amortization expense of intangible assets	'	'	'	57.2	53.4	53.7
Customer Relationships [Member]	'	'	'	'	'	'
Finite-Lived Intangible Assets, Net [Abstract]	'	'	'	'	'	'
Gross amount	54.7	54.5	'	54.7	54.5	'
Accumulated amortization	-21.8	-1.2	'	-21.8	-1.2	'
Weighted average amortization period	'	'	'	'2 years 8 months	'2 years 8 months	'
Amortization expense [Abstract]	'	'	'	'	'	'
Amortization expense of intangible assets	'	'	'	20.5	1.1	0
Licensing [Member]	'	'	'	'	'	'
Finite-Lived Intangible Assets, Net [Abstract]	'	'	'	'	'	'
Gross amount	185.8	185.9	'	185.8	185.9	'
Accumulated amortization	-164.8	-157.8	'	-164.8	-157.8	'
Weighted average amortization period	'	'	'	'9 years 4 months	'9 years 4 months	'
Amortization expense [Abstract]	'	'	'	'	'	'
Amortization expense of intangible assets	'	'	'	7.4	20.4	20.4
Trademarks [Member]	'	'	'	'	'	'
Finite-Lived Intangible Assets, Net [Abstract]	'	'	'	'	'	'
Gross amount	89.6	87.9	'	89.6	87.9	'
Accumulated amortization	-29.7	-25.3	'	-29.7	-25.3	'
Weighted average amortization period	'	'	'	'12 years 5 months	'12 years 4 months	'
Amortization expense [Abstract]	'	'	'	'	'	'
Amortization expense of intangible assets	'	'	'	4.4	0.4	1.4
Core Technology [Member]	'	'	'	'	'	'
Finite-Lived Intangible Assets, Net [Abstract]	'	'	'	'	'	'
Gross amount	327.5	93.8	'	327.5	93.8	'
Accumulated amortization	-66.9	-46.5	'	-66.9	-46.5	'
Weighted average amortization period	'	'	'	'14 years 10 months	'14 years 5 months	'
Amortization expense [Abstract]	'	'	'	'	'	'
Amortization expense of intangible assets	'	'	'	19.4	6.5	6.7
Other [Member]	'	'	'	'	'	'
Finite-Lived Intangible Assets, Net [Abstract]	'	'	'	'	'	'
Gross amount	30.7	43.9	'	30.7	43.9	'
Accumulated amortization	-12.8	-14.1	'	-12.8	-14.1	'
Weighted average amortization period	'	'	'	'7 years 7 months	'6 years 5 months	'
Amortization expense [Abstract]	'	'	'	'	'	'
Amortization expense of intangible assets	'	'	'	7.8	8.4	3.9
In-Process Research and Development [Member]	'	'	'	'	'	'
Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]	'	'	'	'	'	'
Unamortizable intangible assets	$953.80	$279.30	'	$953.80	$279.30	'

Intangibles_and_Goodwill_Goodw

Intangibles and Goodwill (Goodwill) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Goodwill [Roll Forward]	'	'
Balance, beginning	$2,133.80	$1,982.70
SkinMedica acquisition	'	142.7
Purchase of distributor's business in Russia	'	3.8
MAP acquisition	175	'
Exemplar acquisition	14	'
SkinMedica acquisition adjustments	17.6	'
Foreign exchange translation effects and other	-1	4.6
Balance, ending	2,339.40	2,133.80
SkinMedica contractual purchase price adjustment	2.8	'
Specialty Pharmaceuticals [Member]	'	'
Goodwill [Roll Forward]	'	'
Balance, beginning	299.8	150.1
SkinMedica acquisition	'	142.7
Purchase of distributor's business in Russia	'	3.8
MAP acquisition	175	'
Exemplar acquisition	14	'
SkinMedica acquisition adjustments	17.6	'
Foreign exchange translation effects and other	-5.2	3.2
Balance, ending	501.2	299.8
Medical Devices [Member]	'	'
Goodwill [Roll Forward]	'	'
Balance, beginning	1,834	1,832.60
SkinMedica acquisition	'	0
Purchase of distributor's business in Russia	'	0
MAP acquisition	0	'
Exemplar acquisition	0	'
SkinMedica acquisition adjustments	0	'
Foreign exchange translation effects and other	4.2	1.4
Balance, ending	$1,838.20	$1,834

Notes_Payable_and_LongTerm_Deb2

Notes Payable and Long-Term Debt (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Debt Instrument [Line Items]	'	'	'
Total debt	$2,153.90	$1,561.20	'
Current maturities	55.6	48.8	'
Total long-term debt	2,098.30	1,512.40	'
Maximum borrowing limit - committed long-term credit facility and commercial paper program combined	800	'	'
Long-term Debt, by Maturity [Abstract]	'	'	'
2014	55.6	'	'
2015	0	'	'
2016	799.5	'	'
2017	20	'	'
2018	249.5	'	'
Thereafter	997.8	'	'
Interest capitalized in property, plant and equipment	1.8	0.9	1
Bank Loans [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Average effective interest rate (in hundredths)	6.07%	6.06%	'
Total debt	55.6	48.8	'
Real Estate Mortgage; Maturing 2017 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Average effective interest rate (in hundredths)	5.65%	5.65%	'
Total debt	20	20	'
Senior Notes Due 2016 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Average effective interest rate (in hundredths)	3.94%	3.94%	'
Total debt	831	843.9	'
Debt instrument, issuance date	12-Apr-06	'	'
Debt instrument, interest rate, stated percentage (in hundredths)	5.75%	'	'
Debt instrument, face amount	800	'	'
Debt instrument, sales price as percentage of par value (in hundredths)	99.72%	'	'
Debt instrument, maturity date	1-Apr-16	'	'
Debt instrument, unamortized discount	2.3	'	'
Debt instruments, amortization period for debt discount and deferred debt issuance costs	'10 years	'	'
Senior Notes Due 2018 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Average effective interest rate (in hundredths)	1.39%	'	'
Total debt	249.5	'	'
Debt instrument, issuance date	12-Mar-13	'	'
Debt instrument, interest rate, stated percentage (in hundredths)	1.35%	'	'
Debt instrument, face amount	250	'	'
Debt instrument, sales price as percentage of par value (in hundredths)	99.79%	'	'
Debt instrument, maturity date	15-Mar-18	'	'
Debt instrument, unamortized discount	0.5	'	'
Debt instruments, amortization period for debt discount and deferred debt issuance costs	'5 years	'	'
Senior Notes Due 2020 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Average effective interest rate (in hundredths)	3.41%	3.41%	'
Total debt	648.7	648.5	'
Debt instrument, issuance date	14-Sep-10	'	'
Debt instrument, interest rate, stated percentage (in hundredths)	3.38%	'	'
Debt instrument, face amount	650	'	'
Debt instrument, sales price as percentage of par value (in hundredths)	99.70%	'	'
Debt instrument, maturity date	15-Sep-20	'	'
Debt instrument, unamortized discount	2	'	'
Debt instruments, amortization period for debt discount and deferred debt issuance costs	'10 years	'	'
Senior Notes Due 2023 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Average effective interest rate (in hundredths)	2.83%	'	'
Total debt	349.1	'	'
Debt instrument, issuance date	12-Mar-13	'	'
Debt instrument, interest rate, stated percentage (in hundredths)	2.80%	'	'
Debt instrument, face amount	350	'	'
Debt instrument, sales price as percentage of par value (in hundredths)	99.71%	'	'
Debt instrument, maturity date	15-Mar-23	'	'
Debt instrument, unamortized discount	1	'	'
Debt instruments, amortization period for debt discount and deferred debt issuance costs	'10 years	'	'
Committed Long-Term Credit Facility [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Maximum borrowing limit - committed long-term credit facility	800	'	'
Debt instrument, maturity date	31-Oct-16	'	'
Commercial Paper [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Maximum borrowing limit - commercial paper program	$800	'	'

Notes_Payable_and_LongTerm_Deb3

Notes Payable and Long-Term Debt (Derivative Instruments) (Details) (USD $)	1 Months Ended	12 Months Ended			1 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Apr. 30, 2006	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	Three Hundred Million Notional Amount Interest Rate Swap [Member]	Three Hundred Million Notional Amount Interest Rate Swap [Member]	Three Hundred Million Notional Amount Interest Rate Swap [Member]	Three Hundred Million Notional Amount Interest Rate Swap [Member]	Eight Hundred Million Notional Amount Interest Rate Swap [Member]	Eight Hundred Million Notional Amount Interest Rate Swap [Member]	Eight Hundred Million Notional Amount Interest Rate Swap [Member]	Eight Hundred Million Notional Amount Interest Rate Swap [Member]
Derivative [Line Items]	'	'	'	'	'	'	'	'
Interest rate swap, inception date	'	31-Jan-07	'	'	'	28-Feb-06	'	'
Derivative, termination date	30-Sep-12	'	'	'	30-Apr-06	'	'	'
Interest rate swap term	'	'	'	'	'	'10 years	'	'
Derivative term	'	'nine-year, two month	'	'	'	'	'	'
Interest rate derivative, notional amount	'	$300	'	'	'	$800	'	'
Interest rate swap, fixed interest rate (in hundredths)	'	5.75%	'	'	'	5.20%	'	'
Interest rate swap, variable interest rate basis	'	'3-month LIBOR	'	'	'	'	'	'
Interest rate swap, variable interest rate (in hundredths)	'	0.37%	'	'	'	'	'	'
Proceeds upon termination of an interest rate swap	54.7	'	'	'	'	'	'	'
Accrued interest received upon termination of an interest rate swap	3.7	'	'	'	'	'	'	'
Net proceeds upon termination of an interest rate swap	51	'	'	'	'	'	'	'
Unamortized amount of the terminated interest rate swap	'	31.5	44.6	'	'	'	'	'
Gains recognized in income on interest rate swap	'	13.1	13.8	15	'	'	'	'
Amortization of deferred gains on derivatives designated as cash flow hedges from accumulated OCI	'	'	'	'	'	1.3	1.3	1.3
Remaining unrecognized gain on interest rate swap cash flow hedge included in accumulated other comprehensive loss	'	'	'	'	13	3	'	'
Remaining unrecognized gain on interest rate swap cash flow hedge included in accumulated other comprehensive loss, net of tax	'	'	'	'	'	1.8	'	'
Interest rate cash flow hedge pretax gain to be reclassified as a reduction to interest expense during 2014	'	'	'	'	'	$1.30	'	'

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended				12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2012	Jun. 30, 2012	Jun. 30, 2010	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Components of earnings before income taxes [Abstract]	'	'	'	'	'	'	'
U.S.	'	'	'	'	$890.10	$846.80	$705.50
Non-U.S.	'	'	'	'	840.7	684.2	603.7
Earnings from continuing operations before income taxes	'	'	'	'	1,730.80	1,531	1,309.20
Current [Abstract]	'	'	'	'	'	'	'
U.S. federal	'	'	'	'	342.4	378.3	298.2
U.S. state	'	'	'	'	24.7	20.4	32.7
Non-U.S.	'	'	'	'	152.7	103.9	83.6
Total current	'	'	'	'	519.8	502.6	414.5
Deferred [Abstract]	'	'	'	'	'	'	'
U.S. federal	'	'	'	'	-34.8	-72.7	-45.8
U.S. state	'	'	'	'	-12.6	0.1	-18.2
Non-U.S.	'	'	'	'	-14.1	0.3	9.1
Total deferred	'	'	'	'	-61.5	-72.3	-54.9
Total income tax expense	'	'	'	'	458.3	430.3	359.6
Excess tax benefits from share-based compensation	'	'	'	'	37.7	45.7	37.7
Reconciliation of US federal statutory tax rate to combined effective tax rate [Abstract]	'	'	'	'	'	'	'
Statutory rate of tax expense (in hundredths)	'	'	'	'	35.00%	35.00%	35.00%
State taxes, net of U.S. tax benefit (in hundredths)	'	'	'	'	0.90%	1.10%	1.60%
Tax differential on foreign earnings (in hundredths)	'	'	'	'	-9.00%	-8.80%	-9.40%
Other credits (R&D) (in hundredths)	'	'	'	'	-3.00%	-0.90%	-2.00%
Tax audit settlements/adjustments (in hundredths)	'	'	'	'	0.80%	1.30%	1.50%
Other (in hundredths)	'	'	'	'	1.80%	0.40%	0.80%
Effective tax rate (in hundredths)	'	'	'	'	26.50%	28.10%	27.50%
Retroactive benefit of the U.S. R&D tax credit for 2012 recognized in current year	'	'	'	'	15.1	'	'
Unremitted earnings outside the United States	3,828	'	'	'	3,828	'	'
Settlement of U.S. federal income tax audit for tax years 2005 and 2006	'	1.5	'	33.5	'	'	'
Settlement of U.S. federal income tax audit for tax years 2003 to 2006 for acquired subsidiary	'	'	1.1	1.2	'	'	'
Tax deposit paid to the IRS	19.5	'	'	'	'	'	'
Tax credit carryforwards	35.6	'	'	'	35.6	'	'
Tax credit carryforward with a valuation allowance	6.9	'	'	'	6.9	'	'
Deferred tax assets [Abstract]	'	'	'	'	'	'	'
Net operating losses	179.7	'	'	'	179.7	66.6	'
Accrued expenses	130	'	'	'	130	114.4	'
Capitalized expenses	176.5	'	'	'	176.5	182.3	'
Deferred compensation	47.4	'	'	'	47.4	41.7	'
Medicare, Medicaid and other accrued health care rebates	80	'	'	'	80	85	'
Postretirement medical benefits	16.6	'	'	'	16.6	17.8	'
Capitalized intangible assets	38.9	'	'	'	38.9	45	'
Deferred revenue	19.2	'	'	'	19.2	22.3	'
Inventory reserves and adjustments	14.5	'	'	'	14.5	18.7	'
Share-based compensation awards	101.6	'	'	'	101.6	90.2	'
Unbilled costs	28.3	'	'	'	28.3	23	'
Pension plans	52.6	'	'	'	52.6	66.5	'
R&D credits	26.2	'	'	'	26.2	12.7	'
All other	46.3	'	'	'	46.3	30.1	'
Deferred tax assets, gross	957.8	'	'	'	957.8	816.3	'
Less: valuation allowance	-48.9	'	'	'	-48.9	-22.6	'
Total deferred tax assets	908.9	'	'	'	908.9	793.7	'
Deferred tax liabilities [Abstract]	'	'	'	'	'	'	'
Depreciation	0.1	'	'	'	0.1	9.6	'
Developed and core technology intangible assets	153.5	'	'	'	153.5	227.3	'
In-process R&D	348.6	'	'	'	348.6	100.8	'
Total deferred tax liabilities	502.2	'	'	'	502.2	337.7	'
Net deferred tax assets	406.7	'	'	'	406.7	456	'
Net current deferred tax assets	277.9	'	'	'	277.9	249.1	'
Net non-current deferred tax assets	128.8	'	'	'	128.8	206.9	'
Reconciliation of unrecognized tax benefits [Roll Forward]	'	'	'	'	'	'	'
Balance, beginning of period	'	'	'	'	61.9	53	32.5
Gross increase as a result of positions taken in a prior year	'	'	'	'	8.7	20.9	21.8
Gross decrease as a result of positions taken in a prior year	'	'	'	'	-14.6	-12.7	-8.5
Gross increase as a result of positions taken in current year	'	'	'	'	23.3	3.4	16.9
Gross decrease as a result of positions taken in current year	'	'	'	'	0	0	-6
Decreases related to settlements	'	'	'	'	-2	-2.7	-3.7
Balance, end of period	77.3	'	'	'	77.3	61.9	53
Unrecognized tax benefit that, if recognized, would affect the effective tax rate	70.5	'	'	'	70.5	55.2	44.5
Interest expense related to uncertainty in income taxes recognized	'	'	'	'	4.3	2.2	0.5
Accrued interest expense related to uncertainty in income taxes	9.8	'	'	'	9.8	10	'
Reasonably possible decrease in unrecognized tax benefit liabilities during the next 12 months, lower range of change	4	'	'	'	4	'	'
Reasonably possible decrease in unrecognized tax benefit liabilities during the next 12 months, upper range of change	$5	'	'	'	$5	'	'
US Federal [Member]	'	'	'	'	'	'	'
Tax years still subject to examination by tax jurisdiction [Line Items]	'	'	'	'	'	'	'
Open tax years	'	'	'	'	'2005 - 2012	'	'
California [Member]	'	'	'	'	'	'	'
Tax years still subject to examination by tax jurisdiction [Line Items]	'	'	'	'	'	'	'
Open tax years	'	'	'	'	'2000 - 2012	'	'
Brazil [Member]	'	'	'	'	'	'	'
Tax years still subject to examination by tax jurisdiction [Line Items]	'	'	'	'	'	'	'
Open tax years	'	'	'	'	'2008 - 2012	'	'
Canada [Member]	'	'	'	'	'	'	'
Tax years still subject to examination by tax jurisdiction [Line Items]	'	'	'	'	'	'	'
Open tax years	'	'	'	'	'2005 - 2012	'	'
France [Member]	'	'	'	'	'	'	'
Tax years still subject to examination by tax jurisdiction [Line Items]	'	'	'	'	'	'	'
Open tax years	'	'	'	'	'2011 - 2012	'	'
Germany [Member]	'	'	'	'	'	'	'
Tax years still subject to examination by tax jurisdiction [Line Items]	'	'	'	'	'	'	'
Open tax years	'	'	'	'	'2012	'	'
Italy [Member]	'	'	'	'	'	'	'
Tax years still subject to examination by tax jurisdiction [Line Items]	'	'	'	'	'	'	'
Open tax years	'	'	'	'	'2008 - 2012	'	'
Ireland [Member]	'	'	'	'	'	'	'
Tax years still subject to examination by tax jurisdiction [Line Items]	'	'	'	'	'	'	'
Open tax years	'	'	'	'	'2006 - 2012	'	'
Spain [Member]	'	'	'	'	'	'	'
Tax years still subject to examination by tax jurisdiction [Line Items]	'	'	'	'	'	'	'
Open tax years	'	'	'	'	'2009 - 2012	'	'
United Kingdom [Member]	'	'	'	'	'	'	'
Tax years still subject to examination by tax jurisdiction [Line Items]	'	'	'	'	'	'	'
Open tax years	'	'	'	'	'2011 - 2012	'	'

Income_Taxes_Operating_Loss_Ca

Income Taxes (Operating Loss Carryforwards) (Details) (USD $)	Dec. 31, 2013
In Millions, unless otherwise specified
Foreign Tax Authority [Member]	'
Operating Loss Carryforwards [Line Items]	'
Operating loss carryforwards	$76.10
U.S. Federal and State Tax Authority [Member]	'
Operating Loss Carryforwards [Line Items]	'
Operating loss carryforwards	893.6
State and Local Jurisdiction [Member]	'
Operating Loss Carryforwards [Line Items]	'
Operating loss carryforwards with a valuation allowance	$483.90

Employee_Retirement_and_Other_2

Employee Retirement and Other Benefit Plans (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Jun. 30, 2011
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, beginning of year	$869.30	'	'	'
Fair value of plan assets, end of year	933.9	869.3	'	'
Information for pension plans with a projected benefit obligation exceeding the fair value of plan assets [Abstract]	'	'	'	'
Projected benefit obligation	1,098.40	1,061.60	'	'
Accumulated benefit obligation	992.3	965.8	'	'
Fair value of plan assets	901.1	840.6	'	'
Information for pension plans with an accumulated benefit obligation in excess of plan assets [Abstract]	'	'	'	'
Projected benefit obligation	327.5	980.9	'	'
Accumulated benefit obligation	283.5	900.7	'	'
Fair value of plan assets	156.6	762.7	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	933.9	869.3	'	'
Savings and Investment plan [Abstract]	'	'	'	'
Maximum contribution amount as a percentage of an employee's contribution that are subject to Company matching contribution (in hundredths)	4.00%	4.00%	4.00%	'
Employer percentage of match of employee contributions up to maximum level (in hundredths)	100.00%	100.00%	100.00%	'
Employer cost of the plan	23	19.9	18.7	'
Employer percentage of contributions of employees compensation into a sponsored retirement program (in hundredths)	5.00%	5.00%	5.00%	'
Employer cost of the retirement contribution program	25.6	23	19.6	'
Level I [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	354	337.8	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	354	337.8	'	'
Level II [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	579.9	531.5	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	579.9	531.5	'	'
Level III [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	0	0	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	0	0	'	'
Cash and Cash Equivalents [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	16.9	16.2	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	16.9	16.2	'	'
Cash and Cash Equivalents [Member] | Level I [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	0	0	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	0	0	'	'
Cash and Cash Equivalents [Member] | Level II [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	16.9	16.2	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	16.9	16.2	'	'
Cash and Cash Equivalents [Member] | Level III [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	0	0	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	0	0	'	'
U.S. small-cap growth [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	26.1	26.5	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	26.1	26.5	'	'
U.S. small-cap growth [Member] | Level I [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	26.1	26.5	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	26.1	26.5	'	'
U.S. small-cap growth [Member] | Level II [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	0	0	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	0	0	'	'
U.S. small-cap growth [Member] | Level III [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	0	0	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	0	0	'	'
U.S. large-cap index [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	65.3	74	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	65.3	74	'	'
U.S. large-cap index [Member] | Level I [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	65.3	74	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	65.3	74	'	'
U.S. large-cap index [Member] | Level II [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	0	0	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	0	0	'	'
U.S. large-cap index [Member] | Level III [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	0	0	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	0	0	'	'
International equities [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	212.7	201.4	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	212.7	201.4	'	'
International equities [Member] | Level I [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	212.7	201.4	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	212.7	201.4	'	'
International equities [Member] | Level II [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	0	0	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	0	0	'	'
International equities [Member] | Level III [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	0	0	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	0	0	'	'
U.S. treasury bonds [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	86.5	87.3	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	86.5	87.3	'	'
U.S. treasury bonds [Member] | Level I [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	0	0	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	0	0	'	'
U.S. treasury bonds [Member] | Level II [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	86.5	87.3	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	86.5	87.3	'	'
U.S. treasury bonds [Member] | Level III [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	0	0	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	0	0	'	'
Global corporate bonds [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	385.1	345.4	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	385.1	345.4	'	'
Global corporate bonds [Member] | Level I [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	0	0	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	0	0	'	'
Global corporate bonds [Member] | Level II [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	385.1	345.4	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	385.1	345.4	'	'
Global corporate bonds [Member] | Level III [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	0	0	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	0	0	'	'
International bond funds [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	91.4	82.6	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	91.4	82.6	'	'
International bond funds [Member] | Level I [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	0	0	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	0	0	'	'
International bond funds [Member] | Level II [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	91.4	82.6	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	91.4	82.6	'	'
International bond funds [Member] | Level III [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	0	0	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	0	0	'	'
Global corporate bond funds [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	20.4	14.6	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	20.4	14.6	'	'
Global corporate bond funds [Member] | Level I [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	20.4	14.6	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	20.4	14.6	'	'
Global corporate bond funds [Member] | Level II [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	0	0	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	0	0	'	'
Global corporate bond funds [Member] | Level III [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	0	0	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	0	0	'	'
International government bond funds [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	29.5	21.3	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	29.5	21.3	'	'
International government bond funds [Member] | Level I [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	29.5	21.3	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	29.5	21.3	'	'
International government bond funds [Member] | Level II [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	0	0	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	0	0	'	'
International government bond funds [Member] | Level III [Member]	'	'	'	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, end of year	0	0	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	0	0	'	'
Pension Plans [Member]	'	'	'	'
Amounts recognized in accumulated other comprehensive loss (income) [Abstract]	'	'	'	'
Unrecognized actuarial loss	288.7	330	'	'
Amount of actuarial loss expected to be recognized in net periodic benefit cost in next fiscal year	19	'	'	'
Components of net periodic benefit cost (credit) [Abstract]	'	'	'	'
Service cost	28.5	25.7	23.7	'
Interest cost	46.2	43.8	42.6	'
Expected return on plan assets	-45	-43.4	-44.3	'
Amortization of prior service costs (credits)	0	0	0.1	'
Recognized net actuarial losses	31	27	17.3	'
Net periodic benefit cost	60.7	53.1	39.4	'
Change in projected benefit obligation [Roll Forward]	'	'	'	'
Projected benefit obligation, beginning of year	1,084.60	933.2	'	'
Service cost	28.5	25.7	23.7	'
Interest cost	46.2	43.8	42.6	'
Participant contributions	1.5	1.5	'	'
Plan changes	-1	-1.6	'	'
Actuarial (gains) losses	-25.7	93.3	'	'
Benefits paid	-19.8	-17.9	'	'
Impact of foreign currency translation	11.3	6.6	'	'
Projected benefit obligation, end of year	1,125.60	1,084.60	933.2	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, beginning of year	869.3	729.9	'	'
Actual return on plan assets	31.3	103	'	'
Company contributions	42.3	47.1	'	'
Participant contributions	1.5	1.5	'	'
Benefits paid	-19.8	-17.9	'	'
Impact of foreign currency translation	9.3	5.7	'	'
Fair value of plan assets, end of year	933.9	869.3	729.9	'
Funded status of plans	-191.7	-215.3	'	'
Amounts Recognized in Balance Sheet for Defined Benefit Plans [Abstract]	'	'	'	'
Investments and other assets	5.6	5.7	'	'
Accrued compensation	-2.8	-2.7	'	'
Other liabilities	-194.5	-218.3	'	'
Net accrued benefit costs	-191.7	-215.3	'	'
Accumulated benefit obligations for U.S. and major non-U.S. pension plans	1,018	987.3	'	'
Information for pension plans with an accumulated benefit obligation in excess of plan assets [Abstract]	'	'	'	'
Estimated future employer contributions to U.S. and non-U.S. pension plans and other postretirement plan, lower range	30	'	'	'
Estimated future employer contributions to U.S. and non-U.S. pension plans and other postretirement plan, upper range	40	'	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	933.9	869.3	729.9	'
Projected future benefit payments for qualified and non-qualified defined benefit plans [Abstract]	'	'	'	'
2014	27.1	'	'	'
2015	30.1	'	'	'
2016	33.4	'	'	'
2017	37.3	'	'	'
2018	40.7	'	'	'
2019-2023	261.6	'	'	'
Total	430.2	'	'	'
Pension Plans [Member] | Equity securities [Member]	'	'	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Company's target allocation in equity securities for U.S. and non-U.S. pension plans (in hundredths)	30.00%	'	'	'
Pension Plans [Member] | Debt securities [Member]	'	'	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Company's target allocation in equity securities for U.S. and non-U.S. pension plans (in hundredths)	70.00%	'	'	'
Pension Plans [Member] | U.S. Pension Plans [Member]	'	'	'	'
For Determining Net Periodic Benefit Cost [Abstract]	'	'	'	'
Discount rate (in hundredths)	4.23%	4.63%	5.51%	'
Expected return on plan assets (in hundredths)	6.25%	6.75%	7.25%	'
Rate of compensation increase (in hundredths)	4.00%	4.00%	4.00%	'
Expected long-term rate of return on plan assets for next fiscal year (in hundredths)	6.25%	'	'	'
For Determining Projected Benefit Obligations [Abstract]	'	'	'	'
Discount rate (in hundredths)	5.05%	4.23%	'	'
Rate of compensation increase (in hundredths)	4.00%	4.00%	'	'
Pension Plans [Member] | Non-U.S. Pension Plans [Member]	'	'	'	'
For Determining Net Periodic Benefit Cost [Abstract]	'	'	'	'
Discount rate (in hundredths)	4.55%	5.14%	5.57%	'
Expected return on plan assets (in hundredths)	4.36%	4.80%	5.70%	'
Rate of compensation increase (in hundredths)	2.89%	3.04%	3.10%	'
Expected long-term rate of return on plan assets for next fiscal year (in hundredths)	4.56%	'	'	'
For Determining Projected Benefit Obligations [Abstract]	'	'	'	'
Discount rate (in hundredths)	4.19%	4.55%	'	'
Rate of compensation increase (in hundredths)	2.94%	2.89%	'	'
Retiree Health Plan [Member]	'	'	'	'
Amounts recognized in accumulated other comprehensive loss (income) [Abstract]	'	'	'	'
Unrecognized actuarial loss	12.1	19	'	'
Amount of actuarial loss expected to be recognized in net periodic benefit cost in next fiscal year	0.8	'	'	'
Prior service credits	17	19.7	'	'
Amount of unrecognized prior service credits expected to be recognized in net periodic benefit cost in next fiscal year	2.7	'	'	'
Reduction of accrued benefit costs associated with changes to the retiree health plan	'	'	'	-20.5
Reduction of accrued benefit costs associated with changes to the retiree health plan, tax effect	'	'	'	-7.4
Increase in net other comprehensive income associated with changes to the retiree health plan	'	'	'	13.1
Components of net periodic benefit cost (credit) [Abstract]	'	'	'	'
Service cost	1.8	1.7	1.9	'
Interest cost	2	1.9	2.6	'
Expected return on plan assets	0	0	0	'
Amortization of prior service costs (credits)	-2.7	-2.7	-1.6	'
Recognized net actuarial losses	1.4	1.3	1.1	'
Net periodic benefit cost	2.5	2.2	4	'
Change in projected benefit obligation [Roll Forward]	'	'	'	'
Projected benefit obligation, beginning of year	47.9	42.5	'	'
Service cost	1.8	1.7	1.9	'
Interest cost	2	1.9	2.6	'
Participant contributions	0	0	'	'
Plan changes	0	0	'	'
Actuarial (gains) losses	-5.4	2.5	'	'
Benefits paid	-0.5	-0.7	'	'
Impact of foreign currency translation	0	0	'	'
Projected benefit obligation, end of year	45.8	47.9	42.5	'
Change in Plan Assets [Roll Forward]	'	'	'	'
Fair value of plan assets, beginning of year	0	0	'	'
Actual return on plan assets	0	0	'	'
Company contributions	0.5	0.7	'	'
Participant contributions	0	0	'	'
Benefits paid	-0.5	-0.7	'	'
Impact of foreign currency translation	0	0	'	'
Fair value of plan assets, end of year	0	0	0	'
Funded status of plans	-45.8	-47.9	'	'
Amounts Recognized in Balance Sheet for Defined Benefit Plans [Abstract]	'	'	'	'
Investments and other assets	0	0	'	'
Accrued compensation	-1.5	-1.3	'	'
Other liabilities	-44.3	-46.6	'	'
Net accrued benefit costs	-45.8	-47.9	'	'
Information for pension plans with an accumulated benefit obligation in excess of plan assets [Abstract]	'	'	'	'
Estimated future employer contributions to U.S. and non-U.S. pension plans and other postretirement plan, lower range	1	'	'	'
Estimated future employer contributions to U.S. and non-U.S. pension plans and other postretirement plan, upper range	2	'	'	'
Fair Value Of Plan Assets [Abstract]	'	'	'	'
Fair value of plan assets	0	0	0	'
For Determining Net Periodic Benefit Cost [Abstract]	'	'	'	'
Discount rate (in hundredths)	4.21%	4.60%	5.56%	'
For Determining Projected Benefit Obligations [Abstract]	'	'	'	'
Discount rate (in hundredths)	5.02%	4.21%	'	'
Defined Benefit Plan, Assumed Health Care Cost Trend Rates [Abstract]	'	'	'	'
Effect of one percentage point decrease on total service and interest cost	0.5	'	'	'
Effect of one percentage point decrease on postretirement benefit obligation	5.7	'	'	'
Company's assumed ultimate health care trend (in hundredths)	3.00%	'	'	'
Maximum annual increase in benefits under Other Postretirement Plan	3.00%	'	'	'
Projected future benefit payments for qualified and non-qualified defined benefit plans [Abstract]	'	'	'	'
2014	1.5	'	'	'
2015	1.7	'	'	'
2016	2	'	'	'
2017	2.3	'	'	'
2018	2.5	'	'	'
2019-2023	15.9	'	'	'
Total	$25.90	'	'	'

Employee_Stock_Plans_Details

Employee Stock Plans (Details) (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'	'	'
Aggregate number of shares available for future grant under the incentive award plan (in shares)	19,500,000	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'	'	'
Outstanding, beginning of year (in shares)	21,567,000	22,651,000	23,856,000
Options granted (in shares)	4,511,000	4,372,000	5,007,000
Options exercised (in shares)	-3,187,000	-4,928,000	-5,496,000
Options cancelled (in shares)	-874,000	-528,000	-716,000
Outstanding, end of year (in shares)	22,017,000	21,567,000	22,651,000
Exercisable, end of year (in shares)	12,051,000	10,906,000	12,414,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]	'	'	'
Options outstanding, beginning of year, weighted average exercise price (in dollars per share)	$65	$57.47	$51.50
Options granted, weighted average exercise price (in dollars per share)	$105.38	$88.01	$75.95
Options exercised, weighted average exercise price (in dollars per share)	$57.36	$50.02	$48.01
Options cancelled, weighted average exercise price (in dollars per share)	$89.29	$72.39	$60.35
Options outstanding, end of year, weighted average exercise price (in dollars per share)	$73.41	$65	$57.47
Options exercisable, end of year, weighted average exercise price (in dollars per share)	$59.52	$56.25	$53.05
Weighted average per share fair value of options granted during the year (in dollars per share)	$27.58	$22.45	$23.30
Aggregate intrinsic value of stock options exercised	$149.70	$202.40	$172.50
Weighted average remaining contractual life of options outstanding	'6 years 4 months	'	'
Weighted average remaining contractual life of options exercisable	'4 years 8 months	'	'
The Company's closing year-end stock price (in dollars per share)	$111.08	'	'
Aggregate intrinsic value of options outstanding	829.4	'	'
Aggregate intrinsic value of options exercisable	621.4	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]	'	'	'
Restricted share awards, beginning of year (in shares)	1,165,000	1,035,000	886,000
Shares granted (in shares)	178,000	360,000	277,000
Shares vested (in shares)	-406,000	-198,000	-87,000
Shares cancelled (in shares)	-62,000	-32,000	-41,000
Restricted share awards, end of year (in shares)	875,000	1,165,000	1,035,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]	'	'	'
Restricted share awards, beginning of year, weighted average grant-date fair value (in dollars per share)	$67.08	$57.38	$51.20
Shares granted, weighted average grant-date fair value (in dollars per share)	$104.66	$88.75	$76.52
Shares vested, weighted average grant-date fair value (in dollars per share)	$48.20	$57.22	$56.12
Shares cancelled, weighted average grant-date fair value (in dollars per share)	$78.69	$59.87	$54.45
Restricted share awards, end of year, weighted average grant-date fair value (in dollars per share)	$76.59	$67.08	$57.38
Restricted stock units granted to the Chief Executive Officer (in shares)	'	165,000	'
Restricted stock units granted to the Chief Executive Officer, requisite service period	'	'5 years	'
Total fair value of restricted shares that vested	43	17.9	6.9
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]	'	'	'
Expected volatility (in hundredths)	26.22%	25.65%	27.82%
Risk-free interest rate (in hundredths)	1.05%	1.07%	2.54%
Expected dividend yield (in hundredths)	0.20%	0.26%	0.32%
Expected option life	'5 years 8 months 23 days	'5 years 8 months 23 days	'5 years 10 months 6 days
Total unrecognized compensation cost related to non-vested stock options and restricted stock	$202.20	'	'
Months to recognize compensation costs related to non-vested stock options and restricted stock	'46 months	'	'
Weighted average months to recognize compensation costs related to non-vested stock options and restricted stock	'30 months	'	'

Employee_Stock_Plans_Sharedbas

Employee Stock Plans (Shared-based Compensation Expense by Award Type) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based compensation expense by award type [Line Items]	'	'	'
Pre-tax share-based compensation expense	$112.70	$106.60	$84.80
Income tax benefit	-35.8	-34.6	-28
Net share-based compensation expense	76.9	72	56.8
Employee and director stock options [Member]	'	'	'
Share-based compensation expense by award type [Line Items]	'	'	'
Pre-tax share-based compensation expense	90.1	81.1	64.3
Employee and director restricted share awards [Member]	'	'	'
Share-based compensation expense by award type [Line Items]	'	'	'
Pre-tax share-based compensation expense	16.4	19.4	14.8
Stock contributed to employee benefit plans [Member]	'	'	'
Share-based compensation expense by award type [Line Items]	'	'	'
Pre-tax share-based compensation expense	$6.20	$6.10	$5.70

Employee_Stock_Plans_Sharebase

Employee Stock Plans (Share-based Compensation, Allocation of Recognized Period Costs by Report Line) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Pre-tax share-based compensation expense	$112.70	$106.60	$84.80
Cost of Sales [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Pre-tax share-based compensation expense	9.4	9	7.8
Selling, General and Administrative Expenses [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Pre-tax share-based compensation expense	74.1	70.1	55.3
Research and Development Expense [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Pre-tax share-based compensation expense	$29.20	$27.50	$21.70

Financial_Instruments_Details

Financial Instruments (Details) (Other, Net [Member], USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Settled Foreign Exchange Option Contracts [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Gains (losses) recognized in income on derivative instruments	$6.40	$14.20	$2.20
Open Foreign Exchange Option Contracts [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Gains (losses) recognized in income on derivative instruments	10.4	-15.3	11.1
Foreign Exchange Forward Contracts [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Gains (losses) recognized in income on derivative instruments	$5.30	($0.90)	($2.50)

Financial_Instruments_Fair_Val

Financial Instruments (Fair Values Derivatives, Balance Sheet Location) (Details) (Other Current Assets [Member], USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Foreign Exchange Option Contracts [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Fair value of derivative asset	$20.20	$9.90
Foreign Exchange Forward Contracts [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Fair value of derivative asset	$0.20	$0.30

Financial_Instruments_Foreign_

Financial Instruments (Foreign Currency Derivative Insturments Notional Principal and Fair Value) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Foreign Exchange Forward Contract Receive U.S. Dollar [Member]	'	'
Foreign Currency Derivative Instruments Notional Principal And Fair Value [Line Items]	'	'
Notional principal	$35	$44.60
Fair value	0.1	0.3
Foreign Exchange Forward Contract Pay U.S. Dollar [Member]	'	'
Foreign Currency Derivative Instruments Notional Principal And Fair Value [Line Items]	'	'
Notional principal	41.3	39.6
Fair value	0.1	0
Foreign Exchange Contract Put Option [Member]	'	'
Foreign Currency Derivative Instruments Notional Principal And Fair Value [Line Items]	'	'
Notional principal	560.8	501.6
Fair value	$20.20	$9.90

Financial_Instruments_Fair_Val1

Financial Instruments (Fair Value by Balance Sheet Grouping) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
			Carrying Amount [Member]	Carrying Amount [Member]	Fair Value [Member]	Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'	'	'
Cash and equivalents	'	'	$3,046.10	$2,701.80	$3,046.10	$2,701.80
Short-term investments	'	'	603	260.6	603	260.6
Non-current non-marketable equity investments	'	'	20.8	9	20.8	9
Notes payable	'	'	55.6	48.8	55.6	48.8
Long-term debt	'	'	2,098.30	1,512.40	2,163.80	1,673
Other than temporary impairment charge, non-marketable equity investment	$3.70	$3.20	'	'	'	'

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Assets [Abstract]	'	'
Commercial paper	$2,016.80	$1,709
Foreign time deposits	370.3	341.7
Other cash equivalents	1,080.40	685
Foreign exchange derivative assets	20.4	10.2
Deferred executive compensation investments	100.7	81.7
Assets measured at fair value on a recurring basis	3,588.60	2,827.60
Liabilities [Abstract]	'	'
Deferred executive compensation liabilities	93	73.5
Contingent consideration liabilities	225.2	224.3
Liabilities measured at fair value on a recurring basis	318.2	297.8
Reconciliation of the change in the contingent consideration liabilities [Roll Forward]	'	'
Balance, beginning of year	224.3	214.6
Additions during the period related to business combinations	0	6.9
Change in the estimated fair value of the contingent consideration liabilities	70.7	5.4
Payments made during the period	-61.2	-5.1
Foreign exchange translation effects	-8.6	2.5
Balance, end of year	225.2	224.3
Probability of success in meeting development milestones, lower range (in hundredths)	65.00%	'
Probability of success in meeting development milestones, higher range (in hundredths)	75.00%	'
Level 1 [Member]	'	'
Assets [Abstract]	'	'
Commercial paper	0	0
Foreign time deposits	0	0
Other cash equivalents	0	0
Foreign exchange derivative assets	0	0
Deferred executive compensation investments	80.4	66.8
Assets measured at fair value on a recurring basis	80.4	66.8
Liabilities [Abstract]	'	'
Deferred executive compensation liabilities	72.7	58.6
Contingent consideration liabilities	0	0
Liabilities measured at fair value on a recurring basis	72.7	58.6
Level 2 [Member]	'	'
Assets [Abstract]	'	'
Commercial paper	2,016.80	1,709
Foreign time deposits	370.3	341.7
Other cash equivalents	1,080.40	685
Foreign exchange derivative assets	20.4	10.2
Deferred executive compensation investments	20.3	14.9
Assets measured at fair value on a recurring basis	3,508.20	2,760.80
Liabilities [Abstract]	'	'
Deferred executive compensation liabilities	20.3	14.9
Contingent consideration liabilities	0	0
Liabilities measured at fair value on a recurring basis	20.3	14.9
Level 3 [Member]	'	'
Assets [Abstract]	'	'
Commercial paper	0	0
Foreign time deposits	0	0
Other cash equivalents	0	0
Foreign exchange derivative assets	0	0
Deferred executive compensation investments	0	0
Assets measured at fair value on a recurring basis	0	0
Liabilities [Abstract]	'	'
Deferred executive compensation liabilities	0	0
Contingent consideration liabilities	225.2	224.3
Liabilities measured at fair value on a recurring basis	$225.20	$224.30

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Commitments and Contingencies Disclosure [Abstract]	'	'	'
Rental expense	$79	$67	$58.10
Operating Leases, Future Minimum Payments Due [Abstract]	'	'	'
2014	67.8	'	'
2015	47.6	'	'
2016	31.1	'	'
2017	17.1	'	'
2018	11.4	'	'
Thereafter	57.1	'	'
Reserve for the contingent liability related to TRICARE	'	$21.70	'

Product_Warranties_Details

Product Warranties (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Reconciliation of the change in estimated product warranty liabilities [Roll Forward]	'	'
Balance, beginning of year	$34.40	$32.60
Provision for warranties issued during the year	8	9.9
Settlements made during the year	-8.1	-8.1
Increases in warranty estimates	-0.7	0
Balance, end of year	33.6	34.4
Product Warranty Accrual, Balance Sheet Classification [Abstract]	'	'
Current portion	7.6	6.7
Non-current portion	26	27.7
Total	$33.60	$34.40

Business_Segment_Information_D

Business Segment Information (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues [Abstract]	'	'	'
Product net sales	$6,197.50	$5,549.30	$5,144
Other revenues	102.9	97.3	72
Total revenues	6,300.40	5,646.60	5,216
Operating income [Abstract]	'	'	'
Total segments	2,528.20	2,226.80	2,001.40
General and administrative expenses, other indirect costs and other adjustments	594.6	525.3	556.7
Amortization of intangible assets	107.4	66.7	62.6
Impairment of intangible assets and related costs	11.4	22.3	7.6
Restructuring charges (reversal)	5.5	1.5	-0.1
Operating income	1,809.30	1,611	1,374.60
U.S. sales as a percentage of total consolidated product net sales (in hundredths)	62.00%	60.90%	60.00%
Specialty Pharmaceuticals [Member]	'	'	'
Revenues [Abstract]	'	'	'
Product net sales	5,339	4,784.60	4,432
Operating income [Abstract]	'	'	'
Total segments	2,282	1,997.70	1,763.30
Medical Devices [Member]	'	'	'
Revenues [Abstract]	'	'	'
Product net sales	858.5	764.7	712
Operating income [Abstract]	'	'	'
Total segments	$246.20	$229.10	$238.10

Business_Segment_Information_M

Business Segment Information (Major Customers) (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cardinal Health, Inc. [Member]	'	'	'
Revenue, Major Customer [Line Items]	'	'	'
Percentage of product net sales by major customer (in hundredths)	13.00%	14.70%	14.60%
McKesson Drug Company [Member]	'	'	'
Revenue, Major Customer [Line Items]	'	'	'
Percentage of product net sales by major customer (in hundredths)	15.00%	14.60%	13.10%

Business_Segment_Information_P

Business Segment Information (Product Net Sales by Product Line) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenue from External Customer [Line Items]	'	'	'
Product net sales	$6,197.50	$5,549.30	$5,144
Specialty Pharmaceuticals [Member]	'	'	'
Revenue from External Customer [Line Items]	'	'	'
Product net sales	5,339	4,784.60	4,432
Specialty Pharmaceuticals [Member] | Eye Care Pharmaceuticals [Member]	'	'	'
Revenue from External Customer [Line Items]	'	'	'
Product net sales	2,890.30	2,692.20	2,520.20
Specialty Pharmaceuticals [Member] | Botox/Neuromodulators [Member]	'	'	'
Revenue from External Customer [Line Items]	'	'	'
Product net sales	1,982.20	1,766.30	1,594.90
Specialty Pharmaceuticals [Member] | Skin Care and Other [Member]	'	'	'
Revenue from External Customer [Line Items]	'	'	'
Product net sales	466.5	326.1	316.9
Medical Devices [Member]	'	'	'
Revenue from External Customer [Line Items]	'	'	'
Product net sales	858.5	764.7	712
Medical Devices [Member] | Breast Aesthetics [Member]	'	'	'
Revenue from External Customer [Line Items]	'	'	'
Product net sales	377.9	377.1	349.3
Medical Devices [Member] | Facial Aesthetics [Member]	'	'	'
Revenue from External Customer [Line Items]	'	'	'
Product net sales	477.5	387.6	362.7
Medical Devices [Member] | Core Medical Devices [Member]	'	'	'
Revenue from External Customer [Line Items]	'	'	'
Product net sales	855.4	764.7	712
Medical Devices [Member] | Other [Member]	'	'	'
Revenue from External Customer [Line Items]	'	'	'
Product net sales	$3.10	$0	$0

Business_Segment_Information_G

Business Segment Information (Geographic Information) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Product net sales	$6,197.50	$5,549.30	$5,144
Long-lived assets	4,949.40	3,892.70	'
Depreciation and Amortization	244.1	215.1	211.2
Capital Expenditure	171.9	143.3	117.3
United States [Member]	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Product net sales	3,839.40	3,379.10	3,086.30
Long-lived assets	4,274.70	3,242.90	'
Depreciation and Amortization	181.2	153.5	146.7
Capital Expenditure	82.3	75.7	63.3
Europe [Member]	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Product net sales	1,237.80	1,095.50	1,057.40
Long-lived assets	569.9	538.6	'
Depreciation and Amortization	49.6	48.1	49.7
Capital Expenditure	79.7	59.5	45.6
Latin America [Member]	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Product net sales	383	386.3	377.3
Long-lived assets	52.2	55.2	'
Depreciation and Amortization	7.7	8.1	9.4
Capital Expenditure	7.6	6	6.3
Asia Pacific [Member]	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Product net sales	464.1	432.3	389.3
Long-lived assets	51.2	53.8	'
Depreciation and Amortization	5	4.6	4.5
Capital Expenditure	2.3	2	2.1
Other [Member]	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Product net sales	273.2	256.1	233.7
Long-lived assets	1.4	2.2	'
Depreciation and Amortization	0.6	0.8	0.9
Capital Expenditure	$0	$0.10	$0

Earnings_Per_Share_Details

Earnings Per Share (Details) (USD $)	12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Earnings Per Share Disclosure [Abstract]	'	'	'
Earnings from continuing operations	$1,272.50	$1,100.70	$949.60
Less net earnings attributable to noncontrolling interest	3.6	3.7	3.6
Earnings from continuing operations attributable to Allergan, Inc.	1,268.90	1,097	946
(Loss) earnings from discontinued operations	-283.8	1.8	-11.5
Net earnings attributable to Allergan, Inc.	$985.10	$1,098.80	$934.50
Weighted average number of shares outstanding (in shares millions)	296.8	301.5	304.4
Net shares assumed issued using the treasury stock method for options and non-vested equity shares and share units outstanding during each period based on average market price (in shares millions)	5	5.6	5.5
Dilutive effect of assumed conversion of convertible notes outstanding (in shares millions)	0	0	0.3
Diluted shares (in shares millions)	301.8	307.1	310.2
Basic earnings per share attributable to Allergan, Inc. stockholders:	'	'	'
Continuing operations (in dollars per share)	$4.28	$3.64	$3.11
Discontinued operations (in dollars per share)	($0.96)	$0	($0.04)
Net basic earnings per share attributable to Allergan, Inc. stockholders (in dollars per share)	$3.32	$3.64	$3.07
Diluted earnings per share attributable to Allergan, Inc. stockholders:	'	'	'
Continuing operations (in dollars per share)	$4.20	$3.57	$3.05
Discontinued operations (in dollars per share)	($0.94)	$0.01	($0.04)
Net diluted earnings per share attributable to Allergan, Inc. stockholder (in dollars per share)	$3.26	$3.58	$3.01
Stock Options [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Antidilutive securities excluded from earnings per share calculation (in shares millions)	5.5	5.5	4.8
Stock option exercise price lower range (in dollars per share)	$81.06	$75.58	$62.71
Stock option exercise price upper range (in dollars per share)	$113.55	$92.90	$84.40

Subsequent_Event_Details

Subsequent Event (Details) (Subsequent Event [Member], Restructuring Plan 2014 [Member], USD $)	1 Months Ended
In Millions, unless otherwise specified	Jan. 31, 2014
	employees
Subsequent Event [Member] | Restructuring Plan 2014 [Member]	'
Subsequent Event [Line Items]	'
Expected number of positions affected	300
Expected number of positions eliminated	150
Expected total restructuring costs, lower range	$40
Expected total restructuring costs, upper range	$45

Schedule_II_VALUATION_AND_QUAL2

Schedule II - VALUATION AND QUALIFYING ACCOUNTS (Details) (Allowance for Doubtful Accounts Deducted from Trade Receivables [Member], USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Allowance for Doubtful Accounts Deducted from Trade Receivables [Member]	'	'	'
Allowance for Doubtful Accounts Deducted from Trade Receivables [Roll Forward]	'	'	'
Balance at beginning of year	$24.20	$27.60	$25.30
Additions	6.2	0.8	6.6
Deductions	-6.2	-4.2	-4.3
Balance at end of year	$24.20	$24.20	$27.60